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Wound healing and scarring 
Each year, about 10% of the Dutch population undergoes surgery 1, resulting in a scar 
after wounds have healed. In addition, during life virtually everybody will at least once 
experience a minor trauma such as a fall, cut or burn resulting in one or more scars as 
well. Thus, everyone has scars. However, having scars is not a problem per se; it is a sign 
of the healing power of our body. But if wound healing is disturbed problematic scars 
may develop. 
Skin is the largest organ of the human body, which has three main layers: the epidermis, 
the dermis and the subcutis (Figure 1). The epidermis is the most outer layer which has 
a barrier function to protect our body’s interior from influences from outside and which 
prevents water and nutrient loss from inside our body, and helps to maintain a stable 
body temperature 2. The most inner layer of the epidermis consist of basal cells, also 
known as stratum basale, that produces new cells and gets nutrients from the dermis. 
These cells are pushed outwards, flatten, lose their nucleus and form a sealing top 
layer (stratum spinosum, granulosum, lucidum (very thin) and corneum, respectively) 3. 
Underneath the basal layer are the papillary and reticular dermis; rich of collagen, blood 
vessels and containing most skin appendages (exocrine glands, hair follicles, sensory 
corpuscles). If skin damage extends into the deeper reticular dermis this will cause scar-
ring 3. The dermis covers the subcutis that consist of subcutaneous fat and fascia layers 
that give the skin mobility relative to the muscles, tendons and bones in our body and 
isolates our body to prevent heat loss 2.
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Figure 1. Sectional view of the skin
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Wound healing is a complex and well-orchestrated process that follows several over-
lapping phases (Figure 2). Briefly, after the skin has been damaged healing starts with 
Figure 2. Sectional view of skin during wound healing
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hemostasis, which is followed directly by an inflammatory phase that lasts up to 4 to 6 
days. The resulting fibrin cloth, which is rich of released cytokines and growth factors 
serves as a scaffold for neutrophils, monocytes and fibroblasts. Lymphocytes clear the 
debris and bacteria, macrophages enter the wound and promote angiogenesis, fibro-
plasia and keratinocyte formation. After clearing the wound, the proliferative phase 
(day 4-14) starts during which new tissue is formed and the epidermis is restored. 
Keratinocytes reconstitute the epidermis. Fibroblasts, stimulated by platelet derived 
growth factor (PDGF) and epidermal growth factor (EGF), produce collagen type III, gly-
cosaminoglycans and fibronectin that form a matrix. Vascular endothelial growth factor 
(VEGF) stimulates blood vessels to grow which supply this matrix. In the last phase, 
this provisional matrix is remodeled and matures (day 8 to 1 year) to an organized and 
strong scar. During the first 4 to 5 weeks, collagen builds up and thin collagen parallel 
to the epidermis is replaced by thicker type I collagen which is organized along stress 
lines. Eventually, scar strength is around 80% of uninjured skin strength 3, 4. 
Pathologic scarring 
As soon as the previously described delicate healing processes get disrupted, this may 
result in problems from chronic wounds to excessive scar formation like hypertrophic 
and keloid scars. Normal scars first appear as a thin red line, but after maturation they 
turn into a slightly broadened white line. In pathologic scar formation too much tissue 
is formed (Figure 3). 
Figure 2. Sectional view of skin during wound healing (continued)
Classic stages of wound repair: inflammation (a), proliferation (b) and remodelling (c). a, Inflamma-
tion. Depicted is a skin wound at about 24–48 h after injury. A fibrin clot has formed. Bacteria, neu-
trophils and platelets are abundant in the wound. Normal skin appendages (such as hair follicles 
and sweat duct glands) are still present in the skin outside the wound. b, Proliferation. Depicted 
is a skin wound at about 5–10 days after injury. An eschar (scab) has formed on the surface of the 
wound. Most cells from the previous stage of repair have migrated from the wound, and new blood 
vessels now populate the area. The migration of keratinocytes can be observed under the eschar. c, 
Remodelling. This stage lasts for a year or longer. Depicted is a skin wound about 1–12 months after 
repair. Disorganized collagen has been laid down by fibroblasts that have migrated into the wound. 
The healed region does not contain normal skin appendages. From: Gurtner et al. Wound repair and 
regeneration. Nature. 2008;453:314-321 with permission of Nature publishing group
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Figure 3. Normal scar (a), atrophic scar (b), hypertrophic scar (c), and keloid scar (d)
From: Ud-Din and Bayat. Strategic management of keloid disease in ethnic skin: a structured ap-
proach supported by the emerging literature. British Journal of Dermatology. 2013;169 (Suppl. 
3):71–81 with permission of John Wiley and Sons.
Pathologic scarring covers two clinical conditions: hypertrophic and keloid scars. Hy-
pertrophic scars (HTS) are raised, thick, firm and red scars that may itch or give pain. 
They develop early in the maturation phase, are quite common, and tend to regress 
spontaneously after a prolonged maturation phase. Keloid scars are rare (prevalence 
0.1-8.3%, incidence 1-160/1000 patient years)5-8, and may develop months to even years 
after injury, growing outside of original wound borders. They do not regress spontane-
ously and are refractory to many treatments. Beside a very prominent appearance they 
usually cause itch and pain. A higher incidence is found in darker skin types and specific 
sites like the anterior chest, shoulders, and ears are more often affected 9-11. 
Although keloids have distinct clinical features, in clinical practice it can be hard to 
distinguish keloids from HTS and sometimes both conditions even seem to appear 
in one scar. Opinions differ on whether HTS and keloids are truly different conditions 
or whether they are two gradations of the same pathologic process. Aside from clear 
differences in clinical behavior, histological differences have also been shown. Collagen 
bundle thickness is vastly increased in keloids while in normal scars and HTS bundle 
thickness is decreased compared to normal skin 12. Myofibroblasts are present in HTS 
but not in keloids; reversely, mucin is present in keloids but not in HTS 13. 
Arguments that both conditions are similar pathological entities with different quan-
titative deviations have been made 14, 15. There are many similarities between both 
conditions: 1) collagen production is increased, resulting in excess extracellular matrix, 
2) collagen orientation in keloids, HTS, and normal scars is more parallel than in normal 
skin, and 3) mast cells are increased 12, 13. Histological differences can be explained by 
site specific structures and mechanical forces of surrounding tissues. Common theory 
is that ongoing inflammation, which is significantly longer than the standard inflam-
13
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matory phase during normal wound healing, causes excessive scar formation. Various 
immuno- and neuro-inflammatory processes and cytokine leakage by vascular damage 
have been proposed as etiologic factors for this prolonged inflammation 14, 15. Although 
the exact etiology of pathologic scar formation is not entirely clear, several factors that 
affect keloid scarring have been identified (Table 1).
Table 1. Intrinsic and extrinsic factors influencing keloid scarring 
Extrinsic factors Intrinsic factors Local factors
Repeated trauma Skin type Body area
Wound infection Genetic factors Wound tension
Age
Hypertension
Hormonal state
Syndromal
While opinions on differences and similarities on HTS and keloids differ, I am convinced 
that in clinical research a difference must be made. Different definitions have been 
used, however, the most important factor of keloids is growth outside of the original 
wound borders. Continuous growth, symptoms like pain and itch, and no spontaneous 
regression are also used in keloid definitions. In this research project scars were judged 
on growth history (starting late after trauma, continuous growth), shape (invasive in 
healthy skin), size (>0.5 cm beyond the original lesion), and symptoms, if most keloid 
features were present the lesion was classified as a keloid. For experienced observers 
classification on clinical features is usually very clear, and there are major implications 
on treatment choices based on the different clinical behavior of keloids and HTS 9. 
Burden of keloids
Historically wound healing research has focused on objective measurements, like clini-
cal appearance and histological features of different scar types or keloid size reduction 
after various treatments. While these areas are important, the patients’ perspective 
and perception is equally important and nowadays is a standard part of most study 
outcomes. Skin conditions can have just as much impact on quality of life as some 
life-threatening conditions 16. Ten years ago the impact of scars on quality of life was 
gaining attention and it was shown that scars may burden patients 17. Scars affect 
physical comfort and functioning, self-acceptability, social functioning and emotional 
well-being. Patients with pathologic scars also report distress induced by the uncertain 
nature and treatment options of their condition. Obviously, keloids potentially cause a 
Chapter 1
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bigger burden than normal scars do by their appearance and symptoms. But specifi-
cally to what extent keloids affect quality of life was unclear.  
Treatment of keloids
Evidence-based keloid treatment is hampered by scarcely available evidence. While 
there are many papers on current and future keloid treatments, the ideal treatment has 
not been found yet and there is no consensus on the best treatment currently available. 
Over the past few decades no major changes in treatment modalities have taken place 
9, 18. There are several reasons for this:
•	 Preclinical research is difficult because keloids only exist in humans and no research 
animal model is available. Therefore, optimization of new treatments in a standard-
ized living model is not available. Because keloids are affected by many different 
factors, treatment effects cannot be accurately simulated with a fibroblast culture 
or even a fibroblast/keratinocyte double culture. The giant step from in vitro results 
to clinical studies in patients seems to impair treatment development.
•	 Keloids on itself are very heterogenic, with a wide variety of clinical appearance 
from single small lesions to multiple and very large lesions covering entire body 
parts (Figure 4). This makes it hard to compare different groups of keloid patients 
because group sizes are rarely large enough to reach an even distribution. 
•	 The heterogeneity between studies is exaggerated by not clearly differentiating 
between HTS and keloids. HTS are known to spontaneously regress. With adequate 
follow-up length it is impossible to measure treatment effect apart from natural 
regression if all types of scars are combined.
•	 There is a plethora of small case series showing good treatment results of one or 
a combination of several different treatments, but there is a lack of comparative 
studies informing clinicians which treatment strategy is most effective for which 
keloid and/or patient.
15
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Figure 4. Examples of keloid scars
Diff erent fenotypes of keloids. Upper row left to right: keloid of helix, keloid on upper back, prester-
nal keloids, infra-axillairy keloid. Lower row left to right: earlobe keloid, upper back keloid, presternal 
keloids, abdominal keloids. 
Treatment of keloids is challenging; treatment response is poor or keloids recur after-
wards. Specifi cally surgery is infamous for recurrences because the new wound ends 
up in the adjacent and equally keloid prone skin area, starting the same pathologic 
scar derailment right away. Current therapies are based on empirical knowledge, but 
their treatment mechanism is not always completely understood. Table 2 shows the 
most commonly used treatment strategies, the expected results and the treatment 
specifi c drawbacks 9, 18. Publications on many other treatment modalities are available, 
including bleomycin, imiquimod, 5-fl uorouracil, onion extract, photodynamic therapy, 
electrical stimulation, calcium antagonists and interferon therapy 9, 11, 18, 19.
Most clinicians have experience with a few modalities depending on their specialty 
(general practitioner, skin therapeutic, dermatologist, plastic surgeon) and off er a 
limited treatment selection to patients seeking solution for their keloid problems. A 
stepped care approach is often used, starting with a mildly invasive treatment, escalat-
ing to more invasive treatments if necessary. 
Chapter 1
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Table 2. Overview of keloid treatment options most used
Treatment Outcomes Draw backs
Corticosteroid injections 50-100% response
9-50% recurrence
Injection pain, skin atrophy, hypopigmentation
Laser (PDL 585) 57-85% response Painful
Contact cryotherapy 51-76% response Painful, hypo- and hyperpigmentation, skin atrophy 
Surgery 45-100% recurrence Recurrences often bigger than original scar
Surgery followed by 
pressure therapy
0-10% recurrence 6-24 months treatment duration, high treatment 
adherence needed, not applicable on all body areas, 
depends on good pressure garment manufacturing
Surgery followed by 
corticosteroid injections
0-100% recurrence Injection pain, skin atrophy, hypopigmentation, 
recurrences often bigger than original scar
Radiation 10-94% response Stochastic carcinogenic effects, growth interference 
in children
Surgery followed by 
radiation
1-35% recurrence Stochastic carcinogenic effects, growth interference 
in children, wound healing problems
Historical background of this thesis
At the Erasmus MC keloid treatment has been performed for many years by the de-
partments of dermatology, plastic surgery and radiation oncology in collaboration 
with plastic surgery. As a third line referral center we see many problematic keloids 
that are often treated with excision and brachytherapy, which is a very invasive, time 
consuming, and costly treatment with some specific complications. Potentially carcino-
genic stochastic effects are an important issue when treating benign lesions in young 
patients, therefore we searched for keloid treatments that reduce the use of ionizing 
radiation. We tried photodynamic therapy as a promising alternative, but it was very 
painful and less effective for improving scar appearance 19. Consequently, we have not 
incorporated this as a standard alternative for post-excisional brachytherapy. 
Some patients do not react well to intralesional corticosteroids, leading to early surgi-
cal treatment. Because surgery with adjuvant corticosteroids in these cases is also not 
likely to prevent recurrence, treatment with brachytherapy is often indicated sooner 
than usual. If more effective non-surgical treatments would be available, this early jump 
to invasive, last resort treatment could be prevented. 
When a new device for intralesional cryotherapy was promoted the department of 
plastic surgery became enthusiastic based on available evidence 20-23 and was attracted 
to the possibility of effective keloid treatment preventing toxic radiation and hospital 
admittance of our patients. However, before implementing intralesional cryotherapy as 
a standard treatment at our center we wanted to see further proof of its efficacy in a 
randomized clinical trial. 
17
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As for many other conditions in the field of plastic surgery, we deemed patient re-
ported outcomes and quality of life improvement of very high importance. Quality of 
life was not well incorporated in literature on keloid treatment at that time, but now is 
of increasing importance in a time of increasing healthcare costs and need to prioritize 
decisions on treatment compensation. 
Aims and outline of this thesis 
The overall aim of the present research project was to improve health care for keloid 
patients. We started by determining the burden of keloid disease and analyzing what 
factors add to the disease burden. After identifying which factors cause the greatest 
quality of life impairment, treatments can be aimed to improve these factors affecting 
quality of life most. Many keloid patients report pain as their main symptom, however, 
often no treatment is prescribed to relief pain. To explore symptomatic therapy options 
we need to know more of the etiology and kind of pain in keloid patients.  
Our aim to reduce the use of brachytherapy in keloid patients stimulated us to investi-
gate whether other treatments could be effectively used as well and whether radiation 
doses could be reduced. In this way we wanted to provide scientific evidence guiding 
clinicians in their choice of treatment, mainly based on patient reported outcome 
measures. 
Part I   Burden of keloids
Chapter 2
It has been proven that scars in general may impair quality of life 17. Because keloid 
disease is a severely pathologic scar we wanted to establish how much impact such a 
scar has on quality of life and which patient characteristics or aspects of the scars play 
an important role in this burden. We investigated this in a multi-center cross-sectional 
self-administered questionnaire study.
Chapter 3
Pain is an important symptom of many keloid patients, while many matured scars are 
asymptomatic and only some patients suffer from painful scars. To acquire more knowl-
edge on the extent and possible reasons for this problem, we performed a systematic 
review of all available literature on prevalence, etiology and pathophysiology of pain 
in dermal scars. 
Chapter 1
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Chapter 4
Because knowledge on pain in keloid patients is very limited, we wanted to investigate 
the characteristics of pain experienced by keloid patients and see whether this cor-
related to skin innervation patterns of keloids. This might give insight in possibilities for 
symptom relief therapy.
In a pilot study, eight patients completed questionnaires on neuropathic pain and 
on cold intolerance. Afterwards the keloid and a matching control site of normal skin 
were clinically investigated on eleven different sensation modalities that corresponded 
to a certain type of nerve fibers. Shortly after these tests, surgical keloid removal was 
planned and tissue was obtained. After processing we stained, quantified and assessed 
the upper dermal and epidermal nerve fibers in these keloids. We hypothesized that 
clinical and histological findings would correlate. 
Part II   Treatment of keloids
Chapter 5 
In a stepped care approach patients start with non-invasive treatment strategies. 
Fortunately, surgery is not necessary for all patients with keloids. The most used modali-
ties in the Netherlands are silicone gels or sheets and injections with corticosteroids. 
Corticosteroids are widely used and although outcomes differ widely in literature, 
in general good results can be obtained. However, some keloids do not respond to 
corticosteroids, often requiring surgery with brachytherapy because no effect of 
postoperative corticosteroids is expected after surgery if there was no effect of cortico-
steroid injections only. In Asia and other areas around the world injections with other 
agents as the chemotherapeutic agent 5-fluorouracil (5-FU) are also available, but in 
the Netherlands this off-label use of 5-FU is uncommon because of a lack of irrefutable 
proof of efficacy. We systematically reviewed previous research on the use of 5-FU in 
keloid treatment to see whether 5-FU injections should be made available to keloid 
patients in the Netherlands. 
Chapters 6 and 7
Very good results have been reported with intralesional cryotherapy 20-23. But this 
therapy was not formally compared to other treatments that are often used for keloids. 
There were clear advantages of intralesional cryotherapy over our current practice in 
terms of treatment time and costs. A randomized clinical trial comparing intralesional 
cryotherapy to excision with adjuvant corticosteroids, or for more resistant keloids, to 
excision with adjuvant brachytherapy was designed. The trial protocol is presented in 
chapter 6. After unexpectedly disappointing results of intralesional cryotherapy com-
pared to the surgical treatments and due to a problematic inclusion rate the trial was 
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prematurely stopped, but we were still able to analyze our data as planned with mixed 
models described in chapter 7. 
Chapter 8
Apart from the search for alternative treatment options to reduce ionizing radiation, it is 
also feasible to reduce the treatment dose instead of the number of treatments. Radio-
therapy is a worldwide used treatment modality, but many different dose schemes and 
sources are in use. In the Netherlands several hospitals use Iridium-192 high dose rate 
brachytherapy, but all centers use different radiation dosing schemes. A retrospective 
analysis of the results in three Dutch University Medical Centers was done to establish 
the preferred dose scheme for brachytherapy. 
In the general discussion (chapter 9) the results of the present thesis are put into a 
broader perspective and compared to other recent work on the topic of keloid treat-
ment. In addition, I share my opinion on current practice in keloid treatment, the big-
gest challenges, the way I think we can improve patient care and how we can reach 
evidence based medicine in keloid treatment. This thesis contains a summary in English 
(chapter 10) as well as in Dutch (chapter 11). 
Chapter 1
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Abstract
Keloid scars may be painful, itch severely and be cosmetically disturbing. The burden 
of keloid disease, however, has not yet been determined. This study evaluated the 
association of keloid disease with health-related quality of life (HRQL) and identified in-
dicators of burden using a cross-sectional survey study, with one disease-specific HRQL 
measure (Skindex-29) and 2 generic HRQL measures (SF-36 and EQ-5D-5L). A total of 
106 keloid patients with no other skin diseases participated in the study. Having keloid 
disease was associated with a considerable impairment of emotional wellbeing, with 
most impairment on the emotional and mental HRQL. Pain and itch were the strongest 
indicators of HRQL impairment in keloid patients. Having painful or itchy keloids was 
related to low mental and emotional HRQL, implying that patients with keloids require 
access to effective treatment aimed at alleviating physical symptoms.
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Background
Keloids are abnormal scars, which act like benign tumours growing beyond the margins 
of the original wound 1. Additional physical symptoms, such as itch and pain, occur in 
up to 80% of patients 1, 2. Keloid disease can lead to aesthetic, physical and psychologi-
cal complaints in affected individuals 3, 4. Treatment has varying results and is associated 
with a high degree of resistance to treatment and recurrence 5. 
The advent of health-related quality of life (HRQL) measures has greatly improved our 
insight into the burden of skin diseases. Skin diseases (e.g. psoriasis) may negatively 
affect HRQL to a degree comparable to or exceeding that of life-threatening illnesses, 
such as myocardial infarction and heart failure 6. Thus, the impact of skin diseases 
should not be underestimated, and HRQL research is warranted for all skin conditions. 
The limited research available on HRQL of patients with scars shows negative effects 
on physical, psychological and social well-being 3, 4, 7-9. These studies, however, have 
substantial limitations, most importantly, a failure to differentiate between hypertro-
phic scars (HTS) and keloids, while these conditions are distinctly different from one 
another. HTS stay within the original wound margins, are self-limiting, and respond 
considerably better to treatment with lower recurrence rates 10. Preservation of HRQL is 
more likely with favourable symptoms, prognosis and duration of HTS compared with 
keloids. Research on these two conditions combined probably underestimates the 
burden of the more severe condition, keloid disease. In addition, none of these studies 
evaluated the effect of keloids on HRQL using both disease-specific and generic health 
measures. Generic health measures allow comparison of the burden of keloids with 
that of other major diseases. Thus, the degree of burden of keloids can be illustrated 
and the need for effective treatment can be formally prioritized. The combined use 
of different HRQL instruments provides such a broad and sensitive assessment of the 
burden of skin diseases 11. 
In the current study we aimed: (I) to determine the HRQL of patients with keloid disease; 
and (II) to identify indicators of high disease burden.
Methods
The present study was a multi-centre cross-sectional online survey. 
Participants
All adults diagnosed with keloid disease by an experienced physician from the par-
ticipating Departments of Plastic and Reconstructive Surgery and Dermatology at two 
university hospitals were eligible. Diagnosis of keloid disease was made on clinical 
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presentation, most important continuous growth, beyond wound borders, without 
spontaneous regression after one year. Patients were excluded if there was any doubt 
about the diagnosis, or if the diagnosis differed between physicians. Patients, who were 
not proficient in Dutch, no longer had a keloid, or had additional skin diseases, were 
excluded. All respondents completed an online informed consent form and a series 
of self-administered questionnaires between February and May 2014. Non-responders 
were contacted by telephone after three weeks to invite them to participate.
Questionnaires
Patient and Observer Scar Assessment Scale (POSAS). Scar severity was subjectively as-
sessed using the patient scale of this validated scar assessment tool (PSAS), consisting 
of 6 items on pain, itch, colour, stiffness, thickness, and irregularity, as well as an overall 
opinion on the scar. All items as well as the overall opinion were rated on a 10-point 
scale 12. Higher scores represent a more severe scar. A threshold of >3 on the pain and 
itch items was used to indicate substantial symptoms 13, 14.
Skindex-29. This dermatology specific quality of life questionnaire consists of 30 ques-
tions with a five-point Likert-scale. HRQL was scored on an emotional, functional, symp-
tomatic, and summary scale, ranging from 0 to 100 with higher scores indicating worse 
HRQL 15. For improved interpretability of the results, patients were grouped into having 
minimal, mild, moderate, or severe impairment of HRQL, according to anchor-based 
cut-off scores reported by Prinsen et al. 16.
SF-36. This widely used generic HRQL questionnaire contains 36 questions that provide 
scores on 8 different dimensions of functional health and well-being. Scores are given 
on a 100-point scale, with higher scores indicating better quality of life. Norm-based 
physical component summary scores (PCS) and mental component summary scores 
(MCS) (mean 50, SD 10) were calculated using pooled-age-matched norm scores from 
a Dutch urban (Amsterdam) reference population 17. 
EuroQol 5D (EQ-5D-5L). This utility measure describes mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression on a 5-point scale. All possible answer combi-
nations correspond to a single number, where 1 corresponds to perfect health and 0 to 
death. It complements other HRQL measures by representing HRQL in a single number, 
allowing easy comparison of health-states, and it is extensively used in healthcare 
decision-making and health economics 18.  
Independent measures
Socio-demographic and clinical characteristics, including sex, age, skin colour as de-
scribed by Fitzpatrick, location and visibility of the keloid, number of keloids (quantity), 
disease duration, origin of the keloid, previous treatments, and comorbidities, were 
collected.
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Statistical analysis
Characteristics of the study population were analysed using descriptive statistics. 
Outcomes of keloid disease were compared with the Student’s t-test to values of other 
diseases as reported in literature. Two-sided p-values ≤ 0.05 were regarded statistically 
significant. Cohen’s d effect sizes were calculated; values > 0.20 were considered small 
effects, > 0.50 medium effects, and > 0.80 large effects 19. 
Correlations were calculated between the independent variables and the 4 Skindex-29 
scales, the SF-36 PCS and MCS scales, and EQ-5D-5L index scale. Pearson’s correlation 
coefficients (rp) were calculated for normally distributed data, and Spearman’s correla-
tion coefficients (rs) for not normally distributed data. 
Seven multiple linear regression models were made to assess the predictive value of 
the independent variables (sex, age, visibility of the keloid, number of keloids as well as 
all the PSAS variables: pain, itch, colour, stiffness, thickness, and irregularity) on HRQL 
outcomes. Non-normal dependent variables were root-transformed in order to obtain 
a normal distribution. Data were entered, followed by a backward procedure, in which 
non-significant effects (p > 0.10) were removed from the models. Regression coeffi-
cients were standardized (betas) to allow for better comparison of different factors in 
the model, independent of the units of measurement of the variables. A beta of 0.1 
indicates a small effect, 0.3 a medium effect, and 0.5 a large effect. R2 represents the 
amount of variability in the outcome that is accounted for by indicators used in the 
model.
All analyses were executed using IBM® SPSS Statistics version 22 for Mac OSX. Two-sided 
p-values ≤ 0.05 were regarded as statistically significant.
Ethical considerations
The Ethics Board Committees of both participating academic hospitals concluded that 
this study was exempt from approval because of absence of any risk to participants.
Results
Patient characteristics
Of the 280 eligible patients who were invited by post to participate in the study, 70 
could not be reached after 3 attempts, 17 no longer had a keloid, 38 indicated they 
did not wish to participate, 8 had another skin disease besides keloids, and 41 did not 
complete the online survey, leaving 106 patients who successfully completed the 
questionnaires (36 from a dermatology department, and 70 from a plastic surgery de-
partment). The response rate was 57%. Socio-demographic and clinical characteristics 
of the responders are shown in Table 1. Of the non-responders, 49% were male and the 
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mean age was 39.1 years (SD 13.0, range 18–72 years), which was comparable to the 
responders (Table 1).
Table 1. Characteristics of the keloid patients analyzed in the paper
Characteristic N=106 Mean (SD) Range
Age (years) 38.6 (11.9) 18-63
Disease duration (years) 13.8 (10.3) 1-40
N Percentage
Sex Male 51 48.1
Female 55 51.9
Skin color (Fitzpatrick) 1-2 Light 23 21.7
3-4 Colored 44 41.5
5-6 Dark 38 35.8
Number of keloids 1 39 36.8
2-4 31 29.2
5 or more 36 34.0
Secondary Symptoms Pain & itch ≤3 27 25.5
Pain >3 3 2.8
Itch >3 22 20.8
Pain & itch >3 54 50.9
Location of keloids * Head 9 8.5
Ear 16 15.1
Neck 7 6.6
Shoulders 40 37.7
Chest 63 59.4
Back 11 10.4
Abdomen 17 16.0
Arm 9 8.5
Leg 7 6.6
Keloids visible (wearing 
normal clothing)
No 40 37.7
Yes 66 62.3
Origin of keloid Surgical procedure 36 34.0
Piercing 7 6.6
Vaccination 3 2.8
Acne 29 27.4
Traumatic injury 6 5.7
Unknown 25 23.6
Previous keloid treatment * None 4 3.8
31
Burden of Keloids
2
Table 1. Characteristics of the keloid patients analyzed in the paper (continued)
Characteristic N=106 Mean (SD) Range
Silicone sheets 56 52.8
Pressure therapy 4 3.8
Intralesional corticosteroid 82 77.4
Excision 25 23.6
Excision with additive 27 25.5
Radiation therapy 12 11.3
Cryotherapy 27 25.5
Laser 32 30.2
Mean (SD) Range
PSAS Pain 4.21 (2.82) 1-10
Itch 5.84 (2.97) 1-10
Color 6.68 (2.52) 1-10
Stiffness 7.00 (2.43) 1-10
Thickness 7.73 (2.05) 1-10
Irregularity 7.54 (2.21) 1-10
Overall opinion 8.13 (2.05) 2-10
N: number of patients. SD: standard deviation of the mean. PSAS: Patient part of the Patient and Ob-
server Scar Assessment Scale. * Multiple answers were possible, summed percentages exceed 100. 
Dermatology specific HRQL of keloid patients 
Almost half of the patients (and 60% of the females) had severe emotional symptoms 
and about a quarter reported severe problems on the symptomatic and functional 
scale of skin symptoms and functional problems as assessed with the Skindex-29 
questionnaire  (Table 2). Skindex-29 scores of keloid patients from the present study 
were compared with those of eight other skin diseases and with subjects without a skin 
disease (Table 3) 20. All subscales were affected in keloid patients comparable to other 
skin diseases.
Table 2. Overview of Skindex-29 outcomes of the keloid patients analyzed
Skindex-29 Mean (SD)
Impairment Level (%)
Minimal Mild Moderate Severe
Emotional scale 40.9 (26.6) 26.4 17.9 7.5 48.1
Symptomatic scale 36.9 (22.0) 51.9 4.7 16.0 27.4
Functional scale 22.9 (23.9) 62.3 10.4 2.8 24.5
Sum scale 32.5 (22.1) 41.5 17.9 15.1 25.5
SD: standard deviation of the mean. Skindex-29 (dermatology specific quality of life instrument) 
scores on an 1-100 scale, higher scores indicate worse health related quality of life (HRQL). Keloid 
patients are grouped into minimal, mild, moderate and severe impairment on the Skindex-29 scale 
using cut-off scores reported by Prinsen et al. (2010), the distribution over impairment levels for 
each skindex-29 scale is shown. 
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Table 3. Skindex-29 scores of patients with keloid disease compared to other skin diseases adapted 
from Klein et al. (2011). 
Sample 
size
Emotional 
scale 
Mean (SD) Rank
Symptomatic 
scale 
Mean (SD) Rank
Functional 
scale 
Mean (SD) Rank
Keloid disease 106 41 (26) 5 37 (22) 5 23 (24) 5
Without skin disease 107 9 (13) 1 14 (12) 1 4 (8) 1
NMSC/AK 136 20 (19) 2 29 (20) 2 9 (14) 2
Rosacea 29 33 (20) 3 33 (20) 4 16 (18) 3
Psoriasis 44 39 (27) 4 42 (21) 7 23 (27) 5
Acne vulgaris 63 41 (25) 5 30 (19) 3 16 (16) 3
Eczema 102 41 (27) 5 48 (23) 9 26 (26) 7
Dermatomyositis 22 45 (27) 8 42 (25) 7 28 (29) 8
CLE 157 48 (28) 9 40 (23) 6 28 (25) 8
Vulvodynia 280 50 (20) 10 50 (17) 10 44 (22) 10
SD: standard deviation of the mean. NMSC/AK: non-melanoma skin cancer and actinic keratosis. 
CLE: cutaneous lupus erythematosus. Skindex-29 subscale scores for each dermatologic disease 
(adapted from Klein et al. 2011) compared with those in keloid disease. Higher scores and rank 
indicates better health related quality of life.
Generic health-related quality of life of keloid patients 
The outcomes for all the individual dimensions of the SF-36, as well as the PCSs and 
MCSs of the keloid patients were compared with an age-matched Dutch reference 
population, including healthy and unhealthy subjects with a living area and sex distri-
bution comparable to our study population (Table 4) 17. Compared with the reference 
population, keloid patients scored considerably lower on the SF-36 dimensions bodily 
pain, vitality, and social functioning as well as on the MCS, meaning that keloid patients 
reported a worse mental HRQL. The effect size for the MCS was –0.28, indicating a small 
effect 19. This is in contrast to the PCS, which was similar to that of the reference popula-
tion (Table 4).
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Table 4. Overview of SF-36 scores of the keloid patients compared to an age-matched reference 
population. 
Keloid disease 
population 
N=106
Mean (SD)
Reference 
population N=3800 
Mean (SD)
Effect size
Cohen’s d
Student’s t 
test
p-value
Physical Function 90.4 (16.3) 88.6 (19.0) 0.12 0.17
Role Physical 86.8 (29.1) 81.5 (33.4) 0.16 0.07
Bodily Pain 72.8 (25.2) 81.7 (23.3) -0.38 <0.01
General Health 73.4 (19.0) 72.6 (19.9) 0.04 0.67
Vitality 63.3 (21.2) 68.7 (18.9) -0.28 0.01
Social Function 80.1 (24.1) 85.9 (20.2) -0.29 0.02
Role Emotion 81.4 (36.0) 83.2 (32.5) -0.05 0.63
Mental Health 72.0 (20.7) 75.7 (17.5) -0.21 0.07
PCS 50.4 (8.7) 50.0 (10.0) 0.05 0.60
MCS 47.2 (12.0) 50.0 (10.0) -0.28 0.02
SF-36: the 36-item Short Form Health Survey. N: number of patients. SD: standard deviation of the 
mean. PCS: physical component summary score. MCS: mental component summary score. Pooled-
SD, age-matched, urban (Amsterdam) reference population adapted from Aaronson et al. (1998) 
with comparable proportions males (46%). PCSs and MCSs are norm transformed to the reference 
population with a mean=50 and SD=10. The study population is compared to the reference popu-
lation; the effect size is given with Cohen’s d (0.20 small effect, 0.50 moderate effect, 0.80 large 
effect).
To put the effect of keloid disease on HRQL further into perspective, the PCSs and 
MCSs of the keloid patients were compared to those of other common chronic medical 
conditions as well as a group of healthy adults (Table 5) 6, 21. Physical HRQL of keloid 
patients was best of all conditions (mean 50.45, SD 8.7), with only healthy adults scoring 
better. Mental HRQL (mean 47.2; SD 12.0), on the other hand, was affected to a degree 
comparable with other chronic medical conditions like psoriasis, dermatitis, arthritis, 
and cancer.
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Table 5. SF-36 summary scores of patients with keloid disease compared to other medical condi-
tions adapted from Rapp et al. 6.
Sample 
size
PCS 
Mean (SD) Rank
MCS 
Mean (SD) Rank
Keloid disease 106 50.5 (8.7) 2 47.2 (12.0) 8
Healthy adults 468 55.3 (5.1) 1 53.4 (6.3) 1
Dermatitis 214 46.9 (11.5) 3 46.2 (12.1) 9
Cancer 105 45.1 (11.6) 4 48.8 (11.1) 6
Depression 504 45.0 (12.1) 5 34.8 (12.2) 12
Hypertension 2089 44.3 (10.8) 6 52.2 (9.3) 2
Arthritis 826 43.2 (11.6) 7 48.8 (11.1) 7
Myocardial infarction 107 42.6 (10.0) 8 51.7 (8.2) 4
Chronic lung disease 182 42.3 (14.1) 9 44.5 (12.3) 11
Type 2 diabetes 541 41.5 (11.3) 10 51.9 (9.6) 3
Psoriasis 317 41.2 (14.2) 11 45.7 (11.4) 10
Congestive heart failure 216 34.5 (12.1) 12 50.4 (11.1) 5
SF-36: the 36-item Short Form Health Survey. SD: standard deviation of the mean. PCS: Physical 
Component Summary of SF-36. MCS: Mental Component Summary of SF-36. Higher scores and 
rank indicates better health related quality of life. PCS and MCS scores are norm transformed to 
the reference population, with a mean=50 and SD=10. Summary scores for each chronic medical 
condition (respondents were asked whether their doctor had ever told them that they had the 
condition or they now have the condition, adapted from Rapp et al. (1999)) compared with those 
in keloid disease.
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Figure 1. Skindex-29 scores for groups divided by patient and keloid characteristics
Skindex-29 scores are represented as means with 95% confi dence intervals. B age in years. D vis-
ibility of keloids while wearing normal clothing. E number of keloids. F duration of keloid disease 
in years. G-L are values derived from the Patient Scar Assessment Scale. Sk e: emotional scale of 
Skindex-29. Sk f: functional scale of Skindex-29. Sk s: symptomatic scale of Skindex-29. 
Associated factors and predictors of health-related quality of life of keloid 
patients
The relationship between HRQL and the individual independent variables sex, age, skin 
colour, visibility of keloids, quantity of keloids, disease duration, hospital department, 
and all PSAS items were analysed.
Pain and itch were correlated to all Skindex-29 scales (ranging from rs 0.44 to 0.75, p < 
0.001), to both SF-36 component summary scores (ranging from rs –0.24 to –0.29, p < 
0.012) and the EQ-5D-5L index (–0.54, p < 0.001), meaning pain and itch were associ-
ated with nearly all HRQL measures. In addition, scar stiff ness, thickness, and irregularity 
showed high correlations with HRQL outcomes. Duration of disease, skin colour, and 
department type (dermatology vs plastic surgery) showed no signifi cant association 
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with HRQL. Female sex correlated with worse outcomes on emotional, symptomatic, 
and sum scores of the Skindex-29 (rp 0.23–0.24, p < 0.017). 
Regression analyses revealed that pain was a negative HRQL indicator in 6 (moderate 
effect on all Skindex-29 scales, small effect on PCS, and moderate effect on EQ-5D-5L 
index), and itch in 4 (large effect on symptomatic Skindex-29 and moderate effect on 
Skindex-29 sum, MCS and EQ-5D-5L) models, respectively, making these the most con-
sistent and strongest indicators of HRQL. Besides pain and itch, other indicators were age 
(moderate effect on PCS), keloid visibility (small effect on MCS), number of keloids (small 
effect on emotional, functional and sum Skindex-29), scar stiffness (moderate effect on 
PCS and EQ-5D-5L index) and irregularity (small effect on emotional, functional and sum 
Skindex-29). Keloid colour was present as indicator in 2 models, but a more aberrant scar 
colour improved the HRQL, while there was no proof of multi-collinearity. The Skindex-29 
models could explain between 29% and 60% of the variability in outcome (R2) and for the 
PCS, MCS, and EQ-5D-5L index it was 17%, 11%, and 34%, respectively (Table 7).
Table 7. Summary of the multivariate regression analyses for the health related quality of life out-
comes as dependent variable and patient characteristics as dependent variables, in the total group 
and for males and females.  
Skindex-29 (N=106) SF-36 (N=106) EQ-5D-5L 
(N=100)
Emotional
Scale 
Functional
Scale  
Symptomatic 
Scale
Sum
Scale
PCS MCS Index 
value 
Regression R2 0.36 0.29 0.60 0.47 0.17 0.11 0.34
β (p) β (p) β (p) β (p) β (p) β (p) β (p)
Sex
Age -0.25 (0.008)
Visibility -0.19 
(0.048)
Number 0.19 (0.21) 0.18 (0.030) 0.16 (0.028)
Pain 0.45 
(<0.001)
0.35 
(<0.001)
0.29 (0.002) 0.32 (0.004) -0.18 (0.077) -0.28 (0.027)
Itch 0.53 (<0.001) 0.26 (0.030) -0.28 
(0.004)
-0.26 (0.059)
Scar Color 0.31 (0.014) 0.40 (0.001)
Stiffness -0.33 (0.013) -0.30 (0.017)
Thickness
Irregularity 0.19 (0.029) 0.23 (0.013) 0.17 (0.054)
N: number of patients in analyzed group. β: regression coefficient. R2: proportion of variance ex-
plained by the model. SF-36: the 36-item Short Form Health Survey. PCS: physical component sum-
mary score of SF-36. MCS: mental component summary score of SF-36. Number: number of keloids.
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Discussion
In this study HRQL, specifically emotional wellbeing, of patients with keloid disease 
was considerably lower than in a reference population. On the emotional scale of the 
Skindex-29, 48% of all keloid patients and even up to 60% of women reported a severe 
HRQL impairment. On the other hand, impact on the symptomatic and functional 
Skindex-29 scales was less, with 27% and 25% of patients’ HRQL severely affected, re-
spectively, and over 50% of patients’ HRQL only minimally impaired. Also, the generic 
HRQL instrument SF-36 showed impairment of mental HRQL in keloid patients and a 
physical HRQL comparable to that of the reference population. Reinholz et al. 9 found 
similar results on HRQL of keloid patients using the Dermatology Life Quality Index 
(DLQI); specifically symptoms and feelings were affected. 
Factors associated with worse HRQL of keloid patients were pain and itch symptoms 
that are more prominent in keloids than in other scar types. Remarkably, cosmetic 
issues correlated less, or even inconsistently with HRQL. These findings support pri-
ority setting, as surgery for cosmetic issues can be interpreted as “luxury healthcare”, 
instead of a medical need, which relates to its current lower priority in health policy 
decision-making 22. The current study showed that HRQL can be considerably impaired 
in patients with keloid disease, causing reasonable doubt on current priority setting.
Skin colour, age, and disease duration did not interact with HRQL. Generally, pain and 
itch are frequently reported symptoms of keloid disease 1. Of the patients with pain and 
itch scores >3, 70% had severe emotional HRQL impairment (Skindex-29) compared 
with 16% in the group of patients that had low pain and itch scores. Moreover, we 
showed that pain and itch were consistently and strongly associated with HRQL impair-
ment.
The negative effect of keloid disease on the Skindex-29 was much more pronounced 
in women than in men (Figure 1). This sex difference was similarly found on the scar as-
sessment scale (PSAS). In contrast, the generic instrument scores were not affected by 
sex. Sex did not improve the multivariate regression models. Further analysis showed 
that women rated their pain and itch higher, suggesting that these pain and itch symp-
toms may have accounted for the sex difference on HRQL. 
A previous study on HRQL in patients with scars found less pain (26%) and itch (44%) 
complaints and minimal correlations of pain and itch with emotional HRQL 4. These 
discrepancies can be explained by the large differences between keloids and other scar 
types, which are less severe than keloids. 
Furtado et al. 8 specifically studied keloid patients and similarly found that pain and 
itch correlated with worse HRQL. They showed non-visible keloids resulted in worse 
physical HRQL, while we could not find an effect of keloid visibility on physical HRQL. 
However, we did find impairment of mental HRQL in patients with a visible keloid. Vis-
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ible keloids could affect HRQL because they are socially more disturbing. Furtado et al. 
8 explained that in their population non-visible keloids were long-existing recalcitrant 
pre-sternal keloids, resulting in worse HRQL in this group.
High-profile reviews on pathological scarring focused mainly on the morphological and 
disfiguring aspects of keloid disease, and considered the accompanying symptoms of 
secondary concern 23-25. However, the results of our study challenge this view by clearly 
showing that itch and pain symptoms are the main indicators of HRQL impairment. 
Consequently, we believe that these symptoms should be of primary concern in the 
evaluation and treatment of keloid disease, as well as in scientific research on this topic. 
A limitation of the current study is that all patients were recruited from academic hospi-
tals, possibly resulting in a selection bias towards patients with a relatively high burden 
of disease. This could limit the generalizability of the current results to the entire keloid 
patient population. On the other hand, the patients from the present study represent 
those who seek treatment from a medical specialist. The sample was evenly distrib-
uted on sex and contained a variety of skin types, disease durations, age groups, and 
other clinical characteristics and had similar composition to other population-samples 
described in the literature 9. The incomplete response rate could also have introduced 
selection bias. 
Another issue could be the cross-sectional design with online questionnaires for scar 
quality and HRQL assessment that completely relied on self-reports. Patients may think 
that exaggerating their burden may result in better treatment, a higher chance of insur-
ance fees or sick leave. These disease induced benefits, or secondary gains, may have 
influenced their answers. However, a large part of our study group was not currently 
under treatment or clinically re-evaluated, and was probably less affected by secondary 
gains.
Conclusion
Keloid disease is strongly associated with mental and emotional HRQL impairment, 
which suggests a high need for effective treatment and thus a priority in healthcare 
policymaking. HRQL is most severely affected in patients with an itching or painful 
keloid, suggesting that, in these patients, cosmetic appearance is less of a concern than 
physical symptoms.
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Abstract 
Background  Scars can cause pain, even without symptoms of underlying nerve 
damage. A lack of knowledge on intrinsic scar pain hampers effective 
treatment of these complaints.
Objective  Aggregate current knowledge on prevalence, etiology and patho-
physiology of intrinsic pain in dermal scars.
Study Design Systematic review
Setting  University Medical Center
Methods  We searched the Embase, Medline, Cochrane central, CINAHL, Web-
of-Science and Pubmed databases with search terms: scar, skin, 
pain, and etiology/pathology, adding all synonyms of these terms. 
Relevant papers were selected and analyzed by three reviewers. 
Results   Intrinsic pain in scars has low prevalence. However, pathologic scars 
and burns regularly cause pain of high intensity.  Etiology is multifac-
torial, the extent of trauma was an important predicting factor. Nerve 
fiber density did not explain the intrinsic pain when pan-neuronal 
markers were used, while a correlation with an increased number 
of a subtype of C-fibers seems plausible. Nerve growth factor (that 
stimulate these C-fibers) plays an important role in wound healing. 
Thereby, it also sensitizes neurons and promotes inflammation, re-
leasing even more neurotrophic factors. Central sensitization causes 
a long-lasting effect even after wounds are healed. Furthermore, the 
opioid-system, that influences inflammation and healing and pos-
sible systemic sensory alterations after injury are discussed. 
Limitations  Liberal selection criteria challenged the systematic selection of pa-
pers.
Conclusions  Burn and pathologic scars often lead to high intensity pain symp-
toms. This pain has many characteristics of neuropathic pain that 
could be caused by an imbalance of C-fibers subtypes. The scar tissue 
itself may alter the nerve fiber distribution; the imbalance results in 
ongoing neuro-inflammation and pain symptoms. 
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Background
After injury our skin heals by forming scar tissue. Dermal scars can decrease quality 
of life by esthetic, psychological and physical complaints. The latter consists of move-
ment restriction, itch and pain, of which pain gives rise to the most severe burden 1, 2. 
Burn patients and patients with pathologic scars often visit dermatologists or plastic 
surgeons, who often experience difficulties treating the pain complaints. This leaves 
these patients without proper treatment. A better understanding of the mechanisms 
involved in painful scars and their treatment options could improve pain relief for these 
patients. 
Wounds heal by a complex process involving several phases. During the inflammatory 
phase, which starts directly after injury, a blood clot is formed and pro-inflammatory 
cytokines produced by cells like macrophages and mast cells attract neutrophils to 
the wound. Around the fourth day after trauma debris and bacteria are removed by 
the macrophages and neutrophils, furthermore angiogenesis starts, and fibroblasts get 
activated. Hereafter, the proliferative phase lasts for around two to six weeks. Several 
growth factors stimulate the fibroblasts and keratinocytes. Angiogenesis makes growth 
of granulation tissue possible and epithelialization takes place. After the wound is com-
pletely closed, the scar matures for approximately one year. New tissue with collagen 
fibers arranged at random transforms to a well-organized network under mechanical 
stress adding strength to the scar. This occurs by a continuous process of degradation 
and generation of collagen 3. 
A normotrophic scar appears as a thin white line in plane with the surrounding skin. 
Scars can present with different, abnormal phenotypes, like atrophic scars (stretched 
out and thinner than surrounding skin), contracted scars (shorter than the original 
wound), hypertrophic scars (raised, red and itching or painful) or keloids (growing into 
surrounding skin and forming, discolored and itching or painful tumors). Abnormal scar 
types are most likely the result of dysregulation in the wound healing process, but the 
exact mechanisms are not clarified yet. 
Pain is a common symptom during wound healing and it generally occurs in the initial 
phase as a result of tissue damage. Pain complaints generally fade during the phases of 
wound healing and ceases in the maturation phase of healing when a scar has formed. 
If a matured scar is still painful, one possible cause of this pain is a neuroma, which 
originates from a regenerating nerve trapped in fibrotic dermal scar tissue. Neuromas 
have a typical clinical presentation (positive Tinel sign, numbness in the innervation 
area of the injured nerve) and treatment can be directed to eliminate the neuroma 
4. Unfortunately, some patients have painful scars without the typical symptoms ac-
companying a neuroma. The prevalence of pain symptoms in different scar types like 
hypertrophic scars and keloids and the mechanisms behind it are largely unknown 2. 
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In order to generate an effective treatment against painful scars we need to know the 
extent of the problem and the underlying mechanisms causing pain. Therefore, we 
aimed to perform a comprehensive systematic review on the prevalence and intensity 
of pain, and the knowledge of pathophysiology and etiology of pain in dermal scars. 
Methods
Literature Search Methods
We searched the Embase, Medline, Cochrane central, CINAHL, Web-of-Science and 
Pubmed databases. In each database, we used the following search terms: scar, skin, 
pain, and etiology/pathology, adding all synonyms of these terms. The full search terms 
used can be found in the appendix. The search was performed from inception of the 
databases until December 2, 2014.  
We included all English articles that mentioned the prevalence, intensity or a cause of 
pain in dermal scar tissue. To exclude pain caused by wounds and neuromas, we used 
the following definition of a painful scar: persistent pain in a healed scar over 3 months’ 
duration, with allodynia and hyperalgesia adjacent to the scar, and with no sensory 
loss other than over the scar itself 5. In order to include all relevant information we also 
selected reviews. We excluded papers solely based on the treatment of (painful) scars, 
scars in other than dermal tissue, neuromas, and papers otherwise irrelevant to the 
research question. 
First, to select relevant papers two reviewers (EB, LU) independently assessed titles and 
abstracts. In cases of disagreement, a third reviewer (CK) also assessed title and abstract 
and made the final decision on eligibility. To make a final decision about inclusion, the 
full-text of the eligible articles were assessed by two reviewers (EB, LU), if there was no 
consensus the article was discussed by the reviewers until consensus was reached.  The 
references of all selected articles were crosschecked and relevant papers were included 
(Figure 1).
Literature Analysis Methods
For all included papers, two reviewers (EB, LU) independently extracted relevant in-
formation to answer our research question. We searched data on; 1) prevalence and 
intensity of pain in all types of dermal scars, 2) etiology, what biological, psychological 
or environmental factors aggravate pain in dermal scars, and 3) pathophysiology, what 
is the underlying biological mechanism that causes pain in some scars and not in oth-
ers. The collected information of both reviewers was verified by the other reviewer.  
The papers that described pain intensity used different instruments, often the visual 
analog scale (VAS, range 0-10) or numeric rating scale (NRS, written or verbal, range 
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0-10) were used, if other scales were used (i.e. scores ranging 1-5) score were converted 
to a 0-10 scale to improve comparability between papers.
Figure 1. Diagram illustrating the systematic review of literature for selection of studies.
n/a: not available
Results
Our search resulted in 2049 records and after completion of the entire selection process 
52 papers remained with relevant information about painful scars (Figure 1). 
Epidemiology
We found 18 papers with reference to prevalence of scar pain and pain intensity (Table 
1) 6-23. Most studies used questionnaires not suitable for differentiating between neu-
romas and painful scars. Many studies investigated a specific subgroup of dermal scars 
with a high prevalence of pain symptoms, mainly burn scars. These studies did not 
report the prevalence of pain in other scar types. 
Of the 14 papers that reported on pain prevalence eight used a questionnaire, of which 
only four included validated questionnaires. Others used merely a VAS scale, single 
questions, or chart notes. Of the patients with a burn scar 25-68% suffered from pain. 
However, after reviewing the results from these studies nerve damage underneath the 
scar could not be ruled out. Scar pain after surgery with low chance of nerve damage 
occurred in about 10% of patients, with 2% experiencing substantial pain (>3/10).  Sur-
gery with higher risk of nerve damage, like amputation and thoracotomy, more often 
caused painful scars (30-50%) 12. Many of these patients (80% as described by Hoimyr et 
al. 10) showed sensory disturbances distal to the scar, suggesting nerve damage. These 
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results indicate a prevalence of painful scars without nerve damage in less than 2% of 
patients.
Fourteen papers reported on pain intensity; in five papers pain intensity was recorded 
with a self-completed anchored visual analog scale ranging from 0-10cm.  Four other 
papers used a numeric rating scale from 0-10 or from 1-10. The intensity of pain reported 
by burn patients varied from 1.3 to 5.6 on a 10-point scale. Patients with hypertrophic 
scars reported a lower intensity of pain (2.2) compared to patients with keloids (5.4-6.3) 
(Table 1). Patients experience pain from their scars, while sensibility and pain thresholds 
in the scars are raised when they are objectively tested 16, 22. Some studies found that 
pain reduced with time 15, while other studies could not confirm this 17.
None of the studies did a validated quality of life assessment to assess the burden of a 
scar, but some did inquire information regarding impairment of daily life functioning. 
For surgical scars Hoimyr et al. 10 found 6.6% of patients that had a surgical scar had 
pain that impacted their daily life while Maguire et al. 15 found 18% of the patients after 
thoracotomy (40% of patients with pain) had pain that limited daily activities. In studies 
looking at burn scars several aspects are described like difficulties sleeping, or problems 
performing work or social activities, prevalence ranges from 10-20 % with exception 
of Choiniere et al. 7 and Dauber et al. 8 who show a prevalence of 45% and 55-75% 
respectively on these topics 7, 8, 17-19.
In summary, pain in dermal scars without nerve damage appears to have low preva-
lence among patients with scars 12, while specific subgroups of scars, like pathologic 
scars and burns, regularly cause pain. Patients with pathologic scars are also affected by 
pain of higher intensity. 
Etiology
We found different factors that raise the risk of painful scars. Like many conditions 
also painful scars are considered multifactorial and genetic susceptibility has its role 
(although no specific genes are identified). In post-surgical scars, the surgical procedure 
and technique are evidently of influence 12, 14, 15. Further, younger patients are more 
prone to develop painful scars after surgery 10, 12, 15. We found contradicting results on 
whether the length of time after surgery influences pain 10, 15. However, the length of 
time after burn injury did not reduce pain 7, 16, 17, 22. In burns, size and the depth of the 
burn predicted painful burn scars in most studies 7, 16, 17, 21. In contrast to post-surgical 
scars, there was no relation between post-burn pain and age 11, 17, 21, 22. Kehlet et al. 
12 state that females are more often affected with painful scars, but others found no 
difference with gender 7, 10, 11, 15-17, 24. 
49
Pain in Dermal Scar Tissue
3
Ta
bl
e 
1.
 O
ve
rv
ie
w
 o
f r
ep
or
te
d 
pr
ev
al
en
ce
 a
nd
 in
te
ns
ity
 o
f p
ai
n 
in
 d
er
m
al
 sc
ar
s. 
Pu
bl
ic
at
io
n
N
A
ge
 (y
r)
Se
x 
m
al
e 
(%
)
Pr
ev
al
en
ce
 
of
 p
ai
n
Pa
in
 in
te
ns
it
y
D
es
cr
ib
ed
 o
r o
n 
a 
0-
10
 s
ca
le
St
ud
y 
de
si
gn
Sc
ar
 a
ge
 
(m
o)
N
eu
ro
m
as
 
ex
cl
ud
ed
Re
m
ar
ks
Su
rg
ic
al
 
sc
ar
s
M
ag
ui
re
 (1
5)
60
0
55
 
(1
4-
85
)
56
.5
27
%
3.
6%
H
ad
 p
ai
n
Ra
te
d 
pa
in
 se
ve
re
 
Cr
os
s-
se
ct
io
na
l 
St
ud
y 
Q
ue
st
io
nn
ai
re
7-
84
N
o
Af
te
r V
AT
S 
or
 th
or
ac
ot
om
y
H
oi
m
yr
 (1
0)
34
9
60
.9
 ±
 1
6
47
.1
9.
7%
1.
7%
2.
0 
(m
ed
ia
n)
 
ra
te
d 
pa
in
 >
3.
0 
Cr
os
s-
se
ct
io
na
l 
St
ud
y 
Q
ue
st
io
nn
ai
re
µ 
23
 [4
-5
2]
N
o
Cu
ta
ne
ou
s m
el
an
om
a 
re
se
ct
io
ns
Ly
nc
h 
(1
4)
13
33
.1
 
(9
-6
9)
21
.4
27
%
M
ild
Cr
os
s-
se
ct
io
na
l 
St
ud
y 
Q
ue
st
io
nn
ai
re
µ 
31
 [9
-6
6]
N
o
Pl
an
ta
r s
ca
rs
 o
nl
y
Ke
hl
et
 (1
2)
-
-
-
30
-5
0%
5-
10
%
20
-4
0%
5-
10
%
10
%
2-
4%
H
ad
 p
ai
n 
af
te
r
H
ad
 se
ve
re
 p
ai
n 
H
ad
 p
ai
n 
af
te
r
H
ad
 se
ve
re
 p
ai
n 
H
ad
 p
ai
n 
af
te
r
H
ad
 se
ve
re
 p
ai
n 
Re
vi
ew
-
N
o
Am
pu
ta
tio
n/
 S
te
rn
ot
om
y
Br
ea
st
 su
rg
er
y/
 T
ho
ra
co
to
m
y
Ca
es
ar
ia
n 
se
ct
io
n/
 In
gu
in
al
 
he
rn
ia
 re
pa
ir
Bu
rn
 sc
ar
s
D
au
be
r (
8)
35
8
41
 
(3
-9
2)
52
.8
52
%
-
Cr
os
s-
se
ct
io
na
l 
Q
ue
st
io
nn
ai
re
 
µ 
13
6 
[0
-7
32
]
N
o
re
sp
on
se
 ra
te
 2
4%
TB
SA
 5
9%
Va
n 
de
r W
al
 
(2
1)
35
9
32
7
23
2
22
.5
 ±
12
61
-
2.
3
2.
2
1.
9
Lo
ng
itu
di
na
l 
O
bs
er
va
tio
na
l 
St
ud
y
3 6 12
U
nc
le
ar
40
%
 c
hi
ld
 a
ge
 0
-4
22
%
 c
hi
ld
 a
ge
 5
-1
8
M
al
en
fa
nt
 (1
7)
23
6
41
.3
 
(1
8-
97
)
76
36
%
3.
4 
+
/-
 2
.5
6.
1 
+
/-
 2
.4
 (a
t 
w
or
st
)
Cr
os
s-
se
ct
io
na
l 
Q
ue
st
io
nn
ai
re
µ 
47
 [1
2-
10
2]
N
o
71
%
 h
ad
 p
ar
es
th
es
ia
 2
8%
 h
ad
 
no
 se
ns
or
y 
pr
ob
le
m
s
27
%
 h
ad
 p
ai
n 
m
or
e 
th
an
 
on
ce
 a
 w
ee
k.
 P
ai
n 
in
te
ns
ity
 
w
as
 <
2.
0 
in
 7
2%
, 2
.0
 –
 3
.0
 in
 
9%
, a
nd
 >
3.
0 
in
 1
9%
. 
Chapter 3
50
Ta
bl
e 
1.
 O
ve
rv
ie
w
 o
f r
ep
or
te
d 
pr
ev
al
en
ce
 a
nd
 in
te
ns
ity
 o
f p
ai
n 
in
 d
er
m
al
 sc
ar
s. 
 (c
on
tin
ue
d)
Pu
bl
ic
at
io
n
N
A
ge
 (y
r)
Se
x 
m
al
e 
(%
)
Pr
ev
al
en
ce
 
of
 p
ai
n
Pa
in
 in
te
ns
it
y
D
es
cr
ib
ed
 o
r o
n 
a 
0-
10
 s
ca
le
St
ud
y 
de
si
gn
Sc
ar
 a
ge
 
(m
o)
N
eu
ro
m
as
 
ex
cl
ud
ed
Re
m
ar
ks
Bu
rn
 sc
ar
s
M
al
en
fa
nt
 (1
6)
12
1
39
.8
 ±
11
.2
80
65
%
 
ha
d 
pa
in
Cl
in
ic
al
 S
tu
dy
µ 
60
 [1
8-
12
1]
N
o
Ca
uc
as
ia
ns
 o
nl
y, 
qu
an
tit
at
iv
e 
se
ns
or
y 
te
st
in
g 
(Q
ST
), 
27
%
 
ha
d 
pa
in
 m
or
e 
th
an
 o
nc
e 
a 
w
ee
k
Ch
oi
ni
er
e 
(7
)
10
4
42
.3
 ±
14
.1
76
35
%
4.
1+
/-
 2
.0
 
6.
3+
/-
2.
1 
(a
t w
or
st
)
Cr
os
s-
se
ct
io
na
l
Te
le
ph
on
e 
In
te
rv
ie
w
µ 
37
 [1
2-
77
]
N
o
21
%
 h
ad
 p
ai
n 
da
ily
. T
BS
A 
19
+
/-
16
%
Sc
hn
ei
de
r (
19
)
72
43
.6
 ±
1.
5
67
40
%
-
Re
tr
os
pe
ct
iv
e 
Ch
ar
t R
ev
ie
w
>
14
U
nc
le
ar
43
%
 h
yp
er
tr
op
hi
c 
sc
ar
s. 
Pa
in
 
st
ar
ts
 a
ro
un
d 
4 
m
o 
po
st
 b
ur
n 
w
ith
 in
te
ns
ity
 o
f 7
/1
0 
an
d 
de
cr
ea
se
s a
ro
un
d 
7 
m
o.
W
ar
d 
(2
2)
60
34
 
(1
8-
65
)
95
25
%
-
Cl
in
ic
al
 S
tu
dy
µ 
27
 [8
-1
26
]
Ye
s
Fu
ll 
th
ic
kn
es
s b
ur
ns
. 9
7%
 
se
ns
or
y 
im
pa
irm
en
t i
n 
th
e 
sc
ar
.
Ch
oi
 (6
)
37
26
 
(1
-7
8)
54
-
2.
4+
/-
2.
1
Cr
os
s-
se
ct
io
na
l
µ 
88
 [3
-3
60
]
Ye
s
H
yp
er
tr
op
hi
c 
po
st
 b
ur
n 
sc
ar
s, 
m
an
y 
on
 th
e 
ha
nd
 (>
50
%
)
Pa
rn
el
l (
18
)
23
>
18
61
-
1.
3+
/-
0.
8 
2.
3+
/-
1.
7
Cr
os
s-
se
ct
io
na
l 
St
ud
y
<
6
>
6
U
nc
le
ar
10
-7
0%
 T
BS
A,
 It
ch
in
g 
bu
rn
 
sc
ar
s
Iso
ar
do
 (1
1)
22
45
.8
 ±
12
68
59
%
5.
6+
/-
1.
8
Cl
in
ic
al
 S
tu
dy
-
Ye
s
Po
st
 b
ur
n 
hy
pe
rt
ro
ph
ic
 sc
ar
s 
on
 h
an
ds
W
id
ge
ro
w
 
(2
3)
-
-
68
%
-
Re
vi
ew
-
N
o
51
Pain in Dermal Scar Tissue
3
Ta
bl
e 
1.
 O
ve
rv
ie
w
 o
f r
ep
or
te
d 
pr
ev
al
en
ce
 a
nd
 in
te
ns
ity
 o
f p
ai
n 
in
 d
er
m
al
 sc
ar
s. 
 (c
on
tin
ue
d)
Pu
bl
ic
at
io
n
N
A
ge
 (y
r)
Se
x 
m
al
e 
(%
)
Pr
ev
al
en
ce
 
of
 p
ai
n
Pa
in
 in
te
ns
it
y
D
es
cr
ib
ed
 o
r o
n 
a 
0-
10
 s
ca
le
St
ud
y 
de
si
gn
Sc
ar
 a
ge
 
(m
o)
N
eu
ro
m
as
 
ex
cl
ud
ed
Re
m
ar
ks
Pa
th
ol
og
ic
 
sc
ar
s
Le
e 
(1
3)
28
34
 
(2
0-
53
)
46
46
%
6.
3
Cl
in
ic
al
 S
tu
dy
<
24
 (n
=
4)
>
24
 (n
=
24
)
Ye
s
Ke
lo
id
s, 
Q
ST
 
Te
y 
(2
0)
13
25
 
(1
4-
43
)
54
31
%
5.
6
Cl
in
ic
al
 a
nd
 
H
ist
ol
og
ic
 
St
ud
y
>
6
Ye
s
Ke
lo
id
s
Ei
sh
i (
9)
6
50
.2
 
(1
9-
76
)
50
-
5.
4+
/-
1.
4
Cl
in
ic
al
 S
tu
dy
µ 
82
 [1
0-
18
0]
Ye
s
Ke
lo
id
s o
n 
tr
un
k
N
: n
um
be
r o
f p
at
ie
nt
s. 
M
o:
 m
on
th
s. 
Sc
ar
 is
 p
re
se
nt
ed
 a
s 
μ:
 m
ea
n 
[ra
ng
e]
. V
AT
S:
 v
id
eo
 a
ss
ist
ed
 th
or
ac
os
co
pi
c 
su
rg
er
y. 
TB
SA
: t
ot
al
 b
od
y 
su
rfa
ce
 a
re
a,
 u
se
d 
to
 
ex
pr
es
se
d 
ar
ea
 b
ur
ne
d.
 P
ai
n 
in
te
ns
ity
 w
as
 c
on
ve
rt
ed
 to
 a
 0
-1
0 
sc
al
e 
if 
an
ot
he
r s
ca
lin
g 
w
as
 u
se
d 
in
 re
fe
re
nc
e 
pa
pe
r.
Chapter 3
52
Another possible factor related to pain after injury and scar formation are traumatic 
memories associated with the scars. Both anxiety and stress correlate well with the per-
ception of pain sensations 10, 25, 26. Pre-operative anxiety is correlated with post-operative 
pain experience. However, although pre-operative catastrophizing scores (tendency to 
exaggerated pessimism on outcome) correlated with acute post-operative pain, they 
did not correlate with chronic post-operative pain or long lasting painful scars 12. Condi-
tions associated with neuropathic post-burn pain are post-traumatic stress disorder, 
substance abuse and depression 19.
Pathology
Most studies retrieved from the search studied the underlying mechanism of painful 
scars. 
Numerous specialized structures are present in the skin to detect various stimuli. Merkel 
cells in the epidermis and Meissner corpuscles in the dermal papillae both are able 
to detect light touch. Pacini corpuscles, which are specialized to detect pressure, are 
found deep within the dermis or even in the subcutaneous tissue. Pain is transmitted 
through naked nerve endings located in the basal layer of the epidermis. Krause bulbs 
detect cold, whereas Ruffini corpuscles detect heat. Heat, cold, and proprioception also 
are located in the superficial dermis (Figure 2).
Figure 2. General view of skin and subcutaneous tissue, including several skin appendages and 
different sensory organs such as Ruffini bulbs (heat), Meissner corpuscles (light touch), free nerve 
endings (pain), Krause bulbs (cold), and Pacini corpuscles (strong pressure).
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Free nerve fibers are responsible for pain transmission. They consist of both fast trans-
mitting, myelinized Aδ-fibers and slower, unmyelinized C-fibers. Nerves fibers are pres-
ent all over the skin. The density of these fibers differs per body area, varies between 
individuals and between childhood and adulthood. Another but a very relevant factor 
is the technique that is used to visualize the fibers.
This makes it hard to directly compare results between tests and studies, and only ratios 
and conclusions can be used to compare outcome. In neuropathic disease fiber density 
can be affected.27, 28
Nerve fiber density
Abnormal nerve fiber density has often been suggested as the cause for painful scars, 
but evidence is conflicting and weak (Table 2) 20, 29-40. Many differences found in fiber 
density can be attributed to differences in methods of fiber staining, different skin lay-
ers, scar types, and scar age 33, 34, 36, 37, 41. Nonetheless, several factors may increase nerve 
sprouting, such as neonatal age and low opioid receptor availability 38, 42. High nerve 
fiber density can cause pain by inappropriate cross-stimulation as receptors are in much 
closer proximity, resulting in central sensitization 34. However, most painful peripheral 
neuropathies show decreased fiber density, as in diabetic neuropathy or HIV 43. 
Skin nociception is transmitted through myelinated, fast conducting Aδ-fibers that 
transmit sharp acute pain and by unmyelinated slow conducting C fibers, that repre-
sent about 70% of all epidermal fibers and conduct diffuse, burning, aching and dull 
type pain. In general, normotrophic matured scars seem to have less innervation than 
normal skin 30, 33, 37, 39-41, 44. Pathologic and painful scars seem to have richer innerva-
tion than normal skin, as shown by an increased nerve fiber density, specifically in the 
peptidergic (substance P (Sub-P) or calcitonin gene-related peptide (CGRP) immuno-
reactive (IR)) fibers 33, 34, 36, 39-41, 45. The C-fibers are generally divided in peptidergic and 
non-peptidergic fibers, the former are CGRP and Sub-P IR and respond to nerve growth 
factor (NGF), while the latter is P2X3 and IB4 IR and responds stronger to glial derived 
neurotrophic factor (GDNF), the functional difference between these types of C-fibers is 
not yet clarified. However, other groups found lower or no change in nerve fiber density 
in painful scars 30, 32, 46. 
The natural course of wound healing results in increased innervation in the first weeks 
of scar formation, gradually returning to normal or lower levels 29, 35, 41, 45. A disruption 
in the physiologic decrease of nerve fibers might cause painful scars. For example, 
Henderson et al. 35 showed that Sub-P remains elevated for more than 3 months after 
trauma. At that moment the scar contains 89% peptidergic fibers (compared to 57% in 
uninjured skin), which provide pain transmission. This illustrates the disturbed balance 
between peptidergic and non-peptidergic fibers, which is supported by several studies 
30, 35, 40. 
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Pain symptoms did not correlate with nerve fiber density consistently when pan-neu-
ronal markers were used (PGP9.5, S100), while a correlation with an increased number 
of peptidergic fibers (CGRP-IR/Sub-P-IR), either absolute or relative, is thought to be 
likely 34, 47. Clinical sensibility studies in keloid scars showed deficits matching with small 
fiber neuropathy (which is characterized by a lower epidermal nerve fiber density) 13. 
However, in burn scars a fiber specific sensibility impairment was not found 16. 
Finally, independent of nerve fiber density, damage or mechanical compression of Aδ-
fibers and C-fibers by dense scar tissue can also be the cause of pain 11, 26.
Neurotrophic factors
Nerve growth factor (NGF) is an important neurotrophic factor that is required to 
maintain neurons viable. NGF is produced by Schwann cells, but also by keratinocytes 
at the basal-epidermal junction of the skin. NGF is present in high concentrations 
during wound healing as it stimulates keratinocytes to migrate until contact to other 
keratinocytes is re-established. NGF also stimulates melanocytes to form dendrites to 
transport pigment that colors the skin 5. Both wounds that took longer to re-epithelize 
and persons with pigmented skin had higher risk on making pathologic scars and 
might have had higher levels of or prolonged NGF exposure 2. 
Besides its functions in the skin, NGF triggers neuronal sensitization in several ways. 
First, NGF directly affects primary sensory neurons, resulting in hyperexcitability of the 
neurons 48. Second, NGF stimulates sympathetic neurons to produce more neurotrans-
mitters to the branches of these fibers that are in close proximity to the cutaneous 
nociceptors 5, 48, 49. Third, it also activates mast cells, lymphocytes and leucocytes, which 
release inflammatory factors as Sub-P, CGRP and platelet activating factor. CGRP has 
direct stimulating effects on nociceptors and potentiates the effects of other factors. 
Platelet activating factor releases serotonin from the platelets. Serotonin injected in 
skin causes pain at the injection site, and in hypertrophic and red scars histamine, as 
well as serotonin levels are increased 50. Increased vascularization and red appearance 
of scars correlated with more pain symptoms reported by patients 51. The inflammatory 
response stimulates the primary sensory nerves in many ways. On the other hand, while 
Choi et al. 6 found more mast cells in scar tissue than in control skin, they found no 
correlation between mast cells and pain or between itch and pain.  
The amount of NGF produced by keratinocytes is sufficient to affect neuronal growth 
and pain behavior. Experimental studies with laboratory animals showed that damaged 
nerve fibers near keratinocytes caused local NGF levels to rise. This resulted in directed 
and abundant sprouting and hyperexcitability of the damaged axons, resulting is 
clear neuropathic pain behavior 52, 53. Persistent elevated NGF levels, and persistent 
inflammation, can cause permanent hyperinnervation and hyperalgesia 5, 48. This could 
explain why prolonged wound healing, and continued release of inflammatory sub-
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stances (interleukine-1, tumor necrosis factor-alfa) more often results in symptomatic 
pathologic scars 12, 48, 54. Altering this response has been tried in several ways, starting 
as simple as preventing stimulation of free nerve endings, to reduce neuropeptide and 
inflammatory substance release.  An occlusive dressing, for example, can reduce pain 
and scar tissue formation 23.  
In summary, NGF plays an important role in wound healing and therefore scar forma-
tion, but it also sensitizes neurons and promotes inflammation, a process that releases 
other neurotrophic factors.  When the sensitization is distinct this is a long lasting effect, 
and complaints can be present after the skin restored its continuity. 
Pain and itch in scars
Pain and itch often co-exist in pathologic and burn scars, possibly because their mecha-
nisms are closely related. Itch is partly transmitted by C-fibers, which also transmit pain. 
It is hypothesized that weak stimuli of C-fibers produces itch and stronger stimulus 
produces pain sensation 26, 47. Mast cell degeneration can lead to itch as well as pain by 
releasing histamine, leukotrienes, Sub-P, prostanoids and growth factors that activate 
peptidergic C-fibers 9, 45, 47. All these factors result in neuroinflammation that causes itch 
or pain. Histamine levels are high in young burn scars and return to normal levels when 
the scar matures 45, 50. 
Another mechanism that influences itch and pain is the opioid system. Opioid me-
diated regulations are widely expressed in the central nervous system, but opioid 
receptors (MOR, KOR and DOR) are also expressed in the skin where they influence 
skin homeostasis and pain and itch 42, 55. Nerve fiber density (PGP9.5) was increased 
and fiber morphology was changed in MOR and KOR knockout mice.  It seems likely 
that the opioid system caused these effects, because there were no apparent signs of 
increased inflammation (like increased mast cell count and CD4+ count) 42. In humans, 
opioid antagonists can reduce itch that does not respond to antihistamines, but may 
give rise to pain. Opioids reduce pain and can induce itch, which hardly responds to 
either opioid antagonists or antihistamines, indicating that opioid induced pruritus is 
not solely transmitted by histamine 47, 48, 55, 56. In pathologic scars MOR, KOR and DOR 
were all increased, as was anti-nociceptive beta-endorfin (MOR ligand). This activation 
influences peripheral nociception and pruritus 47, 55, 56. Long-term opioid use increases 
pro-inflammatory cytokines in an existing wound, while opioids administered before 
surgery diminish pro-inflammatory response 55. Use of opioids impaired scar strength 
after secondary healing by inhibition of neo-angiogenesis. However, it increased 
strength of incisional wounds by enhanced scar remodeling, with up-regulation of 
transforming growth factor-beta and metametalloproteinase-2 57. 
In summary, opioids influence inflammatory response and wound healing; the direc-
tion is dependent on wound type and opioid timing 55, 57. The coexistence of itch and 
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pain that are both affected by the opioid system, does warrant further research in this 
direction.
Systemic effects
Although scars are well-bounded local lesions, several reports suggested that not only 
local processes play a role in pain perception. Studies investigating sensory functions 
and nerve fiber density using both the contralateral side and other subjects as controls, 
found sensory functions were not only disturbed at the scar area but also at the unin-
jured contralateral skin 16, 31, 34, 46. 
Aberrant sensory functions and increased vulnerability to pain are long-term complica-
tions after neonatal surgery and these effects are not restricted to the scar area 58, 59. It 
seems that the developing peripheral nerve system in neonates is highly influenced 
by painful stimuli. This could affect synaptic connectivity in the central nervous system 
that may have long lasting effects 38, 58. 
In adults, nociceptor activity in burn wounds can activate dorsal horn microglia. This 
activation is key to neuropathic pain development and will also affect pain perception 
in skin adjacent to the scar 60. Patients with chronic pain after burn injury have a high 
amount of CGRP-IR fibers in both the scar and uninjured skin, while in patients without 
pain the scar and uninjured skin both have little CGRP-IR fibers 34.  An animal study on 
burn wounds, showed nerve fiber density (PGP9.5) was diminished 2 weeks after injury. 
This effect was seen at both the injured and non-injured site, albeit stronger at the 
injured site. This decrease in nerve fiber density was present until 12 weeks and maybe 
lasted much longer 31.
Another experimental study, using a painful mechanical scar model did not find 
neuronal activation in the dorsal horn. No neuronal activation (C-fos staining), which 
can occur following the noxious stimuli, was found in their experiment. The activation 
of dorsal horn neurons depends on both mechanical stimulation force and depth of 
anesthesia, which could have influenced these results. They did find aberrations in 
the myelin sheet of the spinal nerve innervating the scarred area matching Wallerian 
degeneration. This can be related to the mechanical hyperalgesia that was found 46. 
There exists some evidence of a more than local response after burn injuries. However, 
the exact location of changes in the central nervous system that cause a different 
sensory ability in burn patients is unclear. By testing the burn scar, the uninjured con-
tralateral dermatome, as well as another uninjured site, a spinal segmental change can 
be detected. However, spinal and supra-spinal integrating systems are hard to test 16. 
On the other hand, there also exist arguments against a systemic effect on pain percep-
tion. Isoardo et al. 11, for example, found that in patients with burns on both sides of 
the body, only one side was painful, which is hard to explain if the pain response in the 
entire body would be affected the same way. 
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Discussion 
We performed a comprehensive systematic review on the prevalence, etiology and 
pathophysiology of pain in dermal scars to give an overview of current knowledge. Al-
though we performed a wide search in six databases, we cannot guarantee inclusion of 
all available papers with any relevance to the subject. We vastly improved our inclusion 
guarantee by checking titles and abstracts of all references from the included papers. 
Also, the liberal selection process, that enabled us to include papers with unexpected 
viewpoints, resulted in a large variety in available literature that made it challenging to 
analyze in a systematic way. 
It is remarkable how little is known about the prevalence of painful scars. Most papers 
addressed burn scars, a specific type of scar known to give rise to pain symptoms. The 
only estimate of the prevalence of painful scars (excluding neuromas) in a general 
population with a surgical scar was 2%. The prevalence of painful scars found in specific 
populations like burn patients, or patients with pathologic scars was studied more and 
is much higher (30-68%). It would be valuable to study pain in scars in a design similar 
to that of Hoimyr et al. 10 to establish whether their results in a general population 
are reproducible and to determine whether pain is solely a problem for burn scars, 
pathologic scars and neuromas or nerve entrapment. 
Although a relationship between the number of nociceptor fibers and pain sensations 
is plausible, various researchers question this hypothesis 20, 41, 61. The highly variable 
nerve fiber densities found in scars cannot clarify this issue. However, the findings are 
directing towards an imbalance between non-peptidergic unmyelinated fibers (IB4-IR 
of N2X3-IR) and peptidergic (CGRP-IR and Sub-P-IR) fibers in painful scars. The same im-
balance is also present after nerve dissection with neuropathic pain 62, 63. Neuropathic 
pain might also appear when epidermal fibers are directly damaged during injury. The 
density of the scar tissue can hamper restoring a physiologic balance between the two 
types of epidermal fibers and cause permanent symptoms 29, 33. Decreasing the scar 
adhesions by, for example, lipofilling can alleviate scar pain according to the study of 
Huang et al. 60. Studying the nerve fiber density and balance in a clinical setting is chal-
lenging but necessary. Neuropathic pain should be objectively assessed, with extensive 
sensory testing and questionnaires, in order to correlate pain with nerve fiber density. 
Consequently, patients have to consent to supply tissue of the scar and control tissue. 
In addition to pan-neuronal markers, also markers differentiating between peptidergic 
and non-peptidergic fibers should be used. 
The neuroinflammatory response is most likely important in the development of pain-
ful scars. But what is the ideal level of inflammation and its perfect timing? Even if we 
would know this, interfering in these processes is not without risks, because factors like 
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NGF and opioids play a role in many more processes than re-innervation and wound 
healing. 
In general it is assumed that pain and underlying causes are local processes, as most 
authors use a control site within the same patient. We presented existing evidence on 
systemic effects of pain on a specific site on the body. Fitzgerald 58 concluded that pain 
early in life causes long term effects on sensibility and pain behavior due to the develop-
ing nervous system. If ongoing neuronal development would be the sole reason for the 
systemic effects of pain in early life, this systemic effect would not exist in adults, with 
complete development of the peripheral nerve system. In order to further investigate 
systemic effects of pain in experimental studies separate control animals can be used. 
In clinical studies control tissue form another subject would, by our opinion, introduce 
too much heterogeneity. 
Conclusions
Our conclusion is that, normotrophic scars are rarely painful (estimated at less than 2%), 
while burn and pathologic scars more often lead to pain symptoms (30%-68%) with 
high intensity (means of 1.9-6.4 on a 10 point scale). With surgical scars the procedure, 
surgical technique and patient age are etiologic factors. For burn scars the size and 
depth of the burn and post traumatic psychological disorders are important. The pain 
in scars, which has many characteristics of neuropathic pain, could be caused by an 
imbalance of peptidergic and non-peptidergic fibers in the scar area. The increased 
density and hard penetrability of the scar tissue may cause the different nerve fiber 
distribution. The latter may also be caused by ongoing neuro-inflammation that at-
tracts and stimulates peptidergic fibers. Future research should try to confirm these 
theories and attempt to alter these reactions to improve the pain in the scar area, 
without interfering with other body systems like the immune system.
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Appendix - Search Terms
Embase 
(scar/exp OR (scar OR scars OR scarr* OR scarif* OR cicatri*):ab,ti) AND (skin/exp OR 
‘skin injury’/exp OR burn/exp OR (skin* OR derma* OR dermi* OR cutis OR cutan* OR 
epiderm* OR burn*):ab,ti) AND (pain/exp OR ‘pain threshold’/de OR ‘pain assessment’/
exp OR (pain* OR allodyn* OR hyperalges* OR hyperesth* OR ache* OR aching*):ab,ti) 
AND (etiology/exp OR immunohistochemistry/exp OR physiology/exp OR pathology/
exp OR pathophysiology/de OR histology/exp OR psychophysiology/exp OR (etiolog* 
OR aetiology* OR etiopath* OR pathogen* OR caus* OR nature* OR origin* OR physio-
path* OR pathophysiol* OR pathol* OR physiol* OR immunohistochem* OR histolog* 
OR psychophysiol* ):ab,ti)
Medline 
(exp “Cicatrix”/ OR (scar OR scars OR scarr* OR scarif* OR cicatri*).ab,ti.) AND (exp “skin”/ 
OR exp “burns”/ OR (skin* OR derma* OR dermi* OR cutis OR cutan* OR epiderm* OR 
burn*).ab,ti.) AND (exp “Pain”/ OR “Pain Measurement”/ OR (pain* OR allodyn* OR hy-
peralges* OR hyperesth* OR ache* OR aching*).ab,ti.) AND (exp “Causality”/ OR exp “im-
munohistochemistry”/ OR exp “physiology”/ OR exp “pathology”/ OR exp “histology”/ 
OR exp “psychophysiology”/ OR etiology.xs. OR physiology.xs. OR pathology.xs. OR 
“anatomy and histology”.xs. OR (etiolog* OR aetiology* OR etiopath* OR pathogen* OR 
caus* OR nature* OR origin* OR physiopath* OR pathophysiol* OR pathol* OR physiol* 
OR immunohistochem* OR histolog* OR psychophysiol* ).ab,ti.)
Cochrane central 
((scar OR scars OR scarr* OR scarif* OR cicatri*):ab,ti) AND ((skin* OR derma* OR dermi* 
OR cutis OR cutan* OR epiderm* OR burn*):ab,ti) AND ((pain* OR allodyn* OR hyperal-
ges* OR hyperesth* OR ache* OR aching*):ab,ti) AND ((etiolog* OR aetiology* OR etio-
path* OR pathogen* OR caus* OR nature* OR origin* OR physiopath* OR pathophysiol* 
OR pathol* OR physiol* OR immunohistochem* OR histolog* OR psychophysiol* ):ab,ti)
CINAHL 
(MH “Cicatrix”+ OR (scar OR scars OR scarr* OR scarif* OR cicatri*)) AND (MH “skin”+ 
OR MH “burns”+ OR TX (skin* OR derma* OR dermi* OR cutis OR cutan* OR epiderm* 
OR burn*)) AND (MH “Pain”+ OR “Pain Measurement”+ OR TX (pain* OR allodyn* OR 
hyperalges* OR hyperesth* OR ache* OR aching*)) AND (MH “immunohistochemistry”+ 
OR MH “physiology”+ OR MH “pathology”+ OR MH “histology”+ OR MH “psychophysiol-
ogy”+  OR TX (etiolog* OR aetiology* OR etiopath* OR pathogen* OR caus* OR nature* 
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OR origin* OR physiopath* OR pathophysiol* OR pathol* OR physiol* OR immunohisto-
chem* OR histolog* OR psychophysiol* ))
Web-of-Science 
TS=(((scar OR scars OR scarr* OR scarif* OR cicatri*)) AND ((skin* OR derma* OR dermi* 
OR cutis OR cutan* OR epiderm* OR burn*)) AND ((pain* OR allodyn* OR hyperalges* 
OR hyperesth* OR ache* OR aching*)) AND ((etiolog* OR aetiology* OR etiopath* OR 
pathogen* OR caus* OR nature* OR origin* OR physiopath* OR pathophysiol* OR 
pathol* OR physiol* OR immunohistochem* OR histolog* OR psychophysiol* )))
PubMed as supplied by publisher 
(((scar[tiab] OR scars[tiab] OR scarr*[tiab] OR scarif*[tiab] OR cicatri*[tiab])) AND 
((skin*[tiab] OR derma*[tiab] OR dermi*[tiab] OR cutis[tiab] OR cutan*[tiab] OR 
epiderm*[tiab] OR burn*[tiab])) AND ((pain*[tiab] OR allodyn*[tiab] OR hyperalges*[tiab] 
OR hyperesth*[tiab] OR ache*[tiab] OR aching*[tiab])) AND ((etiolog*[tiab] OR 
aetiology*[tiab] OR etiopath*[tiab] OR pathogen*[tiab] OR caus*[tiab] OR nature*[tiab] 
OR origin*[tiab] OR physiopath*[tiab] OR pathophysiol*[tiab] OR pathol*[tiab] OR 
physiol*[tiab] OR immunohistochem*[tiab] OR histolog*[tiab] OR psychophysiol*[tiab] 
))) AND publisher[sb]
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Abstract
Keloid scars often cause pain and itch sensations impairing quality of life. Unfortunately, 
keloid patients respond poorly to standard analgesics and anti-pruritic medication. 
It remains unclear why keloid patients experience pain and whether nociceptive or 
neuropathic mechanisms are playing a role. In an explorative study, we examined 
eight patients with keloid scars to identify the type of pain using questionnaires and 
quantitative sensory testing (QST) according to the protocol of the German Research 
Network on Neuropathic Pain before their planned keloid scar excision. After surgery 
skin biopsies were obtained to perform immunohistochemistry for identification of 
nerve fibers with protein gene product 9.5 (PGP 9.5). Pain and sensory characteristics 
were combined with nerve fiber density to explore a correlation possibly providing new 
insights in the pathophysiology. This could be a first step towards a more mechanism 
based improved treatment. 
Our study revealed a wide variation of possible pain mechanisms playing a role in 
keloid tissue; about 50% of the patients experienced neuropathic pain. Using stan-
dardized questionnaires on neuropathic pain and the effect of cold temperature on 
pain symptoms as well as QST, pain experiences varied widely in individual patients. 
In keloid scars, PGP 9.5-immunoreactive nerve fibers showed a decrease in both the 
center and border regions as compared to control skin, which was uniformly significant 
in the epidermis. The border showed a higher nerve fiber density when compared to 
the center. 
The present results suggest that somatosensory differences in keloid scars may show 
aspects of neuropathic pain and are extremely heterogenic. In this small explorative 
study, it is impossible to correlate these findings to the nervous innervation of keloid 
scars to provide an explanation for the pain that is experienced. For the patients expe-
riencing neuropathic keloid pain, a local symptomatic pain treatment seems attractive, 
but its efficacy should first be investigated. 
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Introduction 
Keloid scars are defined as benign tumors that extend beyond the confines of the 
original wound 1. Their etiology is multifactorial, since several local or systemic factors 
resulting in an ongoing inflammatory process after trauma to the dermis add to keloid 
growth 2. Keloid scars may cause distress because of their aesthetically unpleasant 
appearance 3. However, patient burden is mainly caused by pain and itch sensations, 
which occur in a majority of the patients 4, 5, resulting in severe emotional symptoms 
in 48% of the patients (such as low self-confidence, feelings of despair, frustration). 
Unfortunately, these patients respond poorly to standard analgesics and anti-pruritic 
medication and consequently, keloids may seriously affect quality of life 6, 7.
Although many experts have described pain symptoms in patients with keloid scars, 
only few have studied this in detail 4, 8. So far, the cause of pain sensations in keloid scar 
tissue is not well understood. It is unclear whether the pain is nociceptive or neuropath-
ic. Nociceptive pain results from tissue damage or potentially tissue-damaging stimuli, 
while neuropathic pain is initiated by nervous system lesions 9. Damaged nerves can 
result in loss of signals, additional signals (ectopic activity), or a combination of both. 
In keloid scars inflammation could result in nociceptive pain. Neuropathic pain could 
occur if nerves get damaged by either inflammation or dense scar tissue. 
To characterize the type of pain, specific questionnaires for neuropathic pain and cold 
intolerance, and psychophysiological tests like quantitative sensory testing (QST) can 
be used. QST is a set of clinical tests that determines sensory tresholds, e.g. mechanical 
or temperature; different testing protocols are in use for different purposes. The QST 
protocol by the German Research Network on Neuropathic Pain assesses types of nerve 
fibers, allowing us to point out the underlying mechanisms for these phenotypes 10. 
Sensory information reaches the central nervous system through primary afferents in 
the epidermis. Afferents are divided into Aβ, Aδ and C-fiber nociceptors; in QST these 
are represented by the different sensory thresholds 10. It was previously found that 
spontaneous pain is mostly felt at the center of the keloid (77%) and that all patients 
experience pruritus, mostly at the edge of the keloids (92%)4. When provoked, 43% 
experienced allodynia (pain to a non-painful stimulus) and 14% alloknesis (itch to a 
non-itching stimulus). Moreover, thermosensory thresholds to warmth and cold were 
assessed in the keloids and showed a loss of sensory perception in keloids suggesting 
small nerve fiber neuropathy 4. 
While QST allows demonstrating nerve fiber function, skin biopsy with quantification 
of nerve fibers is used to histologically identify these fibers, for which protein gene 
product 9.5 (PGP 9.5), a common pan-neuronal marker, can be used 11. In the clinical 
setting, this is considered the gold standard for determining small fiber neuropathy 12. 
Tey et al. 8 have not found any significant changes in nerve fiber density in keloid scars, 
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while differences in nociceptive sensations between the center and periphery of the 
keloid scar have been found 4, 8. Therefore, it is not clear whether nerve fiber density 
patterns may correlate with experienced pain, elucidating the pain mechanism. 
Up till now, there is sparse literature on the description of pain in keloid scars, its char-
acteristics and whether these are accompanied by nerve fiber abnormalities. The aim 
of the study was to explore the correlation between painful sensations and nerve fiber 
density to get more understanding of the mechanisms playing a role in pain in keloid 
patients. This can be a first step towards a more effective mechanism based therapy.
Material and methods
Study setting and participants
The study was conducted at the Erasmus MC, University Medical Center Rotterdam 
in the Netherlands. Patients who were planned for surgical treatment of their keloid 
scar at our department, between November 2013 and August 2015, were invited to 
participate. The study was approved by the institutional review board as part of a 
larger trial on keloid treatment (NL40235.078.12) and registered (Dutch Trial Register 
NTR4151). All participants provided written informed consent. Inclusion criteria were 
as follows: patients over 18 years old, keloid diagnosed based on clinical characteristics 
(continuous growth, size, color, physical symptoms of pain and pruritus), proficient in 
English or Dutch. 
Patients completed the DN4 13, 14, PainDetect 15, 16 and the CISS questionnaires 17 before 
we performed the QST measurements. After surgery, skin biopsies from the keloids and 
normal skin as control were processed, whereafter stained for PGP9.5 and analyzed. 
Pain evaluation questionnaires
The DN4 was developed in France to compare signs and symptoms in patients with 
chronic pain associated with neurological (peripheral or central) or somatic tissue 
injuries. It has been used often to evaluate pain caused by malignancies. The question-
naire consists of only four questions, two for the patient on pain characteristics and 
accompanying symptoms, and two for the physician on hypoesthesia and allodynia. 
Scores range from 0-10, with a score of four or more indicating probable neuropathic 
pain in the original version. After validation of the Dutch language version it became 
clear a score of five or more indicates probable neuropathic pain 13, 14.
The PainDetect was developed in Germany to identify the neuropathic component 
of patients with back pain. This questionnaire contains nine self-subscribed questions. 
Seven items for pain are graded from 0 to 5, one item on pain course in time is graded 
−1 to +1, and an item on pain radiation is graded 0 to 2. A total score ranging from −1 
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to 38 can be calculated, with higher scores indicating probable neuropathic pain (-1 to 
12: unlikely, 13-18 possible, 19-38 likely neuropathic pain) 15, 16. 
The cold intolerance symptom severity questionnaire (CISS), with a score ranging from 
0-100 contains six questions that give detailed information on the effect of cold tem-
perature on pain symptoms. Because it was mainly designed for cold intolerance of the 
hand, two questions specific for hands were removed, resulting in a maximum score of 
0-86. A score of 30 or higher is considered abnormal cold intolerance 17, 18. 
Scores of questionnaires are given (mean and range) with their interpretation.
Quantitative Sensory Testing 
Quantitative sensory testing (QST) is a noninvasive method to determine the sensation 
and pain thresholds for cold and warm temperatures, and the mechanical sensation 
thresholds by stimulating the skin. Different protocols are used to measure different 
aspects of our sensory system 19. The protocol of the German Research Network on 
Neuropathic Pain (DFNS) 20 was developed to assess the type of fiber. QST testing was 
undertaken by a specialized research nurse (EAMB) using a strict protocol concerning 
time of day during testing, controlled room temperature, phrasing of test instructions. 
We tested on the border of the keloid, which in our experience is the most active part of 
the keloid and also is the location of most physical symptoms 21. Our protocol included 
the cold detection threshold (CDT), warmth detection threshold (WDT), thermal sen-
sory limen (TSL), cold pain threshold (CPT), heat pain threshold (HPT), mechanical 
detection threshold (MDT), mechanical pain threshold (MPT), mechanical pain sensitiv-
ity (MPS), dynamic mechanical allodynia (ALL) and wind-up ratio (WUR) according to 
protocol 10. For all temperature tests a thermo-sensory analyzer TSA II (Medoc Advanced 
Medical Systems, Durham, NC, USA) was used with a probe of 1.6x1.6 cm. In the MPS 
we excluded the 512N pinprick and when the keloid and control spot were on sensitive 
skin, like facial skin, we also excluded the 256N pinprick. We did not test the vibration 
detection threshold (VDT), because the keloid location often does not have a bony 
prominence, or this prominence was covered by keloid tissue, making it impossible 
to perform this test. Also, the pressure pain threshold (PPT) was not performed, as the 
location of some keloids prevented testing keloid tissue only, since underlying sensitive 
tissue would have affected the outcome when pressure was applied.
QST outcome does differ for different body areas, for the different sexes and with age. 
Reference values have been studied for a few body areas often affected, like the face, 
hands and feet. Even in similar sex and age groups the reference values have large 
variation 10. Keloids can arise in both men and women, at different ages, and anywhere 
on the body, but hands and feet are not often affected 22. Therefore, it is unlikely to 
compare keloid QST outcome to the reference values available. However, QST values 
can be compared to the lateral side of the body 10, 20. We used the contralateral site of 
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a keloid site as a control, or when the keloid was situated midline we used the nearest 
unaffected dermatome that was also in the midline. Because the test and control sites 
were different per patient due to where the keloid was located, we provided a qualita-
tive indication of the difference between the test and control site (from --- to +++) for 
each test 10. For all subjects combined, an average qualitative score was given.
Immunohistochemistry
Skin biopsies were obtained after keloid scar excision. The high risk on keloid forma-
tion after skin biopsies prevented us to take biopsies of keloid patients’ normal skin 
as a control to the keloid biopsies 22. Therefore, we included one normal skin biopsy, 
obtained from a different patient, as a control for the staining method. All biopsies 
were immersion-fixed in 2% paraformaldehyde-lysine-periodate (PLP) for 24 hours at 
4° C after removal 23. Thereafter, the dissected tissues were embedded in gelatin blocks. 
Frozen sections (40 μm) were cut with a freezing microtome and collected serially 1:6 
in glycerol containing vials. 
For immunohistochemistry, sections were processed as previously described by Saf-
fari et al 24. In short, the following steps were applied with rinsing between the steps. 
Sections were first treated for antigen unmasking with sodium citrate, followed by 
endogenous peroxidase blocking using 3% hydrogen peroxide. Subsequently, sec-
tions were pre-incubated in a blocking solution containing bovine serum albumin 
(BSA) and incubated for 48 hours at 4° C with the primary antibodies against PGP 9.5 
(1:10.000, Rabbit, Enzo Life Sciences, Lausen, Switzerland) and CGRP (1:30.000, Rabbit, 
Calbiochem, Darmstadt, Germany). Thereafter, sections were incubated with the appro-
priate secondary biotinylated antibody (1:200, Vector Laboratories, Burlingame, CA) for 
90 minutes, followed by Avidin-Biotin Complex (Vector Laboratories, Burlingame, CA) 
overnight at 4° C. The 3,3’-diaminobenzidine reaction 25 was used to reveal antigenic 
sites whereupon the sections were randomly mounted on gelatinized slides, stained 
with 1% Thionin, dehydrated and cover slipped. 
All slides were scanned in single layer of 8 μm into digital images using a Nanozoomer 
series system (Nanozoomer 2.0 series, Hamamatzu, Japan). These images were quanti-
fied using digital microscope software (NDP view) with a 20x to 40x objective. This soft-
ware provides frames (0.2 mm2) in order to count epidermal and dermal nerve fibers in 
center and lateral sides of the keloid scar. The localization region of these frames (center 
or border) was chosen based upon the images taken from the keloid scars, whereafter 
frames were placed at low magnification. For each person, the PGP9.5 IR-nerve fibers 
within the epidermis and upper dermis were counted in two sections 26. From these 
counts, the results were averaged and expressed as the number of fibers per mm2 per 
person. Finally, the results were compared to control skin. 
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Analyses
One observer performed the analyses. In order to determine statistical differences 
in fiber density between patients and control skin, the one-way analysis of variance 
(ANOVA) with a Dunnett’s post hoc test was used for intergroup comparisons. Errors in 
variations were determined as standard error of the mean (SEM) and statistical signifi-
cance was assumed at p <0.05.
By employing descriptive correlation analysis, the correlation between nociceptive 
sensations and nerve fiber density was explored. 
Results 
We included eight patients that completed the questionnaires and QST tests before 
their planned surgery. The patients consented on participating in the study and use of 
the keloid tissue for research (Table 1). Control skin was collected from the chest wall of 
a healthy woman without keloid scars or any other skin diseases. 
Neuropathic pain and cold intolerance questionnaire
The pain which was experienced by keloid patients differed extensively. Using the DN4 
(50% neuropathic pain) as well as the PainDetect (25% neuropathic pain, 38% maybe), 
some patients were likely to suffer neuropathic pain, while others did not. Unfortu-
nately, there was no good agreement between both questionnaires: only 50% of the 
patients showed agreement on DN4 and PainDetect outcomes. In one out of eight 
patients, cold intolerance was experienced assessed with the CISS, while three patients 
scored no points at all on the CISS, reflecting no reaction on cold (Table 1).
Quantitative sensory testing (QST)
The somatosensory tests in keloids showed very different results between patients. 
Cold detection, warmth detection and cold pain thresholds were more sensitive in 
some, but less sensitive in other keloid scars. The heat pain threshold was not affected 
in any keloid, and the cold or warm discrimination threshold was equal or less sensitive 
in keloids. All keloid scars had impaired mechanical detection thresholds, but mechani-
cal pain perception differed between more and less sensitive. Allodynia, pain due to a 
stimulus that does not usually provoke pain, was found in three keloid patients, and 
increased sensitivity of keloid tissue to multiple stimuli (WUR) was not a uniform find-
ing. After averaging the QST findings, overall similar or diminished sensitivity was found 
in keloid scars, compared to the control areas. However, values varied so widely that 
individual patients sometimes had completely different sensory perception (Table 1). 
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PGP 9.5-IR nerve fiber density 
PGP 9.5 stains all types of nerve fibers in the skin. In keloid scars, immunoreactive (IR) 
nerve fibers were identified in the various sections. It was noted that PGP 9.5-IR were 
easily identified in the various sections. In the keloid tissue, epidermal fibers were sparse 
and therefore not presented in all counted slides (Figure 1). 
In the keloid scar of all patients, the epidermal nerve fibers immunoreactive to PGP 9.5 
showed a significant decrease in both the center and border regions as compared to 
control skin (p<0.0001, Figure 2). 
Nerve fibers immunoreactive to PGP 9.5 in the upper dermis of the keloid center were 
significantly lower when compared to control skin. In the border region, only QST 2 
(p = 0.0015), QST 3 and QST 4 (p<0.0001) showed a significant decrease compared to 
control skin. In the other keloid scars, no significant differences in fiber density were 
found at the border (Figure 3). 
Figure 1. Micrographs of PGP 9.5-immunoreac-
tivity in the skin. 
Light micrographs showing PGP 9.5-IR nerve 
fibers in the epidermis and upper dermis in 
control skin (a), center of the keloid scar (b) and 
the border of the keloid scar (c). The dotted line 
indicates the boundary between the epidermis 
and the upper dermis. Arrowheads indicate sev-
eral of the nerve fibers that are found in the skin. 
Magnification, 20x. 
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Figure 2. Density of PGP 9.5-IR epidermal nerve fibers.
Histograms showing the number of PGP 9.5-IR epidermal nerve fibers per mm2 in the center and 
border regions of the keloid scar as com- pared to the control skin. Analysis was performed by using 
the one-way analysis of variance with a Dunnett’s post hoc test. All comparisons were made with 
the control skin (**** P<0.0001). (One-Way ANOVA). The error bars denote the mean ± SEM.
Figure 3. Density of PGP 9.5-IR upper dermal nerve fibers.
Histograms showing the number of PGP 9.5-IR upper dermal nerve fibers per mm2 in the center and 
border regions of the keloid scar as compared to control skin. Analysis was performed by using the 
one-way analysis of variance with a Dunnett’s post hoc test. All comparisons were made with the 
control skin (**P<0.01, ****P<0.0001). The error bars denote the mean ± SEM. 
In the epidermis, a higher nerve fiber density was noted in the border regions of the 
keloid scar when compared to the center regions, which was significant in all keloid 
scars except for QST 4 and 5. Whereas in the dermis, a significantly higher nerve fiber 
density in the border was found in all keloid scars.  
No correlation could be found between nociceptive sensations and nerve fiber density. 
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Discussion 
To improve our understanding of painful keloids, we explored the underlying mecha-
nism of pain in keloid patients by investigating the sensory perception and nerve fiber 
density in the present study. About half of the keloid patients reported neuropathic 
pain symptoms on the questionnaires. The DN4 classified neuropathic pain more often 
than the PainDetect. The PainDetect was developed specifically for back pain, the DN4 
to identify (malignant) neuropathic pain over the entire body. The latter could be more 
fitting to assess pain in keloid patients. 
The QST outcomes showed that in general in keloid scars, mechanical detection 
(Aβ fibers) was impaired, heat pain perception was spared (C fibers) and changes in 
temperature differentiation and detection varied (C and Aδ fibers). Unfortunately, the 
outcomes varied widely and no specific type of affected fiber or sensory modality that 
could predict the pain symptoms of keloid patients could be identified. Our QST find-
ings did not confirm previous findings of impaired cold/warmth perception and heat 
pain perception 4.  
The results on sensory perception did not even show a trend towards a specific sensory 
modality or fiber type that was affected. The perception of keloid patients was found to 
be heterogenic. In part, this may be explained by the large heterogeneity of the condi-
tion. Keloids have many phenotypes; there can be a single small lesion, or patients 
can be covered with many large keloids, appearing anywhere on the body 22. In the 
current study, all keloids were painful and most keloids were located at the chest and 
of similar size (except for patient 4 and 8), controlling some, but not all, heterogeneity. 
When comparing the five presternal keloid scars, these patients did not show similar 
perception, neither in raw values nor in qualitative evaluation. Sensory perception is 
a complex process that is hard to fathom, because multiple signaling pathways are 
involved. 
Lee et al 4 found that pain occurred more in the keloid center and itch more at the 
border. Using QST tests they compared keloids with skin next to the keloid and a 
contralateral control. They did not find differences between skin next to keloid and 
the contralateral control site. However, their probe was 9 cm2, which means a lot of 
unaffected tissue was also covered by the probe and tested, while only the skin next to 
the keloid was targeted. Although we assessed nerve fiber density in the center and at 
the border of the keloid, we measured QST on one spot of the keloid (near the border), 
because the keloid size did not allow measuring multiple sites, even with a smaller 
probe size of 2.6 cm2. 
In keloid patients, pain symptoms should be evaluated more extensively. When neuro-
pathic features are present, an anti-neuropathic pain symptomatic treatment could be 
an option. As keloids are a local problem, local therapy would be the first choice. One 
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report of botulinum toxin A (BTA) injection described a good effect on pain reduction, 
an effect that lasted longer than the motoric effect of BTA injections. Other treatment 
options could be capsaicin or lidocaine ointment. 
In the present study, a higher nerve fiber density was found in the border regions of 
keloid scars compared to the keloid center. Contradictory, Tey et al. 8 found no signifi-
cant differences in nerve fiber density between the center and border regions of the 
keloid scar. Our findings may explain the different sensations in the border and center 
regions, itch and pain respectively found by Lee et al. 4. Unfortunately, this study could 
not confirm this because itch was not measured separately. 
Intra-epidermal nerve fiber density (IENFD) is often decreased in conditions with 
neuropathic numbness (negative symptom) or neuropathic pruritus or pain (positive 
symptom) and indicates small fiber neuropathy when decreased below a certain value 
27. Moreover, Tey et al. 8 investigated 13 keloids of which nine were painful, they did not 
find a correlation between the innervation density of the keloid scar and the intensity 
of itch and pain. In another study, no differences in IENFD were found between oper-
ated and non-operated side in patients with persistent pain after thoracotomy. Based 
on these findings and other recent literature, they claim there is no correlation between 
pain perception and nerve fiber density 28. Furthermore, if a correlation between pain 
perception and nerve fiber density would exist, it can only be shown if very large 
groups are studied.
An important limitation of this study was its explorative character. We only studied a 
very small number of patients. Based on our first findings, much  larger studies should 
be developed, in order to describe a correlation in this heterogenic group. Beside the 
small groups size, another limitation of the present study was the control skin that was 
not taken from the keloid patients but from another patient, because high risk of keloid 
formation made it unethical to take a skin biopsy as control. 
In conclusion, somatosensory differences in keloid scars may show aspects of neu-
ropathic pain and are extremely heterogenic, which makes it impossible to identify 
a specific subgroup of nerve fibers that are affected in keloid disease, or to correlate 
symptoms to nerve fiber density that was uniformly decreased. Because 50% of keloid 
patients experienced neuropathic pain, future studies should evaluate which treatment 
modalities that specifically target neuropathic pain of keloids are effective and whether 
these treatments can decrease disease burden. 
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Abstract
In the 1990s, 5-fluorouracil (5-FU) was introduced as a treatment for keloids; however, 
there is still no consensus on its use. In order to guide clinical practice, a systematic 
review of the clinical evidence on the effectiveness of 5-FU in keloid treatment was car-
ried out. Eight databases were searched on 10 September 2014 using the terms “keloid” 
and “5-FU”, together with all synonyms of these terms. Two reviewers selected original 
research reports using 5-FU alone or combined with a maximum of 2 other therapies. 
Eighteen papers were found that reported either on intralesional 5-FU alone, or on 5-FU 
combined with triamcinolone acetonide (TAC:5-FU) or excision, including 482 patients. 
5-FU treatment was effective in 45–96% of patients, but only TAC:5-FU may perform 
better than TAC alone. Due to a poor level of evidence, further research should establish 
the superiority of repeated intralesional TAC:5-FU injections over TAC alone with several 
doses and injection schedules.
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Background
Excessive scarring is a burden for both patients and specialists. Keloids are painful and 
itchy and, together with their aesthetic burden, have a major impact on patients’ quality 
of life. Although they are benign lesions, they grow into healthy surrounding skin and 
resemble malignant growth patterns. There are wide differences in phenotype due 
to differences in the location, amount and size of the raised, pigmented, pruritic and 
painful lesions 1, 2. 
There are many treatments currently in use for keloids; silicone dressings are least inva-
sive, but strong and reliable evidence for its efficacy is lacking. Cortico steroid injections 
have been the mainstay of treatment, but are not effective in all cases. More invasive 
therapy, such as cryosurgery or conventional surgery with additional corticosteroids or 
radiotherapy, unfortunately has a high risk of side-effects, recurrence and deterioration 
1-4. High levels of therapy resistance, risk of recurrence, and the wide variety of treat-
ment options all mean that treatment of keloids is challenging.
The resemblance of keloids to malignant growth patterns was used in searching for 
other minimally invasive, low-risk treatments; this led us to the chemotherapeutic 
drug 5-fluorouracil (5-FU). 5-FU blocks synthesis of the pyrimidine thymidine, which is 
a nucleoside necessary for DNA replication. Scarcity of thymidine monophosphatase 
results in thymidineless death in rapidly dividing cells 5. 5-FU has already proved effec-
tive and safe in the treatment of glaucoma, another benign condition 6. 
Even though there is no consensus on its value, 5-FU is used internationally to treat 
keloids. We therefore performed a systematic literature review on the effectiveness of 
treatment of keloids with 5-FU.
Methods
In order to collect all available evidence EMBASE, MEDLINE, Web of Science, Scopus, 
CINAHL, the Cochrane Library, Google Scholar and PubMed Publisher were searched on 
10 September 2014, using the terms “keloid” and “5-fluorouracil” together with all syn-
onyms of these terms (i.e. search term EMBASE #1 Keloid: ‘keloid’/exp OR keloid*:ti,ab 
OR cheloid*:ti,ab; #2 5-fluorouracil: ‘Fluorouracil’/exp OR ‘fluorouracil’:ti,ab OR ‘5 
fluorouracil’:ti,ab OR ‘5fluorouracil’:ti,ab OR ‘5 FU’:ti,ab OR ‘5FU’:ti,ab OR Adrucil:ti,ab OR 
Carac:ti,ab OR Efudex:ti,ab OR Fluoroplex:ti,ab; #3: #1AND#2).
Original research reports of randomized controlled trials (RCTs), prospective clinical trials 
and case series involving keloid treatment using intralesional 5-FU alone or combined 
with a maximum of two other therapies were included. We put no limitations on the 
date of publication, the age, gender, ethnicity of study participants, or the duration of 
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disease. Exclusion criteria were: case reports (n ≤ 2), animal studies, studies combining 
more than three different treatments, and language other than English.
First, two reviewers (SS, EB) independently assessed the titles and abstracts of potentially 
eligible studies. In cases of no agreement, a third reviewer (FBN) decided whether the 
article should be selected. Two reviewers independently extracted data from full-text 
copies of all selected studies. To identify other relevant studies, the reference lists of all 
included studies were examined (Figure 1).
We extracted patient characteristics, treatment protocol, and outcomes that were 
reported as recurrence rates, the percentage of observer-rated reduction or improve-
ment, the percentage of patient-rated improvement, and the presence of side-effects. 
The outcomes were converted into 5 levels: no response; 1–25% as poor; 26–50% as 
fair; 51–75% as good; and 76–100% as excellent improvement or flattening of keloids. 
The quality of included studies was assessed on the basis of reproducibility and study 
design.
Results
The literature search identified 284 references to keloid and 5-FU. After the selection 
process, 18 articles were included for critical appraisal. Two papers reported on the 
same cohort of patients; 1 of them was excluded 7, 8. The other reasons for exclusion 
are given in Figure 1. Among the references of the included articles no new original 
research papers were found.
In 1999, Fitzpatrick was the first to report on his wide experience with 5-FU in keloids, 
although not in a scientific setting 9. His publication prompted others to start collecting 
evidence. A total of 482 patients participated in 17 studies dating from 2001 to 2014. 
These studies examined several different methods of treatment with 5-FU. To evaluate 
the efficacy of 5-FU, we used the outcomes of 3 types of treatment: intralesional 5-FU 
alone, 5-FU combined with triamcinolone acetonide (TAC), and excision with 5-FU with 
or without TAC (Tables 1 and 2).
5-FU efficacy in keloid treatment
The use of intralesional 5-FU alone achieved a good or excellent outcome in 45–78% 
of patients. Only one patient was reported as a complete non-responder. Injections 
with 5-FU and TAC resulted in 50–96% good or excellent outcomes, and neither 
non-responders nor recurrence were reported. 5-FU was reported as less, as well as 
more, effective in direct comparison with TAC. Sadeghinia & Sadeghinia 10 who used 
TAC tattooing, an uncommon method of administration, showed better results with 
5-FU than with TAC. Prabhu et al. 11 showed better volume reduction with TAC, also 
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more pain reduction and less adverse  events, although the last 2 were not significant. 
Saha & Mukhopadhyay 12 showed comparable size reduction and recurrence rates, but 
less pain reduction and more adverse events in the 5-FU group. The combination of 
5-FU and TAC (TAC:5-FU) proved more effective than 5-FU alone 13. Also, TAC:5-FU was 
more or equally effective and resulted in fewer adverse events than TAC alone 8, 14, 15. 
Most authors reported no recurrence of disease, while others reported recurrence in 
no less than 25–47% of patients (Table 1). Excision with 5-FU achieves a good result, 
with recurrence rates between 4–19% 16-20. Keloid-free outcome after excision was 43% 
and after excision with 5-FU 75%, when TAC:5-FU was used after excision keloids were 
reduced by 92% 16, 17, 20 (Table 2). A correlation between duration of keloids and treat-
ment response, where younger keloids respond favourably, was found in 2 studies 21, 22, 
while others did not find this correlation 23.
5-FU treatment protocols
Fitzpatrick 9 tried different injection intervals and recommended starting with once-
weekly injections, advice which many others followed 8, 11-14, 17, 21-23. Others used 2- or 
4-week intervals 10, 15, 16, 24, 25 or only once around surgery 18-20. The outcomes do not 
indicate a preference for a specific injection-interval. Where serial injections were used, 
6 studies used 3–6 injections and 8 used 8–16.
None of the authors reported serious side-effects. Six studies found no side-effects at 
all 8, 10, 14, 17, 24, 25. Reported were purpura (20-40%), ulceration (1-65%), and transienthy-
perpigmentation (90%) 9, 11, 12, 15, 21-23. In 6 surgical studies complications of necrosis, wide 
scars (14%) and dehiscence (1–18%) were rarely found 18, 20. No systemic reactions were 
found after local injection 8-10, 12, 17, 21, 22, 24.
Without exception the manufacturer concentration of 50 mg/ml was used when 5-FU 
was used alone. Mild side-effects, due to local toxicity advise against using higher 
concentrations. Lower concentrations would require more volume for the same active 
dose, which increases pain on injection. In combination therapy, the TAC concentra-
tions were very low (TAC:5-FU of 1:45 mg/ml or 4:45 mg/ml); only Davison et al. 16 tested 
TAC:5-FU in 10:37.5 mg/ml and noticed more side-effects than they had with TAC (23% 
vs. 15%, not significant).
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Discussion
This systematic review indicates that the combination of TAC:5-FU may be more effec-
tive than TAC alone in keloid treatment (level C evidence). After keloid excision, 5-FU 
reduces recurrence rates to 4–19%, both on its own and in combination with TAC.
Our literature search resulted in a remarkably high number of reviews (126 of 284 pa-
pers), most of which were mainly on scar or pathological scar treatment, and mentioned 
5-FU only in passing. Due to the unambiguity of our search terms the risk of missing 
relevant publications was minimal, as reflected by the absence of additional includes 
in our reference check. There were, however, several papers in the Asian literature that 
were not in English or that we could not retrieve.
The level of evidence was poor, there were 10 RCTs 8, 10-17, 19, some of which were un-
fortunately executed very poorly, 4 prospective single-arm trials 16, 18, 20, 25, 4 case series 
and an expert opinion 9, 21-24. The problems included a lack of definitions, suboptimal 
study designs and follow-up periods. The studies we found on the novel treatment 
5-FU were small, wherefore the good efficacy reported at first is probably influenced by 
publication bias. More recent studies on 5-FU are less positive in their results 11, 12.
Due to the large heterogeneity between studies, a meta-analysis could not be per-
formed. This is reflected in the lack of a good definition of keloids in 11 of the 18 articles. 
Here less severe hypertrophic scars could be included that positively influence the 
results 8, 15, 26-28. Similarly, outcome measurement technique was poorly described, and 
outcomes were classified in wide ranges (“good result” or “improvement 75–100%”). 
This forced us to do the same 12-25.
With intralesional 5-FU a good to excellent response was found in 45–79% of treated 
cases, and even up to 96% if TAC was added. It is unclear what caused the lowest 
response (45%) 22: it cannot be explained by dose, follow-up time, or number of injec-
tions. The wide range of effectiveness we found is recognized from research on intral-
esional corticosteroid use alone, where a 50–100% response is reported 3. A favourable 
response was seen in small and previous untreated lesions; this phenomenon is also 
known in other keloid treatments 2, 21, 22.
Recently the synergetic effect of TAC and 5-FU was proven in an in vitro study on keloid 
fibroblasts 29. Although the evidence is weak, TAC:5-FU is more effective than 5-FU alone 
and seems to have advantages over TAC alone. The beneficial results of TAC:5-FU com-
pared with TAC are, however, highly dependent on the dose and injection scheme of 
TAC and TAC:5-FU. Khan et al. 14 used low concentrations of TAC, which are less effective 
in keloid treatment, and weekly injections, that due to the long duration of action of 
TAC might cause more atrophy. For TAC:5-FU there is very little evidence on the efficacy 
and safety of TAC concentrations greater than 4 mg/ml, therefore we recommend the 
most frequently used and investigated concentration of 4:45 mg/ml TAC:5-FU. There 
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is insufficient evidence for a statement on the maximum allowed dose in total or per 
scar-surface area.
Weekly injections are mostly used; therefore most evidence is based on this injection 
interval. Although Fitzpatrick 9 states that longer intervals are less effective, this is not 
reflected by the studies we present. However, none of the studies directly compared 
different injection intervals. Also, the number of injections varied widely between stud-
ies (1–16) without a clear correlation with the outcome. When more injections were 
allowed clinical evaluation was used to determine the need for additional treatment.
Even though keloid recurrence is a major problem, some studies fail to report recur-
rence rates. Others have less than a year follow-up period, which is too short to draw 
a valid conclusion on recurrence rates 8, 10, 11, 14-16, 19, 21, 23, 30. Five studies (follow-up 13–52 
weeks) remarkably found no recurrence 13-15, 21, 23. Higher recurrence rates of 25–47% 
were found after 52 weeks or longer follow-up 12, 22, 25. The low recurrence risks found 
can be partly explained by the inclusion criteria or study designs, many studies selected 
patients with more favourably characteristics than the keloid-patient group that is usual 
in most clinics.
Conclusions
Based on this systematic review, we recommend 4:45 mg/ml TAC:5-FU combination 
therapy, injected intralesionally, until a satisfactory response is reached. It is likely that 
approximately 8 injections are needed. However, in order to formulate valid clinical 
guidelines on how to use TAC:5-FU in keloid treatment, more high-level clinical evi-
dence is needed. This will help to establish preferred doses and injection schedules.
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Abstract
Background  Keloids are a burden for patients due to physical, aesthetic and 
social complaints and treatment remains a challenge because of 
therapy resistance and high recurrence rates. The main goal of 
treatment is to improve the quality of life (QoL); this implies that, 
apart from surgical outcomes, patient-reported outcome mea-
sures (PROMs) need to be taken into account. Decision making in 
keloid treatment is difficult due to heterogeneity of the condition 
and the lack of comparative studies.
Methods/Design  This is a multicentre, randomised controlled open trial that 
compares 1) intralesional cryotherapy versus excision and cor-
ticosteroids for primary keloids, and 2) intralesional cryotherapy 
versus excision and brachytherapy for therapy-resistant keloids. 
The primary outcome is the Patient and Observer Scar Assess-
ment Scale (POSAS), a 12-item scale (with score 12 indicating the 
best and 120 indicating the worst scar imaginable). A difference 
of six points on the total score is considered to be of clinical 
importance. Secondary outcomes are recurrence rates, volume 
reduction, Skindex-29 scores, SF-36 scores and complication 
rates. Primary and secondary outcome measurements are taken 
at baseline, and at 2, 12, 26 and 52 weeks postoperatively. For 
analysis, a linear mixed model is used. A total of 176 patients will 
be included over a period of 2.5 years. The protocol is approved by 
the Medical Ethics Committee of the Erasmus University Medical 
Centre Rotterdam and follows good clinical practice guidelines.
Discussion  The outcomes of this study will improve evidence-based decision 
making for the treatment of keloids, as well as patient education.
Trial registration Dutch Trial Register NTR4151.
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Background
Keloids are pathologic scars that grow beyond wound borders and act as a benign 
tumour. The physical, aesthetic and psychological complaints that they cause are of 
great concern 1, 2. 
After injury, the skin heals by forming a scar. Dysregulation of signalling molecules in 
the complex healing process can result in keloid formation, with several times more 
collagen synthesis than for normal skin and normotrophic scars, and a higher ratio of 
type 1 to type 3 collagen 3-7. The etiology of keloids remains unknown. Although it is 
suggested that a relation exists with wound tension, sex hormones, sebaceous gland 
activity, melanocyte concentration and overlying keratinocytes, as well as with genetic 
predisposition, no single theory has proven of value in all aspects of keloids 8-12. The 
highest incidence is seen in patients with a dark skin tone, whereas Mediterraneans, 
South Americans, and Asians are slightly less affected, and Caucasians are the least 
affected (<1%) 2, 12, 13. It was shown that scars give acceptability problems (91%) and 
influence social functioning (82%) in a mixed group of scar types that were mainly 
on visible body sites 1. At least as much problems can be expected for patients with 
keloids, as keloids are often visible on earlobes or so large that they are visible through 
clothing. Besides this major psychosocial burden, keloids give rise to pain and pruritus 
in 80% of keloid patients 1, 2.
Treatment of keloids is challenging because of therapy resistance and high recurrence 
rates, resulting in the search for more treatment options for keloids. Over decades, 
systematic reviews included zero to only three randomised controlled trials per treat-
ment option, with a lot of heterogeneity between the studies 2, 14, 15. In the absence of 
sufficient numbers and methodologically sound randomised trials, no consensus for a 
treatment of first choice has been reached.
In our clinical practice a ‘stepped-care approach’ is generally used; that is, initially, the 
least invasive and safest treatments are used, which are changed to more radical treat-
ments in case of resistance or recurrence.
Because keloid is a benign condition, the main treatment goal should be to relieve the 
burden, which consists mainly of pruritus, pain and aesthetic complaints; all these are 
subjective symptoms. To objectively measure subjective burden (that is, in a reproduc-
ible way) the effects of the treatment options should be assessed using validated scar 
assessment scales and patient-reported outcome measures (PROMs), in addition to 
surgical results such as volume reduction, recurrence and complication rates.
In our centre, the ‘stepped-care approach’ implies that the first step is generally conser-
vative treatment with corticosteroid injections. Other conservative methods, like laser 
therapy and silicone occlusive dressings, have not proven to achieve patient satisfac-
tion in keloid treatment as is clear from recent systematic reviews 14-17. If keloids are of 
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such a size that conservative treatment may not be sufficient, the next step is surgical 
treatment.
Because excision as monotherapy gives a recurrence rate of ≥70%, an adjuvant treat-
ment should be used. The most frequently used adjuvants are corticosteroid injections, 
pressure therapy and brachytherapy (interstitial radiotherapy) 14, 18. Another surgical ke-
loid treatment option that gained popularity some years after several case series were 
published, is intralesional cryotherapy 19-21. As no trials have compared intralesional 
cryotherapy with established conventional therapies, we aimed to explore the position 
of intralesional cryotherapy in the ‘stepped-care approach’.
Objectives
Beginning in November 2012, we initiated a randomised clinical trial in which we 
compare frequently used keloid therapies in the Netherlands: excision and intralesional 
steroid injections, excision and brachytherapy, and intralesional cryotherapy. Outcomes 
are surgical results and PROMs. The results will assist in producing a better ‘evidence-
based’ treatment algorithm for keloid patients.
Methods
Trial design
The design is a multicentre, randomised controlled open trial, which used minimisation 
to control for skin type, location and duration of disease. The trial consists of two parts: 
one for primary keloids and one for resistant keloids. Primary keloids are keloids that 
have not been surgically treated and, to some extent, have responded to corticoste-
roids. Resistant keloids are keloids that recurred after excision or those that did not 
respond to corticosteroids (progression within six weeks after corticosteroid injection).
For the primary keloids we randomise between either intralesional cryotherapy or 
excision and additional corticosteroids. The resistant keloids are randomised between 
either intralesional cryotherapy or excision and brachytherapy. Follow-up assessments 
are in weeks 2, 12, 26, and 52 post-treatment. The follow-up period is based on scar 
maturation, which lasts about one year, and the chance of recurrence that usually oc-
curs within the first year 22, 23.
Patient recruitment
Patients who present with a keloid at an outpatient clinic of the four participating 
centres are considered for the study. A keloid is a clinical diagnosis and is distinguished 
from hypertrophic scars by the clinician’s judgement. The judgement between hyper-
trophic scars and keloid is based on: the growth history, starting early versus late after 
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trauma, remaining stable versus still growing; shape, following initial lesion versus not 
following the initial lesion; and size, <0.5 cm versus >0.5 cm beyond the original lesion.
At a later stage, we will report how many patients with keloids were seen and how 
many were eligible for the study. 
Inclusion criteria are:
1. Keloid with a surgical indication.
2. One to three keloids that can be treated in one session.
3. Minimal size of 1 × 1 cm.
4. Suitable for excision and primary closure.
5. Patient aged between 18 and 75 years.
6. Fully mentally competent.
7. Sufficient knowledge of the Dutch or English language.
Exclusion criteria are:
1. Hypertrophic scars.
2. Scars after burn wounds.
3. Keloids less than one year old.
4. Pregnancy.
5. Use of systemic chemotherapeutics or chronic use of systemic corticosteroids or 
immunosuppressive medication.
6. Hypersensitivity for local anaesthetics, adrenaline, or triamcinolone (primary keloids).
7. Patients not sufficiently fit for brachytherapy (resistant keloids).
8. Severe comorbidity with life expectancy under one year.
Consent procedure
At the first outpatient visit, eligible patients are informed about the study by a member 
of the research staff and written information is provided. After a consideration period 
of at least two weeks, the patient is contacted and registered in the study database 
when the patient wants to participate. Before treatment, a witnessed, written informed 
consent is obtained from all participants, following the guidelines of the local ethical 
committee.
Randomisation (treatment allocation)
Previous studies on keloid treatment showed that specific characteristics are predictors 
of recurrence. Therefore, we want to assure homogeneity between treatment groups 
regarding these characteristics, such as duration of the keloid existence (dichotomous; 
<5 years or ≥5 years) and location of the keloid (categorical; sternal region, auricular 
region and other). In addition, we try to match for skin type because of the strong asso-
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ciation with the development of keloids, but the doubtful relation with recurrence rate 
(categorical; Fitzpatrick type 1 and 2, type 3 and 4, type 5 and 6). Because of the many 
different strata that would be formed and considering the total number of patients to 
be included, we choose not to use permuted blocks but will use the more sophisticated 
technique of minimisation. We will minimise on the three factors previously mentioned. 
The allocation of a new subject is determined by the allocation of the subjects already 
enrolled. We apply a 20% random chance factor to keep allocation predictability at a 
minimum. The software used is the open source program MinimPy (http://minimpy.
sourceforge.net/).
When a patient agrees to participate in the study they irrevocably receive a unique 
identification number, which cannot be changed or removed from the database. After 
completion of baseline measurements, treatment allocation is conducted through a 
central computerized allocation using the locked database for all participating centres. 
Then the physician and the patient are informed of the assigned condition and the 
treatment is planned. In this way, allocation concealment is guaranteed.
Trial interventions
Excision with additional corticosteroid injections
Extralesional excision is performed with minimal margins, and absorbable mono-
filament sutures or permanent monofilament sutures are used for closure (Monocryl™, 
Ethilon™, Ethicon Inc, Somerville, NJ, USA). Surgery is performed by either surgical 
residents who have three years minimum experience, or by plastic surgeons. This 
standardised surgical procedure is not demanding, and we expect no learning curve. 
Many different surgeons (>20) reflect usual clinical practice in keloid treatment. After 2 
weeks, an injection of triamcinolone acetonide 40 mg/ml is given in the newly formed 
scar. The injections can be repeated at 8 and 12 weeks postoperatively.
Excision with additional brachytherapy
Extralesional excision is performed with minimal margins, and absorbable monofilament 
sutures or permanent monofilament sutures are used for closure (Monocryl™, Ethilon™, 
Ethicon Inc, Somerville, NJ, USA). During the procedure, brachytherapy catheters are 
placed direct subcutaneously in order to cover the affected area. Next, a target dose of 
600 to 900 cGy is given followed by one or two doses on the day of operation or the day 
after. After completion of brachytherapy, the catheter is removed 24. 
Intralesional cryotherapy
The Cryoshape needle (Etgar Group International, Kfar Saba, Israel) is positioned in the 
centre of the keloid to guarantee total coverage of the keloid when it is visually frozen. 
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If necessary the Cryoshape needle is repositioned to achieve this. Our procedure dif-
fers slightly from Har-Shai  et al. as we administer lidocaine with epinephrine around 
the keloid instead of intra- or translesional infiltration 21, because in our experience 
injecting through the keloid can be difficult and unnecessary painful for the patient. 
The cryotherapy can be repeated after three months if the desired effect has not been 
achieved.
During the study follow-up patients are not allowed to use additional keloid treat-
ments. If treatment was not effective other treatments will be performed after at least 
26 weeks follow-up. Follow-up measurements will continue as planned and patients 
will receive a request for an additional follow-up measurement 52 weeks after the ad-
ditional treatment.
Blinding
Neither physicians nor patients are blinded for treatment. They cannot be blinded due 
to surgery under local anaesthesia and differences in postoperative selfcare instruc-
tions. Furthermore, during the follow-up assessments, a physician or layperson would 
immediately recognize the treatment type by the resulting wound or scar.
Safety concerns
Treatments applied in the current study are conventional rather than experimental. The 
hospital’s local safety procedures are followed. Possible side-effects are treated accord-
ing to current best practice. No serious adverse events are expected; however, these 
will be reported to the Medical Ethics Committee supervising this study and registered 
with EudraVigilance within two weeks after the investigator is notified of such an event.
The protocol is approved by the Medical Ethics Committee of the Erasmus University 
Medical Centre Rotterdam and follows good clinical practice guidelines and current 
Dutch legislation.
Outcomes
Our primary outcome measure is the Patient and Observer Scar Assessment Scale (PO-
SAS), a 6-item patient questionnaire and a 6-item observer questionnaire. The patient 
and at least two observers (clinician and investigator) will independently assess the 
scar. The scores of the patient will range from 6 for the best imaginable scar to 60 for the 
worst scar imaginable, which is a PROM, the average of the observers scores will also 
range from 6 to 60. The score of the patient and observers will be added to form the 
total score that is our primary outcome, but the scores will also be analysed separately. 
A difference of six points on the total score is considered to be of clinical importance. 
The POSAS is a sensitive instrument that includes both physician and patient opinions 
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of the scar, it has been previously validated, and performs well in a population of mostly 
dark-skinned keloid patients 25-29.
When one or two of the 12 POSAS items are missing at baseline we imputed the mean 
of the other scores of the same assessor. When a follow-up item was missing we im-
puted the last value carried forward. In cases where an item of the second observer was 
missing, we imputed the score of the first observer on the same item.
Secondary outcomes are keloid volume measured using a plaster mold, made before 
treatment, after the skin had completely healed at 12, 26 and 52 weeks. Time to recur-
rence is determined; the physician assesses recurrence at each follow-up visit; and, in 
case of recurrence, the patient is asked how many weeks after treatment the keloid 
recurred. As well as the diagnosis of keloid disease the diagnosis of keloid recurrence is 
a clinical diagnosis based on new growing scar tissue with features of keloid disease as 
described earlier. Photographs are taken at all visits, which will be used for additional 
(partial) observer scores on the POSAS and recurrence assessments. The additional 
observers will reduce bias in these outcomes. For assessing quality of life (QoL) we 
use a disease-specific and a general instrument: the Skindex-29 and the Short Form/
RAND-36 (SF-36), respectively. The Skindex-29 was originally developed for psoriasis 
patients. It consist of 29 questions concerning symptoms, emotions and functioning 
and is, therefore, also suitable for other skin conditions. Questions are rated on a 5-point 
Likert scale. Scores range from 0 to 100, with 0 indicating no compromise on quality of 
life. A score ≥40 indicates a significant negative influence of the skin condition on QoL 
30, 31. Worldwide, the SF-36 is the most frequently used general QoL questionnaire. It 
consists of 36 questions (scored on a Likert scale) addressing eight dimensions (vitality, 
physical functioning, bodily pain, general health perceptions, physical role function-
ing, emotional role functioning, social role functioning, mental health). The dimension 
scores are transformed to a 0 to 100 score, with a higher score indicating a higher QoL 
32, 33.
We will also analyse single item scores of our primary outcome measure POSAS, espe-
cially itch and pain from the patient questionnaire, and items on skin colour, pigmenta-
tion and vascularisation.
Data collection
Data are collected at baseline, before randomisation, and at follow-up assessments 2, 
12, 26, and 52 weeks after treatment. The questionnaires are preferably filled out online, 
although a paper version is also available. All paper questionnaires are scanned and 
stored on a secure disk. The online questionnaires are saved by the online question-
naire program, and a backup is made regularly.
Photographs are taken at all visits. Volume of the keloid is measured at baseline and 
after the skin has completely healed at 12, 26, and 52 weeks after treatment.
109
Cryotherapy vs Excision with Adjuvant in Keloid Treatment - RCT protocol
6
Statistical analysis
Baseline demographic and clinical characteristics will be presented as proportions or 
means and standard deviations (SD) where appropriate. Because of the longitudinal 
data with multiple influencing factors, a sophisticated model is necessary. Mixed mod-
els (also called multilevel linear regression analysis) is a technique that efficiently uses 
longitudinal data and can work with patients’ data even though measures at certain 
time points may be missing.
The units of analysis are the repeated measurements of the patient (first level), not 
the keloid, because we use several QoL measures that are not measurable for the unit 
keloid. The second level will be the individuals participating in the study. If necessary, 
a third level of subgroups with specific characteristics (skin type, duration of keloid 
disease and location of the keloid) can be added. If the third level is shown to improve 
the fit of the model, it will be incorporated in the model. We will use backward elimina-
tion and start with an unstructured covariance structure for intercept and time (slope). 
Simplifications of the random part of the model will be tested using the deviance 
statistic with restricted maximum likelihood. For the fixed part we will postulate a satu-
rated model. We take in account time, logarithm of time and squared time, treatment 
condition and its interactions with time. Nonsignificant effects will be excluded using 
Wald tests. The fit of the final fixed model will be compared with the saturated model 
and will be checked using ordinary maximum likelihood. When characteristics like sex, 
age, skin type, duration of keloid disease and location of the keloid make a significant 
contribution to the model, they will be incorporated in the model 34-37. Differences 
between treatment effects will be expressed in terms of effect sizes, standard errors 
and  P  values. Effect sizes will be calculated by dividing the estimated differences by 
the estimated standard deviation. An effect size of 0.20 is considered a small effect, 
0.50 a medium effect and 0.80 as a large effect 38. All analyses will be performed on 
an intention-to-treat basis. IBM SPSS version 21.0 and SAS version 9.3 will be used to 
perform the analyses.
Sample size calculation
There are no meaningful rules of thumb to estimate the sample size needed for a mixed 
models analysis, because, with random and fixed effects estimations, too many factors 
of uncertainty are involved. Therefore, a standard sample size calculation with a correc-
tion for the design effect based on the intercorrelation was used.
These calculations were performed in SPSS version 20.0 using the mixed-model ANOVA 
procedure as described by Aberson 39. Type 1 error (alpha) was set at 0.05, and power 
(1-beta) on 0.80.
To estimate the effect size and correlation we analysed data of a natural cohort col-
lected by one of the authors (FBN) containing general features of keloid patients and 
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POSAS values before and after treatment with intralesional cryotherapy. This natural 
cohort contains measurements at baseline, and at 12, 26, and 52 weeks after treatment. 
It comprised POSAS observer values from one or two observers and patient values; 
however, many patients lacked values for some time points (56% of follow-up com-
plete). Only a small amount of items were missing, in total 15/3378 (0.44%) items of the 
POSAS data were imputed following the rules described previously.
The assumed medium-sized effect of 0.5, based on a SD of around 15 (Table 1), cor-
responds to 7.5 points on the POSAS scale; this is slightly more than the 6 points that is 
regarded as a clinically significant difference. We assumed a correlation of 0.75 between 
time points; this was difficult to verify in the data of the natural cohort because of many 
incomplete cases.
Table 1. Descriptive statistics
N Minimum Maximum Mean SD
POSAS baseline 73 30 93 60.45 12.276
POSAS 12 wk post op 44 18 85 50.65 15.474
POSAS 26 wk post op 46 17 83 49.23 15.854
POSAS 52 wk post op 33 24 81 46.18 13.959
POSAS overall 196 17 93 53.32 15.20
POSAS = Patient and Observer Scar Assessment Scale score; Wk = weeks; post op = postoperative
The analysis, based on the observed SD and expected correlation and effect size, re-
sulted in a group size of 33 patients, taking into account a 25% loss to follow-up and the 
four treatment groups; this results in a total sample of 176 subjects.
No interim analysis is planned because we do not expect any severe side-effects and, 
by the time a sufficient part of the participants has finished follow-up, almost all par-
ticipants will have had their intervention. No rules related to stopping/withdrawal from 
the study have been specified.
Ethical issues
The risks of undergoing surgical treatment include complications due to undergoing 
anaesthesia and surgery; however, these risks are equivalent to the risks of surgical 
treatment without participating in the study. Only patients not responsive to conser-
vative treatment and who opt for surgical treatment, despite knowing the risks, are 
enrolled in the trial.
Anticipated benefit for the medical world is improved outcome for future patients. The 
results will improve decision making, helping evidence-based guidelines to be devel-
oped for keloid treatment. We aim to determine the place of intralesional cryotherapy 
in the ‘stepped- care approach’ (that is, whether it should be used as second step, be 
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added as an extra step, or has no place at all in the treatment of keloids). If cryotherapy 
is shown to be effective for resistant keloids, then savings can be made by avoiding the 
costly brachytherapy treatment. If cryotherapy is not effective, the patient will receive 
appropriate treatment sooner.
Time frame
We will include patients over a period of 2.5 years and will follow every patient for one 
year, resulting in a total study period of 3.5 years.
Discussion
We have described a trial protocol; this is becoming standard practice when conduct-
ing clinical trials, although surgical trials are somewhat behind medical trials. The 
importance of publishing an extensive protocol is that it addresses questions (that may 
not be answered in the Methods section due to limited space) that might arise on how 
the trial was organised after publication of the results. It also prevents publication bias 
due to inconclusive or negative results. This will be the first randomised controlled trial 
comparing surgical keloid treatments using validated PROMs.
We have presented the problems with power analysis and sample size calculations 
for a more complex but sophisticated statistical model. In this corrected analysis we 
did not rely on assumptions only, but used previously collected data to determine the 
effect size and intercorrelation. The effect size we have chosen is a conservative one in 
order to ensure clinical relevance. When the effect size appears in fact to be smaller, we 
expect to be underpowered. Due to the quantity of work involved in logistics and data 
collection, we made this decision despite the risk of a negative result.
Trial status
At the time of submission of this protocol (August 2013), this study was recruiting 
patients to participate in the study.
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Abstract 
Background  Keloids are a burden for patients due to physical, aesthetic and social 
consequences. Treatment remains a challenge due to therapy resis-
tance and high recurrence rates. The main goals of treatment are to 
improve scar appearance and symptoms and patients’ quality of life 
(QoL).
Methods  A multicentre, randomized controlled open trial that compared 1) 
intralesional cryotherapy with excision and corticosteroid injections 
for primary keloids, and 2) intralesional cryotherapy with excision and 
brachytherapy for therapy resistant keloids. Primary outcome was scar 
appearance assessed with the Patient and Observer Scar Assessment 
Scale. Secondary outcomes were patient reported QoL (Skindex-29, 
SF-36, EQ-5D-5L), recurrence rates and scar volume reduction. For 
analysis, a linear mixed model was used. Power analysis indicated 33 
patients in each group were needed.
Results   The trial was prematurely terminated after inclusion of 26 patients 
due to unexpectedly inferior outcomes after intralesional cryothera-
py. To increase statistical power both surgical treatments combined 
were compared with intralesional cryotherapy. Excision followed by 
corticosteroid injections or brachytherapy improved scar appearance 
and scar symptoms significantly while cryotherapy did not (p<0.001 
and p=0.005, respectively). No statistically significant improvement in 
QoL was observed after both treatments.
Conclusions  Intralesional cryotherapy is inferior to keloid excision followed by 
brachytherapy for resistant keloids. In primary keloids, intralesional 
cryotherapy resulted in mild keloid improvement and, therefore, may 
be used in these patients and specific cases. However, further re-
search on the efficacy of intralesional cryotherapy for primary keloids 
is warranted.
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Background 
Keloids cause a burden on health related quality of life that justifies adequate treatment 
1, 2. Both patients and physicians are challenged due to therapy resistance and keloid 
recurrences. Current opinion is that treatment should follow a stepped care approach 
from conservative, non-invasive treatment to surgical treatment followed by adjuvant 
treatment in case of unsatisfactory results 3, 4. In 2003 a new application of cryotherapy 
for treatment of keloids was introduced by Har Shai et al. 5, after which no recurrences 
were reported. Also, in several other studies equally promising and remarkable results 
were found for both primary and recurrent keloids 6-8, suggesting this treatment could 
replace surgical treatment. 
Because intralesional cryotherapy previously had not been compared directly to 
other treatments, we designed a randomized controlled trial to compare outcomes 
of intralesional cryotherapy to excision and adjuvant treatment, starting inclusion in 
2012 9. Since the start of our trial three studies have been published on intralesional 
cryotherapy, which showed results inferior to the first reports, however, outcomes were 
still reasonable with recurrence rates of 12%, 17%, and 24% 10-12. 
During the course of the present trial patient inclusion was difficult and we unexpect-
edly encountered strikingly inferior outcomes following cryotherapy. Therefore, after 
careful consideration we decided to stop further enrolment of the trial. In the current 
report we present the results of this terminated randomized controlled clinical trial.
Methods
A randomised non-blinded clinical trial was designed to compare intralesional cryo-
therapy to extralesional keloid excision followed by adjuvant treatment divided in two 
groups: 
•	 For primary keloids (not previously treated with surgery) we compared intralesional 
cryotherapy to excision followed by adjuvant triamcinolone acetonide injections. 
•	 For resistant keloids (recurrence after previous surgical treatment or refractionary 
to corticosteroid injections) we compared intralesional cryotherapy to excision fol-
lowed by brachytherapy. 
Adult patients were eligible if they had a burdensome keloid that had not responded 
well to minimally invasive treatment and, therefore, had an indication for excision. Ke-
loids had to be minimally 1 by 1 cm, and feasible for primary closure after excision. The 
trial started at two University Medical Centres, during the trial two other centres were 
added. Treatment allocation was conducted through a central computerised allocation. 
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The trial was approved by the local institutional review board (IRB) and all patients gave 
written informed consent.
Treatments
Excision with additional corticosteroid injections: Extralesional excision was performed 
with minimal margins. After 2 weeks, an injection of triamcinolone acetonide 40 mg/
ml was given in the newly formed scar. If needed, the injections were repeated at 8 and 
12 weeks postoperatively.
Excision with additional brachytherapy: Extralesional excision was performed with 
minimal margins. During the procedure, brachytherapy catheters were placed subcu-
taneously in order to cover the affected area. A target dose of 9 Gy was given followed 
by a second dose on the same day. After completion of brachytherapy, the catheter 
was removed.
Intralesional cryotherapy: The Cryoshape needle (Etgar Group International, Kfar Saba, 
Israel) was positioned in the centre of the keloid to guarantee total coverage of the 
keloid during treatment. When necessary the Cryoshape needle was repositioned. The 
treatment was repeated once after three months when the desired effect has not been 
achieved.
If treatment was not effective, choice of another treatment was allowed after at least 
26 weeks follow-up. 
Outcomes
Primary outcome was scar appearance, assessed with the Patient and Observer Scar 
Assessment Scale (POSAS) score, ranging from 12 to 120 and including a six item 
patient (PSAS) and a six item observer (OSAS) part with separate item scores ranging 
from 1 (resembling normal skin) to 10 (worst scar imaginable) 13, 14. Based on a clinical 
significant difference of 6 points and a standard deviation of 15 we aimed at a size of 33 
patients per treatment arm 9. 
Secondary outcomes were patient reported quality of life (QoL), assessed with the 
disease specific instrument Skindex-29, and generic SF-36, and EuroQol 5D (EQ-5D-5L) 
15, 16. Skindex-29 is a reliable and validated self-report questionnaire of 29 items with 
subscales for symptoms, emotions, and functioning and a sum scale 17, 18. Questions 
are rated on a 5-point Likert scale. Scores range from 0 to 100, with 0 indicating no 
compromise on QoL and a score ≥ 40 indicating a significant negative effect of the skin 
condition on QoL. SF-36 is a reliable and validated self-report questionnaire with 36 
questions addressing eight dimensions of QoL and with a physical and a mental com-
ponent score (PCS and MCS) 19, 20. The scores are transformed to a 0 to 100 score, with 
a higher score indicating a higher QoL. EQ-5D-5L is an outcome measure that is often 
used in health-economics. It has five questions on mobility, self-care, usual activities, 
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pain/discomfort, and anxiety/depression scored on a 5-point scale. All possible answer 
combinations correspond to a single number, where 1 corresponds to perfect health 
and 0 to death 16. 
Other secondary outcomes were scar volume reduction measured by plaster mould-
ing, and pain and itch symptoms that were reported as separate items in the PSAS. We 
measured at baseline, 2, 12, 26 and 52 weeks after treatment. 
Statistical Analyses 
Baseline demographic and clinical characteristics are presented as percentages and 
means with standard deviations (SD) and ranges where appropriate. The surgical and 
intralesional cryotherapy groups for primary and resistant keloids were merged because 
of small group sizes. For each outcome a mixed model (multilevel linear regression 
analysis) was used. The repeated measures in a patient were the first level, the second 
level were the patients. The covariance structures for intercept and time (slope) were 
tested using the deviance statistic with restricted maximum likelihood. The fixed parts 
of the models included time, logarithm of time and squared time, treatment condition 
and its interactions with time 21-23. Characteristics like sex, age, skin type 24, duration of 
keloid disease, keloid type (primary or resistant) and location of the keloid were tested 
whether they made a significant contribution to the models. Differences between treat-
ment effects are expressed in terms of effect sizes, and p-values. Per protocol analyses 
were performed with IBM SPSS version 22.0.
To confirm that scar symptoms (pain and itch) had a strong effect on QoL, as previously 
reported by our group 1, Spearman correlations between differences in scar symptoms 
(pain and itch scores), aesthetic outcomes (patient reported scar colour, thickness, stiff-
ness, and irregularity scores), and differences in QoL measures (Skindex-29, SF-36, and 
EQ-5D-5L) were calculated. 
More detailed information on methods is available in a previously published study 
protocol 9.
Results
During the inclusion period 179 consecutive keloid patients with an indication for 
surgery were referred to the participating centres. Using the inclusion criteria, 74 were 
eligible for our study, but only 26 patients gave informed consent for randomisation. 
Many patients expressed strong treatment preferences withholding them from trial par-
ticipation. Ten patients with primary keloids were included of whom five were allocated 
to keloid excision and corticosteroid injections and five to intralesional cryotherapy. 
In the resistant group 16 patients were included, of whom seven were allocated to 
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keloid excision and brachytherapy (all treated with 2x9Gy) and nine to intralesional 
cryotherapy (Table 1). Most patients had been previously treated with corticosteroid 
injections. If resistant keloids had been excised previously, in 50% intraoperative or 
postoperative corticosteroid injections also had been used. 
Table 1. Patient characteristics
Primary keloid Resistant keloid
Excision w/ TAC Intralesional 
cryotherapy
Excision w/ 
brachytherapy
Intralesional 
cryotherapy
Number of patients 5 5 7 9
Male 2 (40%) 1 (20%) 3 (43%) 5 (56%)
Age in years 
mean ±SD (range) 
30.2±9.6 (18-40) 37.6±17.9 (19-57) 35.0±11.0 (19-48) 32.7±7.9 (22-44)
Skin type I-II* 2 (40%) 1 (20%) 0 2 (22%)
Skin type III-IV* 0 0 1 (14%) 3 (33%)
Skin type V-VI* 3 (60%) 4 (80%) 6 (86%) 4 (44%)
Location thorax 2 (40%) 2 (40%) 0 3 (33%)
Location ear 2 (40%) 1 (20%) 2 (29%) 2 (22%)
Location other 1 (20%) 2 (40%) 5 (71%) 4 (44%)
Duration of keloid  
in years 
mean ±SD (range) 
8.2±9.6 (1-25) 2.6±1.9 (1-6) 6.4±3.7 (2-12) 9.6±9.8 (3-35) 
Keloid volume at 
baseline in mlB
Mean ±SD
1.4±0.8 5.8±6.4 5.7±7.7 8.1±10.4
w/: with postoperative. TAC: triamcinolone acetonide 40mg/ml. FU: follow-up. SD: standard devia-
tion. *According to Fitzpatrick [24]. A Other locations were upper back (2x, 1 cryotherapy group) 
and lower extremity for primary keloids and for resistant keloids upper back (2x cryotherapy group), 
abdomen (3x, 1 cryotherapy group), cheek (2x), neck and lower extremity (cryotherapy group). B 
Keloid dimensions and volume varied widely depending on location; differences were not statisti-
cally significant (primary keloid p=0.054, resistant keloid p=0.265).
One patient with a primary keloid was lost to follow-up. During inclusion we unexpect-
edly noticed a high number of failed intralesional cryotherapy treatments after three 
months follow-up (Table 2); most of these patients opted for treatment from the other 
study arm. Therefore, the inclusion was stopped in accordance with the IRB. 
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Table 2. Scar volume reduction and recurrence between baseline and last on protocol measure-
ment
Primary keloid Resistant keloid
Excision w/ TAC Intralesional 
cryotherapy
Excision w/ 
brachytherapy
Intralesional 
cryotherapy
Number of patients 5 4 7 9
% of baseline 
volume at last FU
mean±SD (range)
90±133 (0-300) 60±38 (33-116) 5±13 (0-33) 99±47 (29-186)
Complete scar 
flattening
20% 0% 86% 0%
Recurrence 80% 25% 0% 22%
Keloid larger than 
baseline
40% 25% 0% 44%
Treatment 
satisfaction
60% 25% 100% 0%
Additional 
treatment
40% 50% 14% 67%
w/: with postoperative. TAC: triamcinolone acetonide 40mg/ml. FU: follow-up. SD: standard devia-
tion.
After follow-up of all included patients had been completed, we performed mixed 
model analyses as planned (Table 3 and Supplementary Table 1). Only treatment and 
time effects were included in the models, because none of the patient and keloid char-
acteristics (sex, age, skin type, duration of keloid disease, keloid type, and location of the 
keloid) made a significant contribution to the models. Despite the small group sizes, 
we found a major and clinically relevant improvement of scar appearance after surgery 
(measured by the POSAS, Cohen’s effect size (d) = -2.03, p<0.001), but not following in-
tralesional cryotherapy (d=-0.49, p=0.122). These results suggest that after surgery scar 
appearance improved significantly more than after intralesional cryotherapy. In both 
treatment groups, observers (OSAS) rated the scars better than patients did (PSAS), at 
baseline as well as after treatment (Table 3). Although PSAS scores also improved after 
intralesional cryotherapy (d=-0.40, p<0.001), they showed much more improvement 
after surgery (d=-1.41, p<0.001). 
Pain and itch symptoms significantly decreased after surgery (d=-0.73, p<0.001 and 
d=-0.90, p=0.005, respectively), while after intralesional cryotherapy no statistically 
significant improvement could be found (Table 3). 
Only small and statistically non-significant QoL changes were observed after keloid 
treatment using the Skindex-29, SF-36 and EQ-5D-5L questionnaires and no differences 
were found between surgery and cryotherapy (Table 3). 
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Table 3. Mixed Model outcome over time for both treatment groups and the difference between 
the treatments
Surgery Cryotherapy Difference
Primary 
outcome
Estimate d  p-value Estimate d  p-value Estimate d p-value
POSAS
Baseline
52 weeks 
71.3
37.7 -2.03 <0.001
71.6
63.5 -0.49 0.122 25.5 1.54 0.001
PSAS
Baseline
52 weeks
40.6
22.6 -1.41 <0.001
41.6
36.5 -0.40 <0.001 12.85 1.01 0.022
OSAS
Baseline
52 weeks
30.5
15.1 -2.39 <0.001
30.0
27.1 -0.45 0.174 12.5 1.94 <0.001
Secondary 
outcomes
Estimate d p-value Estimate d p-value Estimate d p-value
Itch score
Baseline
52 weeks 
6.3
3.9 -0.90 0.005
6.2
5.4 -0.28 0.405 1.7 0.61 0.185
Pain score
Baseline
52 weeks 
4.5
2.7 -0.73 <0.001
5.3
4.8 -0.21 0.592 1.3 0.52 0.324
Skindex-29 
emotional 
Baseline
52 weeks 
33.0
26.2 -0.28 0.265
43.8
36.9 -0.28 0.298 0.07 0.00   0.994
SF-36 MCS
Baseline
52 weeks
46.3
42.6 -0.32 0.188
46.0
48.1 0.18 0.495 5.83 0.50 0.164
EQ-5D-5L
Baseline
52 weeks
0.84
0.80 -0.19 0.558
0.72
0.79 0.31 0.407 0.10 0.50 0.315
Model was developed by backwards selection, first model included sex, age, skin color, location, 
keloid duration, treatment and all interactions with time, time2 and the logarithm of time. POSAS: 
Patient and Observer Scar Assessment Scale (12 items, range 12-120, higher scores indicate poorer 
scars). PSAS: patient part of POSAS (6 items, range 6-60, higher scores indicate poorer scars). OSAS: 
observer part of POSAS (6 items, range 6-60, higher scores indicate poorer scars). Itch and pain 
scores are single items of the PSAS (range 1-10, 10 worst). Skindex-29 is a disease specific quality of 
life (QoL) instrument (30 items, scores 0-100, lower values represent better QoL) with 3 subscales 
and a sum scale. SF-36 MCS: SF-36 mental component score, the SF36 is a general QoL instrument 
with 36 items (scores range 0-100, with 100 representing better QoL, scores are standardized for the 
normal population with mean of 50 and SD of 10). EQ-5D-5L index: EuroQol 5 dimension 5 level test 
is a utility measure (5 item health state with population based preference scores, 0 to 1 with 1 rep-
resenting best QoL). Model values are given for outcomes with highest expected differences. The 
other outcome measures (Skindex-29 functional, symptomatic and sum scales, and SF-36 Physical 
Component Score) did not show significant differences over time for each treatment or between 
treatments.
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Supplementary Table 1. Mixed linear model parameters
Intercept time linear time quadratic time logarithmic
Outcome estimate p-value estimate p-value estimate p-value estimate p-value
POSAS
Surgery 71.3 <0.001 3.98 <0.001 -0.046 <0.001 -29.5 <0.001
Additional cryotherapy 0.311 0.961 -3.53 0.005 0.040 0.016 25.5 <0.001
PSAS
Surgery 40.6 <0.001 1.68 0.017 -0.019 0.035 -13.5 <0.001
Additional cryotherapy 0.977 0.844 -0.930 0.331 0.011 0.393 8.16 0.103
OSAS
Surgery 30.5 <0.001 2.10 <0.001 -0.024 <0.001 -15.3 <0.001
Additional cryotherapy -0.498 0.842 -2.42 <0.001 0.027 <0.001 16.8 <0.001
Itch score
Surgery 6.28 <0.001 0.169 0.280 -0.001 0.484 -1.86 0.025
Additional cryotherapy -0.123 0.906 -0.011 0.958 0.000 0.969 0.644 0.567
Pain score
Surgery 4.49 <0.001 -0.131 0.421 0.002 0.450 0.183 0.830
Additional cryotherapy 0.763 0.417 0.151 0.500 -0.001 0.638 -0.721 0.538
Skindex 29 emotional 
scale
Surgery 33.0 <0.001 1.08 0.357 -0.010 0.505 -8.99 0.139
Additional cryotherapy 10.8 0.266 -0.360 0.823 0.007 0.751 0.165 0.984
SF-36 MCS
Surgery 46.3 <0.001 -0.443 0.421 0.003 0.715 3.02 0.281
Additional cryotherapy -0.316 0.945 0.557 0.456 -0.005 0.624 -2.58 0.504
EQ-5D-5L index
Surgery 0.843 <0.001 0.018 0.178 -0.000 0.141 -0.073 0.284
Additional cryotherapy -0.120 0.161 -0.028 0.149 0.000 0.150 0.143 0.141
Model was developed by backwards selection, first model included sex, age, skin color, location, 
keloid duration, treatment and all interactions with time, time2 and the logarithm of time. POSAS: 
Patient and Observer Scar Assessment Scale (12 items, range 12-120, higher scores indicate poorer 
scars). PSAS: patient part of POSAS (6 items, range 6-60, higher scores indicate poorer scars). OSAS: 
observer part of POSAS (6 items, range 6-60, higher scores indicate poorer scars). Itch and pain 
scores are single items of the PSAS (range 1-10, 10 worst). Skindex-29 is a disease specific quality 
of life (QoL) instrument (30 items, scores 0-100, lower values represent better QoL), the skindex-29 
has 3 subscales and a sum scale. SF-36 MCS: SF-36 mental component score, the SF-36 is a general 
QoL instrument with 36 items (scores range 0-100, with 100 representing better QoL, scores are 
standardized for the normal population with mean of 50 and SD of 10). EQ-5D-5L index: EuroQol 
5 dimension 5 level test is a utility measure (5 item health state with population based preference 
scores, 0 to 1 with 1 representing best QoL). Model values are given for outcomes with highest 
expected differences. The other outcome measures (Skindex-29 functional, symptomatic and sum 
scales, and SF36 Physical Component Score) did not show significant differences over time for each 
treatment or between treatments.
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Mean scar volume reduction was 95% after surgery with brachytherapy, but only 10% 
after surgery with corticosteroid injections, due to recurrences that were sometimes 
even three times larger than the original keloid (Table 2). This shows that keloid excision 
followed by corticosteroid injections has considerable risk on making the condition 
worse. Recurrences were more common after treatment for primary keloids, because 
most recurrences were found after keloid excision followed by corticosteroid injections 
(Table 2). Intralesional cryotherapy, on average gave a 40% scar volume reduction in 
primary keloids and merely 1% in resistant keloids. Thus, primary keloids seemed to 
respond better to cryotherapy than resistant keloids did. 
Correlations between changes in scar symptoms, aesthetic outcome and changes in 
QoL are shown in Table 4. Changes in Skindex-29 sum and emotional subscale scores 
positively correlated to both changes in scar symptoms and aesthetic outcome. Changes 
in the Skindex-29 symptomatic subscale only correlated to changes in scar symptoms, 
and the Skindex-29 functional scale showed a moderate correlation to changes in scar 
symptoms, although not statistically significant (Table 4). Changes in the generic SF-36 
scores correlated to neither changes in physical symptoms nor aesthetic outcome, 
while changes in EQ-5D-5L scores only showed a moderate non-significant correlation 
with changes in physical symptoms.
Table 4. Non parametric correlations between changes in scar symptoms, aesthetic outcome and 
quality of life outcomes
Δ scar symptoms Δ aesthetic outcome
r p r p
Δ skindex-29 emotional scale 0.621 0.001 0.561 0.004
Δ skindex-29 functional scale 0.374 0.065 0.224 0.282
Δ skindex-29 symptomatic scale 0.698 <0.001 0.331 0.106
Δ skindex-29 sum scale 0.633 0.001 0.539 0.005
Δ PCS -0.217 0.297 -0.231 0.266
Δ MCS -0.285 0.168 -0.163 0.437
Δ EQ-5D-5L -0.396 0.062 0.008 0.970
Δ: difference in outcome score between baseline and last available complete measurement. r: 
Spearman’s rho correlations. p: p-value. PCS: SF-36 physical component scale. MSC: SF-36 mental 
component scale. EQ-5D-5L: EuroQOL 5 dimension utility measure.
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Discussion
We performed a randomised controlled trial to compare the effectiveness of different 
invasive keloid treatments. Due to unexpectedly inferior results following intralesional 
cryotherapy, we prematurely stopped inclusion even before 20% of planned inclusion 
was reached. Nevertheless, after surgery with brachytherapy we still found statistically 
significant positive effects on scar appearance, our primary outcome. Unfortunately, 
we were not able to demonstrate an improvement of QoL following different keloid 
treatment strategies. Also, no differences in QoL between keloid treatments was found, 
although scar appearance and symptoms improved significantly more after surgical 
treatment with adjuvant therapy than following intralesional cryotherapy. Our trial fell 
short of statistical power due to prematurely stopping the inclusion. 
The results of the present randomized controlled trial showed that intralesional cryo-
therapy is inferior to surgical excision with brachytherapy for treatment of resistant kel-
oids, which is in contrast to results from previous reports on intralesional cryotherapy 
that showed much better results for treatment of recurrent keloids 5, 8. There are several 
explanations for the difference between our unsatisfactory results of intralesional cryo-
therapy compared to the previous favourable results in other series. First, selection and 
indication bias may have occurred in previous case series, which was precluded by 
randomisation in our study, although it is unclear which keloids would respond bet-
ter to intralesional cryotherapy. Second, outcome measures used were not the same. 
Previously, a non-validated 4-point one question scale was mainly used for patient 
satisfaction, while in the current trial we used the POSAS with good reliability and valid-
ity. Third, after intralesional cryotherapy we encountered permanent pigmentation dif-
ferences that were more striking than after corticosteroid injections or brachytherapy. 
The first reports on intralesional cryotherapy noted no hypopigmentation but only 
had treated fair skinned patients 5, 7. Later reports that included dark skinned patients 
also found permanent hypopigmentation after intralesional cryotherapy resulting in 
less patient satisfaction 10, 11. Finally, publication bias may be a possible explanation 
why only publications showing favourable results of intralesional cryotherapy could 
be found, while reports of other groups that found poor results were not published or 
even written down. 
Scar appearance was rated worse by patients than by observers probably because of 
their different perspective and expectations. Observers may have seen many poor scars 
professionally while patients only had their own scar as a reference. Patients may have 
hoped and expected that treatment would give them a normal looking scar, while 
physicians knew the challenges of keloid treatment and expected aberrant scar ap-
pearance even after effective treatment. Analogous to other areas of plastic surgery, 
patient education on treatment goals and expected outcomes is key in reducing dis-
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satisfaction 25. Also, high hopes of patients may in part explain the high number of 
additional treatment needed in the cryotherapy group. All patients knew about the 
alternative treatment when they gave informed consent, and the hope for a completely 
flattened scar may have fed the wish for additional treatments.
We expected scar appearance to correlate with patients’ QoL, but we were not able to 
demonstrate QoL improvement after different keloid treatment strategies. We found 
a reduction in POSAS score of 47%, but possibly the scar was still so bothersome after 
treatment it did not show QoL improvement, or we lacked statistical power as a result 
of prematurely terminating the study. Obviously, QoL is related to more factors than 
the effects of keloid treatment only. While the effects of keloid treatment on one scar 
can be assessed with the POSAS, this is not possible for QoL measures. Because many 
patients had more than one keloid, these other keloids may still have negatively af-
fected QoL after treatment of only one keloid. This bias may even have increased after 
expanding the inclusion criteria in order to improve patient inclusion. 
Intralesional cryotherapy did seem to improve primary keloids; we found similar 
volume reduction compared to other groups (30-63%), while the keloids treated with 
cryotherapy tended to be larger at baseline (borderline significant p=0.054) 5, 8, 11. Van 
Leeuwen et al. 11 who treated a series of primary keloids with intralesional cryotherapy 
also found a relevant POSAS improvement (39% reduction). Because of the inclusion 
of many resistant keloids in the present trial we could not confirm this finding (11% 
POSAS reduction). Intralesional cryotherapy may be a good option for primary keloids, 
specifically if patients do not want to risk a recurrence larger than the original keloid. 
Further proof of intralesional cryotherapy efficacy compared to other primary keloid 
treatment strategies and the effect of keloid size on intralesional cryotherapy efficacy is 
needed. However, patients should be adequately informed about treatment outcomes 
of both cryotherapy and excision with corticosteroid injections, resulting in relatively 
low patient satisfaction and frequent need for additional treatment. In addition, we 
believe there are indications for cryotherapy use in specific situations. For example, 
in young children when brachytherapy is less suitable, or if after keloid excision the 
resulting defect can only be closed using transposition flaps, resulting in more and 
larger scars.
Analyses were done for on protocol measurements, because in the intralesional cryo-
therapy group more than half of the patients requested additional treatment during 
follow-up. Therefore, considering the high number of measurements off protocol, it 
was not valid and meaningful to perform intention to treat analyses. 
We terminated the trial prematurely, because patients were not satisfied with the 
results of intralesional cryotherapy. At the time the trial was designed neither a Data 
Safety Monitoring Board, nor stopping rules were mandatory following IRB protocol. 
Also an interim analysis was not planned, because we aimed at a higher inclusion rate 
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and, based on available evidence at that time, we had not anticipated such a high 
occurrence of dissatisfaction 6 to 9 months prior to final follow-up. Although we in-
cluded less than 20% of the planned number of patients, prematurely stopping a trial 
to protect patients from harm caused by unnecessary treatments (delay in adequate 
treatment, pain and discomfort after treatment) is always justified 26. 
We previously reported that keloids causing pain or itch symptoms have a high 
negative impact on quality of life 1. The results of the present trial could not completely 
confirm our previous findings but showed that reduction in scar symptoms can lead to 
improved quality of life. Reduction in scar symptoms showed higher correlation with 
disease specific QoL (Skindex-29), and a trend towards general QoL improvement on 
the EQ-5D-5L, while improvement in aesthetic outcome was not as strongly correlated 
to QoL. 
In conclusion, for resistant keloids intralesional cryotherapy is inferior to keloid excision 
followed by brachytherapy.  Intralesional cryotherapy can improve primary keloids and 
may be indicated in these patients and specific cases, but further research on the ef-
ficacy of intralesional cryotherapy for primary keloids compared to other treatments is 
warranted.
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Abstract
Background  Extralesional  keloid excision followed by brachytherapy is cur-
rently considered the most effective treatment. However, the optimal 
brachytherapy dose and fractionation scheme is unknown and radia-
tion may have considerable side effects. Because keloid formation is a 
benign condition, often in young patients, it is particularly important 
to minimize these adverse effects. Therefore, it is key to find the opti-
mal radiation fractionation scheme for keloid treatment.
Methods  Patient cohorts from three centers treated with keloid excision 
followed by 2x9 Gy, 3x6 Gy, or 2x6 Gy high dose rate (HDR) brachy-
therapy were retrospectively compared regarding recurrence (after at 
least 12 months follow-up) and complications (after at least 1 month 
follow-up), using logistic regression analyses.
Results   A total of 238 keloids were treated. An overall full recurrence rate of 
8.3% was found. After correction for confounders (sex, skin color, ke-
loid location, keloid duration) no statistically significant differences in 
recurrence rates could be discerned between fractionation schemes. 
There were 12.8%  major and 45.6%  minor complications. Lower 
radiation dose resulted in significantly less complications (OR 0.35, 
p=0.015).
Conclusions  After excision of resistant keloids, HDR brachytherapy with a biologi-
cal equivalent dose around 20 Gy is recommended based on both 
low recurrence and complication rates.
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Introduction
Keloids are benign fibro-proliferative lesions, which may impair quality of life due to 
itch, pain, and aesthetic disfigurement  1, 2. Because of substantial therapy resistance 
and high recurrence rates, many treatment options are available with little consensus 
on which is best. Intralesional corticosteroids injection is widely used as primary treat-
ment, with response rates of 77-90% and recurrence rates of 9-50% 3-5. If non-invasive 
therapy fails, there is little evidence which invasive technique gives maximal efficacy 
with minimal morbidity. Since 1909, radiation therapy has been successfully used to 
treat keloids 6. Currently, its combination with excision is considered the most effective 
keloid treatment with reported recurrence rates under 5% 7. However, it is an invasive 
technique that may have considerable side effects. It seems key to find the optimal 
balance between maximum efficacy and minimum side effects by determining the 
optimal radiation fractionation scheme.
In the last century different radiation modalities and doses have been used for keloid 
treatment. Evaluation of all modalities combined showed that a biological equivalent 
dose (BED) of at least 30 Gy is needed to achieve recurrence rates under 10% 8. Previ-
ous research on radiation after excision of keloids showed that high dose rate (HDR) 
brachytherapy gives favorable results compared to external radiation or low dose rate 
(LDR) brachytherapy 7, 9. A short interval from surgery to start of radiation and hypofrac-
tionation is currently recommended 7, 10, 11. These recommendations are largely based 
on results from studies using external beam radiotherapy (EBRT), since there exist only 
few studies on HDR brachytherapy 7, 8. Because brachytherapy and EBRT are different 
techniques, radiation schemes  cannot  be directly extrapolated and goal BEDs may 
differ.
HDR brachytherapy radiation schemes that have been reported for keloid treatment 
vary considerably with total doses of 10-20 Gy in two to six fractions starting within 24 
hours after surgery, resulting in recurrence rates of 0-44% 9, 10, 12-17. This clearly illustrates 
more knowledge is needed on how to use HDR brachytherapy best in keloid treat-
ment, by identifying the optimal fractionation scheme with high efficacy on recurrence 
combined with low rates of side effects.
Within a relatively small area in the Netherlands with similar population characteristics, 
three University Medical Centers provide keloid treatment with HDR brachytherapy 
after excision. Each center has been using a different radiation scheme for several years, 
which enabled a comparison of the long-term results of these three HDR brachytherapy 
schemes.
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Methods
All consecutive patients who had been treated with keloid excision followed by HDR 
brachytherapy at University Medical Center Rotterdam (Erasmus MC) from 2010 to May 
2014, University Medical Center Utrecht from 2009 to 2014, and VU Medical Center Am-
sterdam from 2003 to 2009 were included. The HDR brachytherapy radiation schemes 
remained unchanged during these periods.
In general, all centers used one standard after-loading catheter with an Ir192 source. 
At Erasmus MC (center 1) the catheter was implanted subcutaneously at the closed 
wound of the excised lesion. Subsequently, simulation films or a CT scan were obtained 
and treatment planning was performed with the most distant localization according to 
protocol being 1 cm outside the target. After optimization of the implant, 2 fractions 
of 9 Gy prescribed to the skin and/or a distance of 0.5 cm from the source train were 
applied. The inter-fraction time interval was minimally six hours.
At University Medical Center Utrecht and VU Medical Center (center 2 and 3) a 6 Gy frac-
tion was applied within 3 hours after surgery. The next day one (center 3) or two (center 
2) additional fractions of 6 Gy were given separated by at least six hours. The catheter 
was fixed between the subcutaneous and intradermal layers of stitches, entering and 
exiting at the extreme edges of the surgical wound. The fractions were dosed with 
100% at 0.5 or 0.6 cm. Only when multiple catheters were used, a planning CT was 
made. Part of the cohort of center 3 was previously published 16.
The following data were retrospectively collected from patient charts: sex, age, skin 
type, number of keloids, size and location of treated keloid, pain and itch symptoms, 
cause and duration of keloid, previous treatments, acute complications after treatment, 
(partial  or full) recurrence of keloid and additional treatments needed after excision 
combined with brachytherapy. In case follow-up was less than 1 year or important 
information was missing in the medical file, telephone interviews were performed. If 
during the course of data collection new information was noted in the medical files, 
these patients’ data were updated.
Primary outcome was keloid recurrence, scored as ‘no recurrence’, ‘partial recurrence’ or 
‘full recurrence’.  ‘No recurrence’ was defined as a scar that was not raised anymore and 
did not grow, ache or itch. If the scar was raised, but smaller than the original keloid, and 
pain and itch were still present, it was scored as a ‘partial recurrence’. If compared to the 
original keloid no improvement in size, pain or itch was achieved, it was classified as a 
‘full recurrence’ 18. The type of any additional treatment given for the same keloid, after 
excision followed by brachytherapy, in our opinion also indicated the extent of recur-
rence. When invasive treatments had been used for a recurrence, this was considered 
suggestive of a fully recurred keloid. The best fitting recurrence classification was made 
based on postoperative scar size, symptoms and additional treatments. Keloids were 
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only evaluated on recurrence when follow-up was more than one year to enable an 
accurate report 19.  
Secondary outcomes were complications following treatment. Complications were 
defined as ‘minor’ when they were treated conservatively (i.e., dehiscence, wound 
infection treated with oral antibiotics, radiation dermatitis grade 2, pigmentation dif-
ferences), and defined as ‘major’ in case of surgical treatment, re-admittance, or major 
impact on patients’ quality of life (i.e., radiation dermatitis grade 3 or 4, chronic wounds 
more than 3 months after surgery, pigmentation differences that needed treatment by 
tattooing or laser therapy).
The study was assessed by the institutional review board (IRB) of the Erasmus MC  (MEC-
2015-226) and followed national legislation, and the declaration of Helsinki.
Statistical Analysis
Exact tests (categorical data) or ANOVAs (continuous data) were used to compare 
outcomes between the centers. We performed  binominal logistic regression  analy-
ses. To decide which covariates had to be included in the first model, we evaluated 
differences in keloid characteristics between cohorts and knowledge from previous 
studies 19-23. Block 1 included the centers and block 2 included sex, age, skin type (light, 
tinted, dark), keloid location (upper trunk, ear, other), and duration of keloid. We did not 
correct for  previous treatment because these data were not available for all centers. 
Missing values in characteristics were imputated for primary outcome analysis (max 
7%). P-values <0.05 were considered statistically significant. All statistical analyses were 
performed using IBM SPSS Statistics for Macintosh version 22.0 (IBM Corp. Armonk, NY: 
IBM Corp.)
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Treatments
Complete data after chart review
or from publication
Keloids included
in analysis
Patients 43 54 49
86 87 65Keloids
Patients 17 0 14
31 0 22Keloids
Patients 16 32 19
35 52 21Keloids
Patients 2 2 10
2 2 14Keloids
Patients 8 20 6
18 33 8Keloids
Center 1 Center 2 Center 3
2x9 Gy 3x6 Gy 2x6 Gy
Phone Interviews
Completed
Declined
Not reached
Recurrence (fu > 12 mo)
Complications (fu ≥ 1 mo)
100% 92% 92%% of total
77 64 52Keloids
90% 74% 80%% of total
86 80 60Keloids
Figure 1. Overview selection of keloids in analyses
fu: follow-up, mo: months
Results
After combining data from the chart review and telephone interviews, we were able 
to analyze 226 out of 238 keloids (95%) (Figure 1). There existed diff erences between 
the three centers in relevant patient and keloid characteristics (Table 1). For example, 
skin types diff ered; center 2 treated much more fair skinned keloid patients (40%) than 
center 1 (9%). Center 1 treated more keloids that were present for a longer period 
of time than the other centers (15 vs. 7 years). Center 1 treated more patients with 
multiple keloids instead of a single keloid (1 keloid: center 1, 17%, center 2, 28%; >10 
keloids: center 1, 27%, center 2, 17%). Acne (32%), surgery (23%), piercings (21%), and 
trauma (19%) were the most frequent causes of keloid formation. Center 1 had treated 
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most posttraumatic keloids (33%), center 2 most keloids caused by acne (44%), and 
center 3 most by piercings (32%). 
Table 1. Patient and keloid characteristics per center.
Center 1
2x9 Gy
Center 2
3x6 Gy
Center 3
2x6 Gy p
PATIENTS n=43 n=54 n=49
Male n (%) 24 (55.8) 26 (47.3) 19 (38.8) 0.263
Age years mean (SD) 36.4 (14.3) 32.9 (15.0) 34.4 (14.7) 0.509e
Previous keloid 
treatment
non-operativea n (%) 6 (14.0) 13 (25.0) 17 (37.8) 0.087
operativeb n (%) 34 (79.1) 35 (67.3) 26 (57.8)
KELOIDS n=86 n=87 n=65
Male n (%) 38 (44.2) 45 (51.7) 26 (40.0) 0.343
Age years mean (SD) 39.0 (13.4) 32.2 (13.1) 34.9 (14.7) 0.005e
Skin typec I or II n (%) 8 (9.3) 35 (40.2)d      13 (20.0)d <0.001
III or IV n (%) 23 (26.7) 28 (32.2)d      7 (10.8)d
V or VI n (%) 55 (64.0) 12 (13.8)d      26 (40.0)d
Location upper trunk n (%) 45 (52.3) 36 (41.4) 25 (38.5) 0.180
ear n (%) 22 (25.6) 28 (32.2) 28 (43.1)
other location n (%) 19 (22.1) 23 (26.4) 12 (18.5)
Keloid size length (cm) mean (SD)
range
5.3 (4.9)
1-26
4.3 (3.5)
0.7-21
5.4 (5.0)
1-26
0.228e
width (cm) mean (SD)
range
2.2 (1.5)
0.5-8
1.8 (1.2)
0.5-7
2.4 (1.6)
0.5-8
0.076e
Previous 
treatment
non-operativea n (%) 12 (14.0) 39 (45.9)d     23 (35.4)d <0.001
operativeb n (%) 53 (61.6) 39 (45.9)d      30 (46.2)d
Pain present n (%) 45 (67.2)      43 (58.1)      43 (66.2) 0.461
Itch present n (%) 52 (80.0)      51 (68.9)      40 (61.5) 0.066
Duration of 
keloid
years mean (SD) 14.7 (9.4)d     7.3 (6.3)d       7.0 (6.6)d <0.001e
Follow-up time months mean (SD)
range
30.9 (15.7)
1-70
43.7 (34.9)
0-109
40.6 (30.5)
0-116
<0.001e
Follow-up time 
>1 year
months mean (SD) 
range
34.6 (13.2)   
13-70 
58.3 (28.9)  
17-109 
50.1 (26.5)
12-116
<0.001e
Characteristics are given with Exact tests to compare the treatment groups (Fisher’s or Fisher-Free-
man-Halton’s) or one-way ANOVA when indicated. aSilicone sheets, topical treatments, intralesional 
corticosteroids injections, lasers. bCryotherapy, Surgery with or without adjuvant treatment. cSkin 
type according to Fitzpatrick. dTotals do not add up to group totals due to missing values. eOne-way 
ANOVA.
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Because these differences between the cohorts could affect treatment outcomes, we 
corrected for sex, skin type, keloid location and keloid duration. After correction for 
these confounders, no statistically significant differences in recurrence rates were found 
between the three centers (Tables 2 and 3). The odds on a full recurrence were higher 
for males than for females, no significant effect of the other covariates was found. 
Table 2. Keloid recurrences and treatment complications per center
Center 1
2x9 Gy
Center 2
3x6 Gy
Center 3
2x6 Gy Total
PRIMARY OUTCOME n=77 n=64 n=52 n=193
   Full recurrence 7 (9.1) 2 (3.1) 7 (13.5) 16 (8.3)
   Partial recurrence 10 (13.0) 13 (20.3) 6 (11.5) 29 (15.0)
   No recurrence 60 (77.9) 49 (76.6) 39 (75.0) 148 (76.7)
SECONDARY OUTCOME n=86 n=80 n=60 n=226
   Major complicationa 16 (18.6) 11 (13.8) 2 (3.3) 29 (12.8)
Severe wound dehiscence 1 (1.2) 0 (0.0) 0 (0.0)
Severe infection 4 (4.7) 0 (0.0) 0 (0.0)
Dermatitis grade 3/4 0 (0.0) 0 (0.0) 0 (0.0)
Hyperpigmentation needing 
treatment
1 (1.2) 1 (1.3) 0 (0.0)
Hypopigmentation needing 
treatment
1 (1.2) 4 (5.2) 0 (0.0)
Chronic wound (>3 months) 12 (14.0) 9 (11.3) 2 (3.3)
   Minor complicationa 49 (57.0) 32 (40.0) 22 (33.7) 103 (45.6)
Wound dehiscence 19 (22.1) 8 (10.0) 11 (18.3)
Infection 5 (5.8) 6 (7.5) 4 (6.7)
Dermatitis grade 2 23 (26.7) 6 (7.5) 0 (0.0)
Hyperpigmentation 35 (40.7) 11 (14.2) 8 (13.3)
Hypopigmentation 33 (38.4) 25 (32.5) 3 (5.0)
   No complication 28 (32.6) 41 (51.3) 37 (61.7) 106 (46.9)
All data given are n (%).a Wound dehiscence was severe in case of surgical treatment or re-admit-
tance to the hospital, infection was severe in case of re-admittance or surgical treatment, pigmen-
tation differences were severe only when treated (with for example tattooing or laser treatment). 
Numbers do not add up because some keloids had both minor and major complications.
Before treatment with excision and brachytherapy, keloids caused symptoms of itch 
(62-80%) and pain (58-67%) in a majority of cases. After treatment, symptoms disap-
peared or diminished in many patients (no itch 70-79%, less itch 15-25%; no pain 86-
89%, less pain 6-8%). Following treatment, only two patients reported more itch and 
one more pain symptoms.
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The occurrence of minor and major complications is shown in Table 2. Most complica-
tions, and more severe complications were found for center 1, less in center 2, and even 
fewer in center 3. After correction for confounders, there were no significant differences 
between treatment with 2x9 Gy and 3x6 Gy in recurrence rates and complications, but 
there were significantly less complications following 2x6 Gy compared to 2x9 Gy (Table 
3) (OR 0.35, p=0.015). Keloids at the upper trunk had an increased risk of complications 
(OR 2.5, p=0.032), and ear keloids had the least risk on complications (OR 0.43, p=0.05). 
A complication that occurred was an increase in pain following treatment. In one 
patient pain eventually completely disappeared, but another suffered from severe pain 
and regretted being treated with excision and brachytherapy. Also permanent alopecia 
was reported twice.
We observed 23 chronic wounds after treatment. However, there was a wide variation 
in consequences of these wounds. Twenty eventually healed without intervention; for 
one wound this took over a year and three wounds healed only after surgical debride-
ment. One female patient was treated with 2x9 Gy for a keloid on the back, which 
had recurred after previous treatment with excision and 2x9 Gy brachytherapy. Sub-
sequently, longstanding crusts became wounds that showed no signs of healing after 
surgical debridement (two times). Finally, seven months later she was operated again 
and the area that had been irradiated during both previous treatments was completely 
excised into healthy skin. After wide undermining, the wound edges could be closed 
primarily after which the area was treated with brachytherapy for the third time. Again, 
wound healing was complicated by a long-standing wound dehiscence due to tension, 
but after four months the wound had completely healed and showed no recurrence.  
Table 3. Outcomes of binary logistic regression analyses corrected for sex, skin type, location, and 
keloid duration
PRIMARY 
OUTCOME
Full recurrence
95% 
Confidence 
interval
SECONDARY 
OUTCOME
Any complication
95% 
Confidence 
interval
Odds p-value Lower Upper Odds p-value Lower Upper
Constant 0.037 0.013 1.464 0.570
Center 2: 3x6 Gy 0.551 0.534 0.084 3.598 0.646 0.321 0.272 1.533
Center 3: 2x6 Gy 3.086 0.106 0.787 12.106 0.352 0.015 0.151 0.819
Sex 0.219 0.013 0.066 0.725 0.741 0.341 0.401 1.372
Skin type III-IV 1.845 0.498 0.314 10.835 1.311 0.521 0.573 2.996
Skin type V-VI 2.594 0.290 0.443 15.182 2.109 0.098 0.871 5.106
Upper trunk 0.849 0.836 0.181 3.989 2.476 0.032 1.082 5.666
Ear 1.071 0.930 0.230 4.982 0.429 0.050 0.184 0.999
Duration of keloid 1.064 0.089 0.991 1.144 0.982 0.425 0.940 1.026
p-values considered statistically significant if α<0.05.  
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Another female patient who had been previously treated for an earlobe keloid with 
excision followed by 10 Gy in 2 fractions on separate days with 8 MeV electron beam, 
presented 21 years later with a basal cell carcinoma at her earlobe. Due to her suscep-
tibility to make keloids and expected deformity with surgical treatment, it was treated 
with radiotherapy.
Discussion
By retrospectively comparing patient cohorts from three different centers, we found 
in the present study that after extralesional keloid excision a brachytherapy radiation 
scheme of 2x6 Gy at 0.5 cm seems to be equally effective preventing recurrences as 
schemes using higher doses (2x9 Gy or 3x6 Gy), with a lower risk of complications, like 
infections, chronic wounds and apparent pigmentation differences.
Excision followed by radiation is widely considered the most effective treatment for 
keloids, and more specifically HDR brachytherapy seems to be the optimal radiation 
modality 7, 21, 24. When reviewing existing studies, selection bias and variation in design 
may hamper strong evidence to support this. However, in our experience excision with 
brachytherapy is the current golden standard for the treatment of itching or painful 
resistant keloids  25-27, which was confirmed by the low recurrence rate of 8.3% in the 
present study. Also important is the good effect of this treatment on the relief of itch 
and pain, which causes the largest burden in keloid disease 1, 2.    
Kal et al.8 recommended a BED of over 30 Gy. Based on the analysis of results with EBRT 
and HDR brachytherapy combined, they showed a recurrence rate of <10% with a BED 
>30 Gy. Our present results show that a similar recurrence  risk can be reached with 
a BED as low as 19 Gy. Guix et al.13 described a recurrence rate under 10% with even 
a lower BED of 16 Gy (4x3 Gy). In center 3 three keloids had not received 2x6 Gy after 
excision as planned, resulting in even a lower radiation dose, and two of them had a 
recurrence (67%).  If these keloids would be excluded the recurrence rate of center 3 
would be 10%. This indicates that 2x6 Gy brachytherapy might be the lower limit for 
effective keloid prevention, which is in line with recent findings of Mankowski et al.21, 
who reported a BED of 20 Gy is needed for recurrence rates <10%. Contrary to these 
findings regarding brachytherapy, recent attempts of EBRT after keloid excision with 
a BED under 30 Gy failed and these groups increased their dose 19, 20. Van Leeuwen et 
al.7 promote hypofractionation to even a single fraction, however, recent results of a 13 
Gy single fraction scheme lead to 24% recurrence, which is inferior to results found with 
2 to 4 fractions 28.
For resistant keloids a full recurrence rate under 10% is a good result. Partial recurrences 
were considered successful treatments if a stable state was reached and pain and itch 
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were relieved, but it is important to mention partial recurrence when informing the 
patient about the treatment. Many patients hope and believe that after treatment 
their scars will disappear and are therefore often disappointed by the aesthetic result. 
Patients should know that the treatment goal is to improve symptoms and keloid size, 
but that usually an optimal aesthetic result is not achievable.
In the present study we found much higher complication rates than previously de-
scribed  7, 8, 21. This could be explained because we actively searched the patient files 
for side effects and reported them in detail, while in literature complications are often 
not even reported. An important finding of the present study is that the lowest dose 
resulted in fewer complications.
Radiation can have carcinogenic effects that depend on dose, organ and age. Usually 
carcinogenesis becomes apparent after more than 10 to 20 years, and because the first 
publication on HDR brachytherapy was in 200113, it is hard to give an accurate estima-
tion of the risk. Radiotherapy has been long used in keloid treatment and most cohort 
studies have reported no carcinogenicity, which gives no certainty when patients are 
not followed for more than 10-20 years. Some case reports exist on radiation induced 
malignancies after keloid treatment, but causality cannot be proven  29. In general, 
radiation for keloid treatment is considered acceptable. We must be confident of the 
right indication: keloids that cause symptoms and are therapy resistant. Furthermore, 
we have to keep patient age in mind and use an appropriately low radiation dose, 
because radiation induced malignancies definitely occur following treatment of benign 
diseases 29, 30.  
The geography of the Netherlands enabled a unique possibility to compare similar 
populations treated with different fractionation schemes during similar time-periods. 
Most studies have compared historical cohorts in periods quite far apart that could 
cause differences in outcomes due to inevitable improvements in equipment, tech-
nique and perioperative care. A drawback of our study design is a possible confounding 
by indication, caused by different physicians deciding that treatment with excision and 
brachytherapy was indicated. Excision with brachytherapy is considered a last resort 
treatment for aggressive, resistant keloids. Some keloids without any previous treat-
ment in our cohorts had been treated straightaway with brachytherapy. However, most 
of these patients had previously suffered from other keloids that had been treated with 
many modalities with disappointing results, so they were not willing to go through the 
range of therapeutic options again.
The retrospective design of our study raises some limitations, due to missing data in the 
chart reviews and recall bias during interviews. This could have caused an underestima-
tion of the occurrence of complications in the postoperative period. Recurrence mostly 
occurs in the first year after treatment, but can also occur several years later.  Follow-up 
of at least one year is needed to correctly estimate the recurrence risk. In our analysis 
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of recurrences we used a minimum period of 1 year after surgery but fortunately the 
mean follow-up time of all centers was much longer.
In conclusion, a BED of more than 30 Gy has been the standard in radiation plan-
ning after keloid excision, but our results show that with HDR brachytherapy a BED 
lower than 30 Gy performs very well on recurrence as well as complication rates. We 
recommend using a lower radiation scheme of 2x6 Gy to reduce complications and 
minimize  stochastic  effects. For improved patient convenience, low risk on catheter 
dislocation, easier in house logistics and lower costs, planning both fractions on the 
day of surgery, with at least six hours in between, is a promising option that should be 
further analyzed in the future.
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This thesis aimed to improve care for keloid patients. As outlined in the introduction, 
this was done by evaluating the burden of keloids and by providing evidence on ef-
ficacy of keloid treatment. In the present chapter the main findings are discussed in the 
context of recent literature and clinical experiences, with recommendations for clinical 
practice and future research.
Part I   Burden of keloids
Historically, keloid research has focused on observer ratings or objective measurements. 
Nowadays, medicine has changed and patient reported health related quality of life 
(HRQL) has gained attention. High burden was found in several other skin conditions, 
which makes it essential to measure HRQL in all skin conditions.
Although patient reported outcomes (PROs) and HRQL are becoming increasingly im-
portant outcomes in keloid disease, still only a few studies exist that invariably show the 
large impact of keloid disease 1. We determined that keloids have a considerable burden 
on HRQL, specifically on the emotional or mental HRQL components. Assessed with 
a disease-specific HRQL instrument, patients reported to suffer from keloids as much 
as from psoriasis, eczema, rosacea, cutaneous lupus erythematosis, or acne vulgaris. 
Assessed by a generic HRQL instrument, physical functioning was hardly affected, but 
mental HRQL was clearly diminished even more than with arthritis or congestive heart 
failure. We found pain and itch scores are the most important predictors of burden on 
the different HRQL instruments (Chapter 2: Emotional Quality of Life is Severely Affected 
by Keloid Disease: Pain and Itch Are the Main Determinants of Burden).
In order to measure these PROs accurately good and validated instruments are needed. 
As generic HRQL measures do not include concepts like ‘appearance’, a disease specific 
instrument is needed. Mundy et al. looked into disease specific tools specifically for 
scars and found four options of which the Patient-Reported Impact of Scars Measure 
(PRISM) met most of the validation criteria 2. We used another disease specific HRQL 
instrument: the Skindex-29, developed for psoriasis, but validated and used in many 
other skin diseases. It includes questions on symptoms and appearance of the skin 
condition. When evaluating longitudinal data, PROs responsiveness is very important, 
sometimes needing a very specific tool to detect clinically relevant changes. For ex-
ample, Guy et al. developed a HRQL tool for head and neck keloids because they did 
not find the expected high burden on a generic or ‘total body’ keloid instrument 3. The 
Skindex-29 has shown responsiveness (although not for keloids/scars) and the ability 
to use it in more than one condition, enabling comparison between diseases, which is 
impossible if the tool would have been designed for one condition only.
Chapter 9
148
The importance of pain and itch in keloid burden has been confirmed by others 3, 4, even 
in a group of visible keloids only. Of these facial keloid patients, 48% sought medical 
treatment because of their pain symptoms, and physical symptoms were considered to 
have the greatest effect on HRQL. Unfortunately, the effect of pain and itch reduction 
on the burden of keloids has not been addressed yet.
The majority of keloids are painful, but burn scars can also be painful, however, not 
much is known about the prevalence of painful normal scars. After review of the litera-
ture, we found only one study addressing pain in scars in general (not a subgroup of 
pathologic scars) in a proper way, finding pain in 9.7% of scars after cutaneous surgery, 
which in 1.7% was moderate or severe (Numeric Rating Scale >3) 5.
Pathologic and burn scars have the highest pain intensity (up to 6/10). Pain symptoms 
did not correlate with overall nerve fiber density consistently, while a correlation with 
an increased number of peptidergic fibers, either absolute or relative, might be present 
(Chapter 3: A Systematic Review on Prevalence, Etiology and Pathophysiology of Intrinsic 
Pain in Dermal Scar Tissue). In pain perception different types of fibers transmit the 
signals. We analyzed pain in keloids more in-depth to evaluate its nociceptive and neu-
ropathic components to find possible therapeutic options. However, sensitive charac-
teristics differed substantially between patients, making it impossible to assign pain to 
a specific type of fiber. About half of the patients were classified with neuropathic pain. 
In contrast to the heterogeneity of the sensitive characteristics of keloids, their dermal 
and epidermal nerve fiber density was uniformly decreased compared to normal skin, 
independent of their sensation profile (Chapter 4: Sensory Perception and Nerve Fiber 
Innervation in Patients with Keloid Scars). In contrast to what we expected we could not 
correlate nerve fiber density to the patients’ pain symptoms.
A recent review on neuropathic pruritic and pain symptoms stated that dysfunction 
of unmyelinated C-fibers (warmth detection, heat pain and cold pain thresholds) and 
thinly myelinated Aδ-fibers (mechanical pain, heat pain and cold detection threshold) 
are of special interest 6. Intra-epidermal nerve fiber density (IENFD) is often decreased 
in conditions with neuropathic numbness (negative symptom) or neuropathic pruritus 
or pain (positive symptom), a value below the 5th percentile is indicative of small fiber 
neuropathy 6. Because only the standard (age and sex dependent) IENFD of the lower 
leg is known, in our pilot we could not calculate the percentiles and whether these 
corresponded to the results of the DN4 or Pain Detect questionnaires or QST results. 
Another study by Springer et al. 7 evaluated post-thoracotomy pain with objective 
measures (among others QST and IENFD), like we did for painful keloids in chapter 4. 
On QST they found changes, but no distinguishing profile. They did not find a correla-
tion of pain with fiber density and claimed this is in line with most recently published 
findings. Like us, they concluded too much heterogeneity precludes a clear functional 
or structural profile discriminating patients with pain from those without pain.
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Despite our efforts, no further insight in the structural mechanism behind keloid pain 
could be found. Symptoms and pain characteristic differ widely between patients and 
some suffer neuropathic pain; this makes evaluation of pain for each patient important 
to ensure an individualized treatment approach.
I am convinced pain and itch are main determinants of burden in keloid patients and 
that controlling these symptoms should be the main goal of treatment. In our prema-
turely terminated randomized controlled trial (RCT; Chapter 7: Intralesional Cryotherapy 
versus Excision with Corticosteroids or Brachytherapy for Keloid Treatment: A Randomized 
Controlled Trial), we found pain and itch reduction, but could not show a quality of life 
improvement, probably because the study was underpowered. Others were able to 
show HRQL improvement after successful keloid treatment (no recurrence) 8, 9, under-
scoring that successful treatment can relieve the burden of keloid patients.
Recommendations for further research
•	 For future studies, evaluating keloids incorporating a HRQL instrument is inevitable. 
More data will provide more opportunities to determine which factors (e.g., pain) 
cause disease burden, and will inform us how improving these factors (after treat-
ment) improves HRQL.
•	 As we deem pain and itch important factors in HRQL of keloid patients, relief of 
these symptoms should be the main treatment goal. Most recent studies only 
looked at symptom reduction as a secondary outcome, while we would advocate 
making this (or an instrument including this) the primary outcome.
•	 Hardly any literature on epidemiology of keloids or scar pain in general is available, 
while it could help us understand the size of the problem better. In this century only 
Sun et al. 10 and Kipora et al. 11 have studied keloid prevalence, showing a prevalence 
of 0.3% and 8.3% in a Taiwanese and Kenyan population, respectively. No recent 
numbers are available for Caucasian, Indian, Arabic or Hispanic patients.
•	 At our institution we only evaluate keloid patients’ pain routinely with a numeric 
rating scale from 1 to 10. If pain is a patient’s main symptom we should additionally 
determine whether the pain has neuropathic features. We should start evaluating 
if symptomatic care with common topical medical treatments for neuropathic pain 
(i.e., capsaicin or lidocaine cream, Botulinium toxin injections) or even systemic 
neuromodulators (i.e., amitryptalin, pregabalin) are effective in treating keloid pain, 
can control these symptoms and improve HRQL.
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Part II   Treatment of keloids
Keloid treatment is a challenge for both patients and physicians due to high therapy 
resistance, recurrences and several treatment side effects. A large variety of treatments 
is available. Several treatment algorithms have been described, but there is no overall 
consensus on keloid treatment. In the next paragraphs my findings are discussed and 
recommendations are given based on my experience and the studies described in this 
thesis.
Importance of information
During the work on this thesis, I regularly evaluated keloid patients, of whom many had 
not been well informed about their condition prior to their consultation and conse-
quently had no idea of the treatment options and difficulties. Some of them had been 
previously treated, but they had only been informed about the provided treatment at 
that time, and other options had not been discussed. With better patient education and 
counseling, like in many other conditions 12, patients can feel more in control of their 
treatment. Control is what patients may be looking for when bothered with a scar that 
is ‘out of control’. Only after proper education and acknowledgement of the severity 
of their condition, patients felt at ease and a good patient-physician relation could be 
build.
For other conditions and treatments it has been shown that patient satisfaction with 
treatment is dependent on patient satisfaction with information before treatment and 
the quality of the physician-patient-relation 13. Also in keloid treatment, with often poor 
to moderate aesthetic outcomes, which is not desired by patients, treatment satisfac-
tion may rise with good patient education, managing expectations about outcomes. 
On the other hand, knowledge about available treatments may also encourage patients 
to press for these treatments. Even in case their keloid is actually not suitable for it, and 
demanding referral to other departments or hospitals.
If medical conditions are benign, not life-threatening, and severity can be judged by the 
patient; HRQL improvement is the main treatment goal. When many treatment options 
exist that all suffer from some disadvantages to patients, patient and doctor together 
should make a decision about the treatment plan. To do right to patient autonomy, 
built trust and improve understanding (therefore it is important to have one physi-
cian doing follow-up), leading to better treatment adherence and maybe even better 
outcomes 12, 14. In summary, adequate patient information, a good physician-patient 
relation (follow-up by same physician), and shared decision-making will add to HRQL 
improvement.
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Stepped care approach
Among experts there is agreement on a stepped care approach in keloid treatment 
options, although the specific steps sometimes differ 15-21. Due to treatment side effects, 
stepped care approaches should be standardized, with each step losing successfully 
treated patients, exposing a decreasing number of patients with therapy resistant ke-
loids to more invasive treatments. 
Mostly three steps are described moving from non-invasive (e.g. silicones, topical 
corticosteroids, pressure), to minimally invasive (e.g. corticosteroids injections, other 
injectables, lasers) to invasive treatment with surgery and adjuvant treatment (e.g. 
corticosteroids injections, brachytherapy). In our experience silicones and topical treat-
ment can be beneficial to other treatments but are not sufficient as a stand-alone keloid 
treatment. Also, for the last invasive step a distinction between surgery with adjuvant 
treatment and surgery with radiotherapy could be made to differentiate this last resort 
treatment, with long-term risks due to ionizing radiation, from other treatments. Finally, 
different steps should be made for primary and recurrent keloids (Figure 1; Chapter 7: 
Intralesional Cryotherapy versus Excision with Corticosteroids or Brachytherapy for Keloid 
Treatment: A Randomized Controlled Trial). 
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Figure 1 Proposed treatment algorithm
5-FU: 5-fluorouracil
Unfortunately, options within different steps can be limited. In part due to local practice 
(availability of lasers, medications or instrument makers) and treatment availability (reg-
istered medications, use of chemotherapeutic protocols). But also, because evidence 
comparing different treatments is not up to current standards of evidence-based 
medicine, which makes it harder to convince institutions of the added value of a certain 
treatment modality in patient-care and change institutions practices and treatment 
availability. 
In general, it is recommended to use conservative treatments whenever possible, at 
the moment the main conservative treatment modality available is corticosteroid 
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injections. Unfortunately, not all keloids respond to corticosteroids, which leaves many 
physicians without any other option than surgery. While the efficacy of many other 
treatments has been shown, no definite statement can be made on the comparison of 
corticosteroid injections with other conservative treatments. In chapter 5 we compared 
the effect of 5-fluorouracil (5-FU) injections with corticosteroid injections and found 
that 5-FU alone is not more effective than triamcinolone acetonide (TAC) injections. 
However, a combination therapy may be more effective, and might have a positive 
effect in keloids that do not respond to corticosteroids only.
At the same time, others were also trying to answer this exact question with a review 
of available evidence 22-24. Carroll and Patel 22 performed a non-systematic review, 
including 5 papers of which 3 RCTs, and they suggested that although more studies 
are needed, combination therapy is likely to give optimal results. Shin and Kim 24 only 
investigated the additional use of 5-FU or TAC after keloid excision; they included 2 and 
4 studies, respectively, without providing inclusion criteria. The 2 included studies on 
additional 5-FU use were the most favorable. In addition, also a small arbitrary selec-
tion of available papers on surgery in combination with corticosteroid injections was 
included and they compared it to all kinds of controls (e.g. excision with radiotherapy). 
They concluded that the additional use of 5-FU is highly effective and that TAC has no 
effect on recurrence reduction after excision. However, these conclusions were based 
on incomplete data and flawed analysis. Shah et al. 23 published a systematic review 
one year after ours was published; they included additional case-reports and a double 
publication. Conclusions similar to ours were drawn, but they considered there exists 
enough evidence to routinely start using 5-FU/TAC combination therapy in keloid 
treatment. Recently, one case report 25 showed good results with 5-FU/TAC, but no 
comparison to TAC alone has been published. Furthermore, no new comparative stud-
ies on 5-FU efficacy, specifically in combination with TAC, have been published since 
our review was published. 
To our opinion, our findings still need further research. The group of Dr. Niessen in the 
VUmc (Amsterdam, Netherlands) wanted to provide this evidence, but current Dutch 
regulations for chemotherapeutic use made the treatment so costly that a trial could 
not be funded and consequently, 5-FU injections for keloids are probably not feasible 
as standard of care in the Netherlands. 
Intralesional cryotherapy and excision followed by brachytherapy
Brachytherapy has been used for years in keloid treatment and current literature still 
regards it as the most effective treatment option preventing recurrences 26, 27. Over 
time different ways of radiation delivery have been used, and new methods are be-
ing explored with the goal to lower patient discomfort and radiation dose on healthy 
tissue. Recently, a topical application of a radiation source was very effective in a small 
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series 28. The reach of only 11 mm depth can be a limitation for bigger keloids. But an 
advantage of topical application is that no new wound healing process with an inflam-
matory phase can excite keloid growth. It could also be a solution for keloids covering 
such large areas that wound closure, let alone tension free closure, is impossible. 
Another more controversial approach for severely affected keloid patients was sug-
gested by Ogawa et al. and Komatsu et al. who used transposition flaps to close the 
big defects created after excision of large keloid areas and delivering 20 Gy radiation 
at both flap recipient and donor incisions 29, 30. While using skin transpositions in keloid 
surgery is usually considered a risk because lengthening the incision lines can give rise 
to recurrence of a bigger keloid, they averted this by prophylactic radiation treatment 
of the donor site incisions, exposing a much larger area to ionizing radiation. Whether 
these techniques will evolve to be beneficial to other ways of application should be 
confirmed.
However, ionizing radiation does come at a cost. Reports of malignancies in radiated 
tissue after keloid treatment do exist 31, 32 and we also found a patient with a basal cell 
carcinoma on the earlobe years after keloid excision and brachytherapy of the same 
area (Chapter 8: Optimal High Dose Rate Brachytherapy Fractionation Scheme after Keloid 
Excision. A Retrospective Multicenter Comparison of Recurrence Rates and Complications). 
In general, we can state that when needed radiation is justified, but in a dose ‘As Low 
As Reasonably Achievable’ (ALARA principle). Beside serious stochastic effects, there 
are also acute radiation effects that can be problematic, specifically wound healing 
problems. Therefore, the priority is to use as little ionizing radiation as possible.
We tried to decrease our ionizing radiation dose in keloid treatment in two ways. First, 
we investigated whether intralesional cryotherapy, a new promising treatment, could 
reduce the number of patients needing brachytherapy (Chapters 6 and 7: Intralesional 
Cryotherapy versus Excision with Corticosteroids or Brachytherapy for Keloid Treatment: 
A Randomized Controlled Trial). No doubt, intralesional cryotherapy has been proven 
superior to topical cryotherapy 33, 34. Unfortunately, our RCT had to be terminated pre-
maturely, because too many patients were not satisfied with intralesional cryotherapy 
results. On the other hand, our study with limited statistical power was able to show 
that for resistant keloids, excision with brachytherapy is superior to intralesional cryo-
therapy. In the small group of primary keloids, cryotherapy performed better than in 
resistant keloids and excision with corticosteroids had higher recurrence rates than 
excision with brachytherapy (the first was performed in primary keloids and the latter in 
resistant keloids). However, group sizes were too small to determine how intralesional 
cryotherapy performs compared to excision with corticosteroids. A recent review of 
intralesional cryotherapy effects on keloids showed slightly more volume reduction 
compared to our results in primary keloids; just like us they also found no complete 
keloid eradication and similar recurrence rates 35.
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Second, we studied whether a lower radiation dose could be used. Currently, we 
cannot replace excision with brachytherapy with intralesional cryotherapy, but we 
found a benefit of a lower radiation dose on acute radiation effects (Chapter 8: Optimal 
High Dose Rate Brachytherapy Fractionation Scheme after Keloid Excision. A Retrospective 
Multicenter Comparison of Recurrence Rates and Complications). After correction for 
confounders (sex, skin color, keloid location, keloid duration), no statistically significant 
differences in recurrence rates could be discerned between fractionation schemes with 
2x9 Gy, 3x6 Gy and 2x6 Gy, but significantly less minor and major complications as 
infections, wound dehiscence and chronic wounds were found. This shows a BED of 20 
Gy is sufficient to control keloid recurrence. Subsequently we use 2x6 Gy at our center, 
instead of one fraction per day we give both fractions on the operative day to minimize 
the risk of overnight catheter dislocation,  reduce hospital admission costs and to meet 
patients’ preferences. 
Need for a keloid treatment guideline 
In case a patient is referred to our outpatient clinic with an earlobe keloid we usually 
start conservatively with serial triamcinolone acetonide injections. If this patient would 
visit another hospital, it could well be that a different treatment would be prescribed. 
For example; 5-FU with or without TAC injections are often used in Asia; in other regions 
dermatologists have more experience and availability of lasers; some centers have 
very competent medical instrument makers that can make good pressure devices; a 
radiotherapist works with ionizing radiation and might suggest brachytherapy as an 
option. Occasionally, patients are treated for many years without good effect, while 
paradoxically sometimes a patient is referred for radiation as a primary treatment.
Due to above mentioned undesired variation in clinical practice, it seems like every 
keloid patient follows a different path through our healthcare system. In the Nether-
lands, care for keloid patients could be improved if keloid patients would be offered an 
evidence-based, standardized health care path (stepped care) with identical therapeu-
tic options, including shared-decision making. A multidisciplinary guideline, including 
general practitioners, dermatologists, plastic surgeons, radiotherapists and general 
surgeons, could facilitate this 36. 
So what could a guideline offer? It would lead to awareness of treatment difficulties 
among general practitioners and stimulate standardized referrals. In my opinion, der-
matologists could best provide the conservative and minimally invasive treatments, 
because they often have experience with and access to topical and intralesional medi-
cal treatments, but also lasers and cryotherapy. They regularly perform serial treatments 
including long-term follow-up of patients and their outpatient clinics are suitable to 
build on a long-term patient-physician relation. If after set periods of time the first treat-
ment steps are not successful, patients are referred for surgical treatment. These latter 
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patients are preferably assessed at a joint outpatient clinic, to decide what the surgical 
plan will be. 
A guideline can also aid physicians in informing patients on treatments outside of their 
own experience and inform them what centers do provide this treatment if doctor 
and patient decide on the patient’s best option. A guideline also can suggest what 
appropriate treatment periods are for the particular treatments. In times of expand-
ing health-care costs and limited resources, cost reduction can be made by reducing 
practice of ‘lower value care’ by providing a ‘best practice’ guideline 14, 37.
Recommendations for further research 
•	 Future research should focus on finding good conservative or minimally invasive 
treatments as alternative to serial intralesional corticosteroid injections for patients 
that show poor results with corticosteroids injections and that are not suitable for 
surgery or wish to stay with conservative treatment.
•	 Further research is needed to establish the place of intralesional cryotherapy (if any) 
within the treatment steps (stepped care). Whether it should be a step between 
minimally invasive treatment and surgery, whether it belongs to the same step as 
excision followed by corticosteroids, or whether it could completely replace exci-
sion followed by corticosteroids. Another topic of interest would be to investigate 
whether primary keloids all react well to intralesional cryotherapy, or whether cer-
tain keloid and patient characteristics have impact on the response (e.g., younger 
age, smaller keloids) predicting treatment effect.
•	 The outcomes of our (Erasmus MC Rotterdam) new radiation protocol after keloid 
excision (2x6 Gy HDR Ir192 brachytherapy on day of surgery with at least 6 hours 
apart) should be prospectively evaluated and maybe compared to the 2-day sched-
ule (VUmc Amsterdam). 
•	 The feasibility of large flap surgery with prophylactic brachytherapy and non-inva-
sive radiation skin patches for keloids covering large body areas should be further 
explored.
Future research on keloids outside the scope of the present thesis
Etiology
Research on the etiology of keloids was not part of the present thesis. Keloids are fibrous 
tumors, accompanied by an aggravated inflammatory response of the reticular dermis. 
Although over the years groups have tried to find out what exactly causes keloids, it 
seems to be a multifactorial condition. No proven or universally accepted pathway has 
been identified. The theory of Ogawa’s group is that after trauma or inflammation the 
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inflammatory response is prolonged and aggravated by mechanical tension on the 
skin (local factor), and hypertension or increased systemic inflammatory factors (due to 
large wounds or allergic reactions) in genetically prone people (several chromosome 
loci and SNPs have been identified) 38.
It has been extensively shown that in keloids inflammatory factors like IL-1, IL-6, TNF-α, 
and TGFβ are increased. Authors showing that an inflammatory factor is elevated in 
keloids often have proposed that it could be the target of new treatments. But, keloids 
only exist in humans and no animal or laboratory models completely cover the bio-
logical behavior of keloids, prohibiting translational research. Currently, the step from 
bench to patient in therapeutic options is too big; a good keloid model would mean 
large steps forward could be made in collecting evidence on therapeutic options. Prog-
ress in that area is being made 39, but no animal models with intact immune reactions 
have scars showing keloid behavior.  Building a good pre-clinical model is probably 
only possible when the causative factors of keloids have been elucidated. Although 
much progress has been made, we do not know when an optimal keloid model will 
become widely available.
Revision of study design hierarchy 
During my training as a medical doctor, I was taught the golden standard in evidence-
based medicine is a randomized controlled trial (RCT). This is also the current opinion 
advocated by major medical journals and the Dutch ministry of health, wellbeing and 
sports (VWS), which requires evidence from RCTs to support whether treatment is ef-
fective or not. At the start of my research period when I was writing a research proposal 
to compare treatment effects, we therefore did not hesitate to design a randomized 
controlled trial. However, during my research period doubts set in when inclusion 
proved to be extremely difficult due to strong treatment preferences of patients, 
consequently not consenting with randomization. This problem often occurs, more in 
surgical trials compared to medical trials, because patients have stronger preferences 
regarding surgical options than between one pill and another 40, 41. 
In hindsight, with a non-randomized design we could have collected much more data 
on our outcomes. The question rose: When does large group size win over randomiza-
tion? More sophisticated designs are available to tackle this problem, like the ‘patient 
preference trial’ 42. Using this design, patients that refuse randomization are still fol-
lowed and outcome collection is the same as for randomized groups. This makes it 
possible to analyze whether the randomized arms and parallel arms differ on baseline 
characteristics, and outcomes can be analyzed for all patients (where they should be 
considered a cohort) or for randomized patients only. If we would have anticipated on 
high refusal of informed consent, this would have been a preferable design.
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There is no doubt on the value of RCTs, however, because methodology of cohort 
studies has improved, various forms of bias have been reduced. It has been shown that 
a single RCT can be as flawed as a single cohort, and that predictions from multiple 
cohorts do not differ from predictions based on RCTs 43. One is not always superior to 
another and level of evidence should be judged per paper. This has been shown more 
than a decade ago, but still we hold on to the hierarchy in study designs. Furthermore, 
RCTs are expensive and might not be the best use of limited research funds, specifically 
if they turn out unsuccessful. 
For future (keloid) research on treatments that are both available outside of study 
context, I recommend to anticipate on low patient consent with randomization and 
take this into account when choosing a study design. Less well-known designs like the 
‘patient preference trial’ may be the preferred option! 
Collective data collection
Even better than an innovative study design would be continuously monitoring 
outcomes in clinical quality and research registries that eventually will improve our 
insight in keloid treatment effects and practice even more, because all patients that are 
nationally treated are included annually. What data should be registered, and whether 
that will be detailed enough to be valuable, without taking up too much time, is a chal-
lenge. If every physician would collect outcomes the same way, effect of treatments 
could be compared. That is what is needed, because case reports or case series in a 
heterogeneous condition without any reference to other treatments is almost without 
value. Specifically, with the amount of variation within the condition, keloid disease and 
usual small groups sizes in studies, it would be ideal to follow all patients treated in the 
Netherlands. 
In more rare and severe diseases, the urge to do this is more prominent and proved 
to be of value, enabling several studies that would not have been possible without 
centralized data collection 44. Baugh et al.  internationally collected data on a specific 
brain tumor, with clinical data, images, biopsy tissues and molecular DNA and RNA data. 
This resulted in a more intensive collaboration between clinical, translational and basic 
scientists, enabling projects on disease-model development, epidemiology, identifying 
in what patient treatments works and when it does not. This comes with a time and 
costs investment, a national registry collecting this much data is very costly. However, 
registries enable major improvements in medical care and simultaneously reduce costs 
making it worthwhile 44, 45.
Value based healthcare 
Some of the topics discussed above are part of a greater development in healthcare: 
the shift from volume driven care to outcomes driven care, also known as value based 
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healthcare. In 2009, Michael Porter shared his opinions on how healthcare should 
change 46. He believes a completely different approach on health will improve care 
while reducing costs. It includes preventive care, accessible health insurance, measur-
ing health value and how treatment improves value, and promoting reimbursement by 
added value instead of number of treatments. Healthcare providers’ role in this transition 
is changing how health or value is measured, in objective measures, patient reported 
outcome measures (PROMs) and patient reported experience measures (PREMs), prov-
ing treatments add to the value that matters most to patients (Figure 2). Finding the 
right measures is not an easy task. The instrument should measure the right dimensions 
and cover all concepts of interest 2, but should also be easy and quick in use to have 
patients take it every visit. Internationally, the importance of measuring outcomes in a 
proper way is growing, groups of experts together with patients are carefully selecting 
outcome measures based on what is most important for them 47. Subsequently, stan-
dard outcome sets have been defined for a number of conditions. So far, no outcome 
set has been developed for keloids or scars, or even one skin disease, but it is a matter 
of time before they will be available. 
Figure 2. Diagram illustrating value based healthcare
When these standardized outcomes are measured, caregivers should discuss the 
outcomes with their patients to personalize treatments to the individual values of the 
patients. But they can also be used for comparison to other practices and learn from 
colleagues that are top performers 14, 45. You can evaluate whether changes in health 
care have affected outcomes; see whether an improvement has paid off or whether 
cost-savings have impacted on value gain. And eventually, it might also be used by in-
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surance companies to implement value-based payment. So, with measuring outcome 
values correctly, we can see where we are, where we need to go, and what we need to 
do to get there at the best rate.
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This thesis aims to improve care for keloid patients. Keloids are fibroproliferative le-
sions that can develop after an exaggerated inflammatory response to a trauma of the 
dermis. 
In Chapter 1 skin anatomy, normal wound healing and different types of disturbed 
wound healing are described. Within pathologic scarring two types exist: hypertrophic 
scars and keloids. Their main differences in clinical behavior are highlighted. Several 
factors that can provoke keloid scarring are given. The sparse existing literature on 
patient burden of keloids is discussed, as well as the challenges in keloid treatment, 
and evidence-based treatments. 
Part I   Burden of keloids
First, the burden of keloid disease was assessed using validated disease specific and 
general health related quality of life (HRQL) questionnaires, afterwards, factors which 
add to the disease burden were identified. The identification of the factors that cause 
the greatest HRQL impairment, enables us to target treatments accordingly. 
Many keloid patients report pain as their main symptom, however, often no treatment 
is prescribed to relief pain. To explore symptomatic therapy options, a systematic re-
view on the etiology of pain in scars and a pilot study investigating several sensible 
characteristics of keloids were performed.
Main findings
Chapter 2
•	 Having keloid disease was associated with a considerable impairment of emotional 
wellbeing, with most impairment on emotional and mental HRQL. 
•	 Pain and itch were the strongest predictors of HRQL impairment in keloid patients. 
•	 Treatment should aim at alleviating physical symptoms of keloids.
Chapter 3
•	 Burn and pathologic scars often lead to high intensity pain symptoms. 
•	 Scar pain has many characteristics of neuropathic pain that could be caused by an 
imbalance of C-fibers subtypes. 
•	 Scar tissue itself may alter the nerve fiber distribution; the imbalance results in 
ongoing neuro-inflammation and pain symptoms.
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Chapter 4
•	 Somatosensory differences in keloid scars can show aspects of nociceptive or neu-
ropathic pain and are extremely heterogenic.
•	 No specific subgroup of nerve fibers that may be affected in keloid disease could be 
identified. 
•	 No correlation could be shown between keloid symptoms and epidermal and up-
per dermal nerve fiber density.
In part I, the importance of pain and itch symptoms on quality of life was shown, which 
has been confirmed by other groups. Unfortunately, our (prematurely terminated) trial 
did not show an improvement in quality of life after successful keloid treatment, defined 
as pain and itch reduction, most likely due to statistical under-powering. However, other 
groups were able to show quality of life improvement after successful keloid treatment. 
Due to their high impact on disease burden, reduction of pain and itch symptoms 
should have a more prominent role in keloid treatment and research. During the initial 
patient consultation, the frequency and impact of pain should be clarified, differentiat-
ing between nociceptive and neuropathic pain. If neuropathic pain is the main symp-
tom, local symptomatic therapy (e.g. capsaicin patches or botox) should be tried in 
future studies to find out whether symptoms are relieved and quality of life is improved. 
Part II   Treatment of keloids
At our center, we were searching for ways to reduce the use of post-surgical brachy-
therapy in keloid treatment after we had encountered some complications with this 
treatment. When the new, promising treatment with intralesional cryotherapy was 
promoted we hypothesized that use of ionizing radiation could be decreased if other 
successful treatment options became available. Therefore, a trial was designed to evalu-
ate the efficacy of intralesional cryotherapy compared to surgical excision with either 
adjuvant corticosteroid injections or brachytherapy. In the Netherlands, several differ-
ent brachytherapy schemes and doses are currently in use, but there is no evidence 
on which scheme performs best. Our aim to reduce the use of brachytherapy in keloid 
patients stimulated us to investigate whether other treatments could be effectively 
used as well and whether radiation doses could be reduced. In this way we wanted to 
provide scientific evidence guiding clinicians in their choice of treatment, mainly based 
on patient reported outcome measures. 
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Main findings
Chapter 5
•	 Serial intralesional 5-fluorouracil injections were effective in 45–96% of keloid pa-
tients.
•	 Combination therapy with triamcinolone acetonide (a corticosteroid) and 5-fluoro-
uracil may perform better than triamcinolone acetonide alone.
Chapter 6 and 7
•	 Intralesional cryotherapy is inferior to keloid excision followed by brachytherapy for 
resistant keloids. 
•	 In primary keloids, intralesional cryotherapy resulted in some keloid improvement 
and therefore may be used in these patients and specific cases. 
Chapter 8
•	 A recurrence rate of 8.3% was found after keloid excision followed by postoperative 
high dose rate (HDR) brachytherapy, independent of 2x9 Gy, 3x6 Gy or 2x6 Gy radia-
tion schemes.
•	 In 12.8% of patients major complications occurred, e.g. chronic wounds and infec-
tions. Complications were more often seen with increasing radiation doses.  
•	 After excision of resistant keloids, high dose rate (HDR) brachytherapy with a bio-
logical equivalent dose of 20 Gy is recommended based on both low recurrence 
and complication rates.
In the general discussion (Chapter 9) the effects of patient information, physician-pa-
tient-relation, and shared decision making on outcomes are discussed. These concepts 
should be incorporated more in keloid patient consultations to achieve higher treat-
ment satisfaction rates. Consequently, the rationale behind a stepped care approach in 
keloid treatment can be explained and a treatment plan can be made together with the 
patient. If required, this plan will be adjusted based on the treatment response.
The beneficial effects of radiation on keloids is further explored, new less and more 
invasive techniques are described. However, we should not forget about stochastic 
effects in the  young keloid patient population. We also reported a patient with a basal 
cell carcinoma after keloid treatment, and more malignancies after radiation to treat 
a keloid have occurred. The indication should be carefully made and the dose should 
be as low as reasonably achievable. Unfortunately, intralesional cryotherapy is not an 
effective alternative treatment option for resistant keloids, and consequently cannot 
decrease brachytherapy indications. 
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A more uniform referral and treatment plan could further improve care for keloid pa-
tients as well as reduce costs. This could be reached by developing a multidisciplinary 
guideline. It will improve coordinated care and reduce low value care. 
Finally, improvements in basic research on keloid etiology are discussed, including the 
necessary animal model that enables translational research. In addition, recommenda-
tions are given how future research projects could be more profitable, choosing the 
right patient reported outcomes, choosing the most fitting study design or building 
on national registries for collection of scientific data and outcomes. When taking this all 
together (patient information, patient perspective, shared decision-making, outcome 
collection, adjusting treatment plans based on outcome) a value-based approach to 
keloid care is provided. Only when we will succeed in creating these conditions needed 
for value-based keloid care, we will be able to truly improve our care for keloid patients. 
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Het onderzoek beschreven in dit proefschrift had als doel de zorg voor keloïdpatiënten 
te verbeteren. Keloïden zijn overmatig woekerend littekenweefsel ofwel fibroprolifera-
tieve, posttraumatisch laesies van de dermis die ontstaan door een ongecontroleerde 
inflammatoire reactie. 
In Hoofdstuk 1 worden ter introductie de anatomie van de huid, de normale wond-
genezing en de verschillende soorten verstoorde wondgenezing beschreven. Zowel 
hypertrofische littekens als keloïden worden onder pathologische littekens gerekend. 
De belangrijkste verschillen in klinisch gedrag tussen deze twee typen littekens worden 
uitgelegd. Daarbij is het van belang onderscheid te maken tussen de twee typen in 
onderzoek en bij behandeling. De diverse factoren geassocieerd met het ontstaan 
van keloïden worden beschreven. Bovendien wordt een overzicht gegeven van de 
spaarzame literatuur over de invloed van keloïden op de kwaliteit van leven, de moei-
lijkheden bij onderzoek naar keloïdbehandeling en de verschillende behandelopties. 
Deel I   Ziektelast van keloïden
Om de grote invloed van de aandoening te illustreren, hebben we de ziektelast van 
keloïden bepaald en gekeken welke factoren het meeste aan de ziektelast bijdragen. 
Wanneer de factoren met de grootste impact op kwaliteit van het leven bekend zijn, 
kunnen behandelingen specifiek worden gericht op het verbeteren van die factoren 
die de kwaliteit van het leven het meest kunnen verbeteren. Veel keloïdpatiënten rap-
porteren pijnklachten als een groot probleem, maar behandelingen richten zich zelden 
op deze pijnklachten. Om symptomatische behandelopties te verkennen, hebben we 
zowel een literatuurstudie gedaan naar pijn in littekens alsook een pilotstudie naar de 
pijnsensaties ten gevolge van keloïden.
Voornaamste bevindingen
Hoofdstuk 2
• Keloïdpatienten hebben een aanzienlijk verminderde kwaliteit van leven, met de 
meeste beperking op het emotionele en mentale welbevinden.
• Pijn en jeuk hadden de sterkste invloed op kwaliteit van leven bij keloïdpatiënten.
• Behandeling zou zich moeten richten op het verlichten van fysieke symptomen van 
keloïden.
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Hoofdstuk 3
• Brandwondlittekens en pathologische littekens leiden vaak tot een hoge pijninten-
siteit.
• Pijn in littekens heeft veel kenmerken van neuropathische pijn die kan worden 
veroorzaakt door een disbalans van C-vezelsubtypes.
• Het littekenweefsel kan de zenuwvezeldichtheid veranderen; een disbalans resul-
teert in een voortdurend neuro-inflammatoir proces dat pijn veroorzaakt.
Hoofdstuk 4
• Somatosensorische afwijkingen in keloïdlittekens, tonen aspecten van nociceptieve 
en van neuropathische pijn, maar deze afwijkingen zijn extreem heterogeen tussen 
de patiënten.
• Er kan geen specifieke subgroep van zenuwvezels worden aangewezen die zijn 
aangedaan bij keloïden.
• Er kon geen correlatie worden aangetoond tussen klachten en zenuwvezeldicht-
heid in de epidermis of oppervlakkige papillaire dermis.
In deel I toonden we het belang van pijn- en jeuk-symptomen op de kwaliteit van 
leven van keloïdpatiënten aan; dit is ook door andere onderzoekers bevestigd. In de 
beschreven voortijdig gestopte studie (hoofdstuk 6 en 7) verminderden pijn en jeuk na 
een succesvolle keloïdbehandeling, maar zagen we geen verbetering van de kwaliteit 
van leven na deze behandeling. Andere studies lieten wel een verbetering in kwaliteit 
van leven na een succesvolle keloïdbehandeling zien; waarschijnlijk kwam dit in onze 
studie niet naar voren door te kleine onderzoeksgroepen. 
Vanwege de grote invloed op de ziektelast van keloïdpatiënten zouden pijn en jeuk 
symptomen een meer prominente rol moeten krijgen in de spreekkamer en in keloï-
donderzoek. Tijdens de anamnese moeten de frequentie en invloed van pijn worden 
besproken en dient onderscheid te worden gemaakt tussen nociceptieve en neuropa-
thische pijn. Wanneer neuropathische pijn de belangrijkste klacht is, zouden we kun-
nen onderzoeken of lokale symptomatische therapie (bijvoorbeeld capsaïcinepleisters 
of botox injecties) pijn en jeuk vermindert en de kwaliteit van leven verbetert.
Deel II   Behandeling van keloïden
In het Erasmus MC waren we op zoek naar manieren om het gebruik van postopera-
tieve brachytherapie voor keloïdbehandeling te verminderen vanwege het optreden 
van complicaties. We veronderstelden dat het gebruik van ioniserende straling kan 
worden verminderd wanneer er andere succesvolle behandelingsopties beschikbaar 
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zouden zijn. Toen de nieuwe, veelbelovende behandeling met intralesionale cryothe-
rapie werd geïntroduceerd, werd dan ook een onderzoek gestart. Er werd een klinische 
studie opgezet om de werkzaamheid van intralesionale cryotherapie te vergelijken 
met keloïdbehandeling door operatieve verwijdering en aanvullende corticosteroid 
injecties of bestraling door middel van brachytherapie. In deze studie hebben we 
patiënt-gerapporteerde uitkomstmaten gebruikt. 
Daarnaast worden op dit moment in Nederland verschillende doseringen bestraling 
met brachytherapie gehanteerd ter voorkoming van recidief keloïdvorming, maar het 
is niet duidelijk welke dosis optimaal is. We wilden de resultaten van de verschillende 
behandelingen naast elkaar leggen om wetenschappelijk bewijs te bieden voor de 
best werkzame dosis.
Voornaamste bevindingen
Hoofdstuk 5
• Seriële intralesionale 5-fluorouracil injecties waren effectief bij 45-96% van de kelo-
idpatiënten.
• Alleen combinatietherapie met triamcinolone acetonide (een corticosteroïd) en 
5-fluorouracil is mogelijk effectiever dan alleen triamcinolone acetonide.
Hoofdstuk 6 en 7
• Intralesionele cryotherapie is inferieur aan excisie gevolgd door brachytherapie als 
behandeling voor resistente keloïden.
• Voor primaire keloïden verbeterde intralesionele cryotherapie de keloïden, daarom 
zou bij deze patiënten en in specifieke gevallen voor intralesionale cryotherapie 
gekozen kunnen worden.
Hoofdstuk 8
• We vonden een recidiefkans van 8,3% na keloïd-excisie met postoperatieve bra-
chytherapie, onafhankelijk van het gebruikte stralingsschema (2x9 Gy, 3x6 Gy of 2x6 
Gy).
• Bij 12,8% van de patiënten traden ernstige complicaties op, waaronder chronische 
wonden en infecties. Complicaties werden vaker gezien bij een hogere stralingsdo-
sis.
• Na excisie van resistente keloïden wordt brachytherapie aanbevolen met een bio-
logische equivalent dosis (BED) van 20 Gy, vanwege de lage kans op recidieven en 
complicaties.
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In de beschouwing (hoofdstuk 9) wordt de invloed van informatievoorziening aan de 
patiënt, de arts-patiëntrelatie en gedeelde besluitvorming op de behandeluitkomsten 
besproken. Deze concepten zouden nog meer moeten worden toegepast in de zorg 
voor keloïdpatiënten om patiënttevredenheid na behandeling te verbeteren. De rede-
nen voor een trapsgewijze opbouw van de behandelingen kunnen worden uitgelegd 
en gezamenlijk kan een behandelplan worden opgesteld. Zo nodig kan dit plan worden 
aangepast op basis van resultaten gedurende de behandeling.
Onderzoek naar nieuwe technieken voor keloïdbehandeling met bestraling worden 
besproken, zowel meer als minder invasieve opties. Toch moeten we niet voorbijgaan 
aan de stochastische effecten van ioniserende straling in deze jonge patiëntengroep. In 
dit proefschrift wordt bijvoorbeeld een patiënt gerapporteerd met een basaalcel carci-
noom na keloïdbehandeling met bestraling. Ook in de literatuur zijn beschrijvingen van 
maligniteiten na bestraling van een keloïd te vinden. De indicatie voor het gebruik van 
brachytherapie moet zorgvuldig worden gemaakt en de dosis moet zo laag mogelijk 
zijn. 
Helaas is intralesionele cryotherapie niet effectief gebleken als alternatieve behandel-
optie voor resistente keloïden en kan deze behandeling de brachytherapie indicaties 
niet verminderen. Wat verder de zorg voor keloïdpatiënten kan verbeteren en kan re-
sulteren in lagere behandelkosten, zijn meer uniforme verwijzingen en behandelplan-
nen. Dit kan bereikt worden door een multidisciplinaire richtlijn te ontwikkelen. Het zal 
de gecoördineerde zorg verbeteren en gebruik van minder effectieve behandelingen 
verminderen.
Tot slot wordt aandacht besteed aan de vorderingen in basaal onderzoek naar het 
ontstaan van keloïden en het ontwikkelen van een diermodel dat translatieonderzoek 
mogelijk moet maken. Tevens wordt geadviseerd hoe toekomstige onderzoekspro-
jecten meer kunnen opleveren door de juiste uitkomstmaten en de meest geschikte 
onderzoeksopzet te kiezen, als ook door het opzetten van nationale registraties die 
behandeluitkomsten of wetenschappelijke gegevens verzamelen. Patiëntinformatie, 
patiëntperspectief, gedeelde besluitvorming, uitkomstverzameling, aanpassing van 
behandelingsplannen op basis van uitkomst; tezamen vormen deze kenmerken de 
onderdelen van ‘waardegedreven’ gezondheidszorg. Pas wanneer we erin slagen de 
voorwaarden te creëren die nodig zijn om ‘waardegedreven’ keloïdzorg te bieden, zul-
len we de zorg voor keloïdpatiënten echt kunnen verbeteren.
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PhD Portfolio
Summary of PhD training and teaching
Name PhD student: E Bijlard
Erasmus MC Department: Plastic and Reconstructive 
surgery, and Hand surgery
Research School: NIHES
PhD period: March 2012 – December 2017
Promotor(s): Prof.dr. S.E.R. Hovius
Supervisor: Dr. M.A.M. Mureau
1. PhD training
Year Workload
(ECTS)
General academic skills 
- BROK/GCP Refresher course
- Research Integrity Congress, Erasmus MC
- Medical Business Masterclass, ABN-Amro Amsterdam
- Didactic skills. Deel BKO. 
 Teach the Teacher 1, workshop Omgaan met groepen, workshop 
individuele begeleiding. 
 Desiderius School Erasmus MC
- Science in transition. Symposium. Erasmus MC 
- Research Integrity training for PhD students
 9, 16, 23 april 2013, Medische Ethiek Erasmus MC
- Biomedical English Writing and Communication Course. Erasmus 
MC 
- Good Clinical Practice
2016
2015
2014
2014
2014
2013
2013
2011
0.2
0.2
0.3
2 
0.2
2 
4 
Specific medical courses 
- Stralingshygiëne 4A/M voor medisch specialisten. Leiden
- Microsurgery training. Skillslab Erasmus MC. 
 4 hours/week, start May 2012 – June 2015   
- Workshop Tendon reconstruction. Skillslab Erasmus MC
- Workshop Nerve reconstruction. Skillslab Erasmus MC
- Workshop local transposition flaps. Skillslab Erasmus MC  
- LifeCell Masterclass Breast Reconstruction. AMC, Amsterdam 
2016
2012-2015
2013/2014
2013/2015
2013/2015
2013
1
14
0.2
0.2
0.2
0.2
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Presentations
- ASPS meeting. “Long-term Results of Excision followed by 
Brachytherapy for Keloid Treatment” Los Angeles, USA
- Voorjaarsvergadering NVPC. “Langetermijnresultaten van 
keloïdbehandeling met excisie gevolgd door brachytherapie in het 
Erasmus MC” Eindhoven.
- ASPS meeting. “Intralesional Cryotherapy versus Excision with 
Corticosteroids or Brachytherapy for Keloid Treatment” Boston, USA.
- Najaarsvergadering NVPC. “Een vergelijking tussen intralesionale 
cryotherapy, excisie met corticosteroïden of met brachytherapie in 
de behandeling van keloïden” Amsterdam.
- European Academy for Dermatology and Venereology Spring 
Meeting. E-poster presentations: Burden of keloid disease; 5-FU in 
keloid treatment: A systematic Review. Valencia, Spain.
- Presentation of my research (department of dermatology Erasmus 
MC, Esser foundation, department of plastic surgery VU medical 
center)
2016
2016
2015
2015
2015
2012-2013
1
0.5
1
0.5
1
0.3
Conferences attendance
- NVPC Scientific Meeting, Multiple locations
 April 2012, October 2012, April 2013, October 2013, April 2014, 
October 2014, October 2015, May 2016, October 2016
- Kortjakje Zondagschool voor Plastische Chirurgie 
 Kasteel Kerckebosch, Zeist 
 November 2012, November 2013, March 2014, March 2015  
- 25th Esser Course. Oncoplastic breast reconstruction
 Esser Course. Farewell professor Hovius. Rotterdam.
 World congenital Hand Congress. Rotterdam.
 24th Esser Course. Ins and outs of nose reconstruction
 22nd Esser Course. What’s new in breast reconstruction. 
 20th  Esser Course. Masterclass Neuropathic Pain
- Wound Congress. Rotterdam.
- Reconstructive Surgery Trial Network day. London, UK.
- NVSCA meeting 
2012-2015
2012-2015
2017
2016
2015
2014
2014
2013
2016
2016
2014
2
0.3
0.3
0.3
0.6
0.3
0.3
0.3
0.3
0.3
0.2
2. Teaching and Lecturing
Year Workload (ECTS)
Lecturing
- Anatomie van de hand 2h 2012 2e jaars studenten.
 Snijzaal Erasmus MC
- Introductie plastische chirurgie 1 h januari 2013 2e jaars keuze 
onderwijs. Onderwijscentrum Erasmus MC
2012
2013/2015
0.3
0.3
Supervising practicals and excursions, Tutoring
- Tutor 1st year medical students 
- Microsurgery course November 2012, January 2013, November 
2014, April 2015. Skillslab Erasmus MC
- Practical course Minor curriculum: Tendon reconstruction 2012. 
Skillslab Erasmus MC
2014-15
2013
2012
1
2
0.3
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Supervising Master’s theses
- Lisa Uiterwaal: Systematic Review: Causes of pain in scars 
 18-03-2013 to 16-08-2013
- Elise Bijlard: Optimizing Immunohistochemistry protocols 
 22-04-2013 to 2-08-2013
- Casimir Kouwenberg: Burden of Keloid Disease
 02-12-2013 to 18-07-2014
- Frank de Jongh: Influence of Keloid characteristics in treatment 
decisions
 01-04-2014 to 02-10-2014    
- Xavier Harmeling: Systemic oncologic treatment and breast 
reconstruction – A meta-analysis
 01-04-2014 to 19-12-2014
2013
2013
2014
2014
2014
3
3
3
3
3
3. Other
Year Workload (ECTS)
- Chair of the Resident representation of Zaans Medical Center
- Member Wetenschappelijke Koepel NVPC
- Website editor ‘Heelkunde region 1’
- Organizing annual social program of the department of plastic and 
reconstructive surgery and hand surgery
- Organizing 19th Esser Course To the Base of the Thumb: Sponsoring
- Organizing 21st Esser Course Wide Awake: Sponsoring 
- Organizing 23rd Esser Course. On your nerves: Promotie en drukwerk
2016-2017
2016-2017
2016
2012-2014
2013
2013
2014
3
3
1
1
2.5
2.5
2.5
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Ken ik je uit het Erasmus MC?
Wat is onze
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Ben je
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Dr Mureau, Marc, Bedankt!
Jouw vertrouwen was voor
mij het beste mentorschap
Bedankt voor het
beoordelen van
mijn manuscript
Heb je me
begeleid?
Bedankt voor je
begeleiding!
Wat ben je dan?
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Dank je voor het
kunnen delen van
lief en leed. De
toren overleefd!
Ari’s?  
Zijn we vrienden?
Bedankt voor de
nodige afleiding.
Work hard, play
hard
Ja
Nee
Ja
Ja
Nee
Ne
Patient
Po
li,
 P
O
K 
of
 s
ec
re
ta
ria
at
Pl
as
tis
ch
e 
on
de
rz
oe
ke
rsStaf & Ass
(Skills)lab
Ik zie er naar uit om komende
jaren, samen met jullie, uit te
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Bedankt voor je
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Carin, wat fijn dat iemand weet
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maken. Bedankt voor alle hulp! 
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